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Endothelins (ETs) are a family of three 21 amino-acid vasoactive peptides ET-1,
ET-2 and ET-3 that mediate their effects via two G-protein couple receptors ETAR and
ETBR which are expressed on various cell types. Apart from their physiological role in
vasoconstriction, there is emerging evidence supporting the role of endothelin axis (ETaxis) in cancer. Due to the expression of ET receptors on various cell-types, ET-axis can
exert pleotropic effects and contribute to various aspects of cancer pathobiology.
Several studies have provided a fragmented picture of the diverse roles or ET-axis in
various tumors. However, the comprehensive picture of the pathobiological role of this
axis in any given cancer is poorly understood.
Given that PC epitomizes the complexity of tumor microenvironment (TME),
which is an active player in disease progression and therapy resistance, the overarching
goal of this dissertation was to define the role of ET-axis in this lethal malignancy.
Specifically, the dissertation was aimed at defining the expression pattern of ET axis in
PC TME and elucidating the pathobiological significance of ET axis in PC.
Immunohistochemistry (IHC) analysis of surgically resected tumor tissues from PC
patients indicated expression of ECE-1, ET-1, ETAR and ETBR expression in both
primary and metastatic lesions. In addition to tumor cells, ETAR and ETBR expression
was observed on blood vessels (BV), stromal cells including stellate cells and infiltrating
immune cells. The expression of ETAR and ETBR in various cellular compartments was
also analyzed using marker for tumor cell (CK19), blood vessel (CD31), stellate cell
(alpha SMA) and macrophages (CD68 and F4/80). Importantly, analysis of survival data
showed ETBR positivity on BV is correlated with poor prognosis of the PC patients.
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Bioinformatics analysis of TCGA database revealed high positive correlation of the profibrotic gene signatures with both ETAR and ETBR particularly Collagen I (Col1A2,
Col3A1, Col5A2, Col6A3), Platelet derived growth factor receptor beta (PDGFRβ),
Fibroblast activation protein (FAP), suggesting a pro-fibrotic role of ET axis in PC.
In the second part of the dissertation, we studied the impact of ET-axis inhibition
in autochthonous tumors that develop in genetically engineered mouse model (KPC).
Treatment with dual ET receptor antagonist Bosentan induced cell death in the
autochthonous tumors, decreased IHC signal for extracellular matrix proteins (α-SMA,
Collagen I, Fibronectin and CTGF). Transcriptomic analysis using fibrosis gene array
indicated anti-fibrogenic effects of Bosentan in KPC tumors. Further, treatment of murine
pancreatic stellate cells (PSCs) and human cancer associated fibroblasts (CAFs) with
recombinant ET-1 in vitro induced the expression of pro-fibrotic genes was abrogated by
selective inhibition of ETAR (BQ123) and ETBR (BQ788) signaling with synergistic effects
observed with dual receptor inhibition. Further, ET-1 stimulation induced a significant
increase in the p-ERK and p-AKT in a time dependent manner and dual receptor
antagonist Bosentan significantly attenuated the ET-1 mediated induction. Our study
also demonstrates that targeting ETAR with a specific inhibitor BQ123 enhances
perfusion selectively in the tumor and reduces hypoxia in xenograft PC tumors.
The third part of the dissertation describes a possible involvement of ET axis in
inflammation associated pancreatic tumor progression in presence if mutated KrasG12D.
The expression of ET axis components initially is restricted to pancreatic acinar and islet
cell compartment in physiological conditions. However, during inflammation or injury the
acinar expression is abrogated and is seen in early pre-cancerous lesions and
neoplastic cells. The reprogramming of acinar phenotype into early pre-neoplastic
lesions indicates an essential role of ET axis in pancreatic acinar to ductal metaplasia.
This trans-differentiation is followed by excessive accumulation of ECM proteins and
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inflammatory reaction in the pancreas, indicating further involvement of ET axis in
influencing micro-environmental factors in initiation and progression of pancreatic
cancer.
The fourth part of the dissertation describes the generation of the mouse model
aimed at delineating the role of ET-1 in PC progression. Genetically engineered mouse
model of PC (K-rasG12D; Trp53R172H/+; Pdx-1-Cre) that harbors a Kras and p53 mutation in
the pancreas were crossed with the ET-1 flox/flox mice.
Taken together, studies in this dissertation demonstrate that ET axis plays a
pleotropic role in the TME, and targeting ET axis can modulate the obstructive and
immunosuppressive TME and make it potentially more amenable for chemotherapy and
immunotherapy.
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CHAPTER 1 A
Introduction
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1. Synopsis
Pancreatic cancer (PC) represents one of the deadliest malignancies with high
incidence worldwide and poor survival. Despite recent advances in the treatment,
modest benefits have been achieved. The complex tumor microenvironment of PC
including desmoplasia, poor and heterogeneous blood flow, and a hypoxic environment
limits the delivery and efficacy of therapeutic drugs. Endothelin (ET) isoforms, endothelin
converting enzymes (ECEs) and receptors (endothelin A receptor, ETAR and endothelin
B receptor, ETBR) referred to as the ET axis, plays a vital role in vascular homeostasis
and tumor progression. Recently, role of ET axis is regulating various aspects of the
tumor microenvironment has gain considerable interest such as a potential target for
clinical opportunities and improving the clinical cancer management. The presence of
well-characterized antagonist(s) for each of the molecular components of the axis holds
promise for the treatment of cancer, however, the application of ET antagonists in PC
therapy warrants further investigation. This review outlines and discusses the multiple
roles of the ET axis in cancer progression, with major emphasis on pancreatic
inflammation, cancer and cancer microenvironment.
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2. Introduction to Endothelin(s)
PC is among the most aggressive and intractable human malignancies and is a
leading cause of cancer related deaths worldwide. Despite intensive clinical research
efforts the last decade, we have witnessed the failure of many clinical trials with only
marginal increase in survival benefit [1] [2]. A striking histological feature of PC is a
pronounced desmoplastic tumor stroma comprised of cancer-associated fibroblasts,
pancreatic stellate cells, infiltrating immune cells, macrophages and perturbed vascular
network. The interactions between these cell types makes a dynamic reactive
microenvironment around the pancreatic ductal cells which serves as physical barrier for
drug delivery [3] [4]. In PC, the microenvironment under goes constant change in its
composition during the course of tumor progression and the stromal compartment out
numbers the tumor cells [5]. The autocrine and paracrine secretions of these cellular
components with the tumor cells facilitate tumor progression. In the micro ecology of
tumor progression, growth factors exchange between these participating players
stimulate

proliferation,

migration,

extracellular

matrix

synthesis,

invasiveness,

angiogenesis and metastasis of cancer cells [6] [7] [8]. One such mediator that is
secreted by the cancer cells and tumor microenvironment components, is endothelins
(ET) family members, first identified by Yanagisawa et al in 1988 form the porcine
endothelial cells [9]. The ETs comprise three, 21 amino acids, endogenous, vasoactive
isoforms ET-1, ET-2 and ET-3. ETs are characterized by a single alpha helix and two
intra-molecular disulfide bridges produced by endothelial and epithelial cells and are
widely distributed in various tissues. The pleiotropic effects attributed to this family of
endothelin ligands are mediated by two G protein couple receptors, ETA receptor (ETAR)
and ET B receptor (ETBR) [10] [11]. Collectively, endothelins, their receptors and the
endothelin converting enzymes are referred as “endothelin (ET) axis” which participates
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in physiological functions such as vaconstriction vasoconstriction, vasodilation, cell
growth, differentiation and hormone production. Pathophysiological implication of the
axis is seen in aberrant expression of the ET-1 and the receptors in congestive heart
failure, pulmonary hypertension, diabetes, and renal failure [12] [13]. Recently, the ET
axis was implicated in signaling and formation of signaling complexes by coupling to
other G family of proteins as well as scaffold proteins like β-arrestin [14]. In addition to its
potent vasoconstrictive ability, aberrant expression of ET axis is also reported in many
solid tumors such as breast, ovarian, prostate, bladder and lung cancers [15]. The
autocrine and paracrine feedback loops between tumor cells and stromal cells facilitated
by ET axis promotes tumor growth by activation of diverse array of signaling networks
such as proliferation, apoptosis, formation of new vessels, immune modulation, invasion
and metastatic dissemination [16]. As a result, the cellular behavior of ET axis depends
on environmental cues and insults from the microenvironment. This review outlines the
role of ET axis in physiological and pathological conditions of the pancreas with potential
implications for future therapy
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3. The Endothelin System
ET isoforms are synthesized in a three-step process. The primary translation
product is a 212 amino acid pre-proendothelin and is cleaved by furin proteases to yield
a biologically inactive 38 amino acid (pro-peptide) endothelin-1. The pro-peptide form is
then processed by endothelin converting enzymes (ECEs) to yield the biologically active
21 amino acid cyclic peptide (Figure 1). Of the three isoforms, ET-1 is the most well
characterized which is synthesized and released continuously from endothelial cells. In
humans ET-1 gene maps to chromosome 6, contains five exons, four introns and 5’ and
3’ flanking regions that spans approximately 6.8 kb of DNA. The mature ET-1 peptide
has two disulfide bridges. Its carboxy terminus is for receptor binding and the amino
terminus is required for determining the receptor binding affinity, which makes it unusual
compared to other bioactive peptides. The expression of the pre-proET-1 is determined
by transcription activation of EDN1 gene and is under the control of TATA box containing
promoter [17]. Regulation of the EDN1 gene occurs at the level of transcription and is
induced by different stimuli including hormones (insulin, cortisol, aldosterone, leptin, and
adrenaline), growth mediators (angiotensin II, transforming growth factor beta, and
inflammatory mediators), shear stress and hypoxia. Various transcription factors are
known to stimulate the transcriptional activation of EDN1 gene such as functional
activator protein-1 (AP-1), proto-oncogenes (c-fos, c-jun), hypoxia inducible [17, 18]
factor-1 (HIF-1), GATA protein binding-2, transforming growth factor-β (TGF-β) at the
proximal promoter and nuclear factor-κB (NF- κB), interferon-γ (IFN- γ), tumor necrosis
factor-α (TNF- α), E box and nuclear factor of activated T cells (NFAT) at the distal
promoter. Once activated, ET-1 activates several signaling pathways such as protein
kinase C (PKC), c-JUN terminal kinase, insulin like growth factor, mitogen activated
protein kinase (MAPK) and epidermal growth factor receptor (EGFR). In addition, the
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tissue specific regulation of ET-1 is accomplished by epigenetic modifications. For
example, in renal duct cells and fibroblasts, EDN1 is hypo methylated and hyper
methylated respectively to influence transcriptional activity [19]. Also, in embryonic stem
cells using a stable reporter gene system, methylation increased the level of EDN1 in
endothelial cells [20]. In renal epithelial cells Stow et al showed that aldosterone
stimulated ET1 expression by methylation at H3 lysine 4 residues [21]. In breast cancer
cells, Matteucci et al demonstrated an impairment of ET-1 expression and decreased
mRNA level due to epigenetic disturbances [22].The presence of AUUUA motifs at the
3’-untranslated region of EDN1 mRNA is responsible for regulating mRNA stability [23]
[24]. The ET-1 mRNA has a short half-life and half-life of secreted ET-1 peptide in
circulation is 1 min [15]. In endothelial cells, dual pathways synthesize ET-1. In regulated
pathway, ET-1 is stored in the secretory granules known as Weilbel-Palade bodies,
which are responsible for maintaining the vascular tone. Once activated in response to
external stimulus, these bodies de-granulate and fuse with the plasma membrane,
releasing its contents causing further vasoconstriction [25]. ET-1 is also released from a
constitutive secretory pathway that appears to be the prime secretory mechanism
operating at the level of transcription in most cell types [26]. Additionally, the clearance
of ET-1 is a dynamic process and is governed by two pathways. Using Chinese Hamster
Ovary (CHO) and COS cells, Bremnes and colleagues demonstrated that both ET
receptors follow different routes of intracellular trafficking following a clathrin dependent
endocytosis [27]. After co-localization in early Rab5 endosome upon ET-1 stimulation,
ETAR recycling progressed through a pericentriolar dependent pathway and appeared
on the plasma membrane whereas ETBR is subject to degradation through the
lysosomal pathway and is responsible for clearance of ET-1. Abassi et al studied the
metabolism in vivo and suggested the catabolism of ET-1 is by neural endopeptidase
EC.3.4.24.11 [28]
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ECEs belong to the M13 group of proteins and has three isoforms: ECE-1, ECE2 and ECE-3. These enzymes share 59% homology with each other and their function is
inhibited by phosphoramidon [29]. ECE-1 and ECE-2 are most prominent ECEs, belong
to the type II membrane bound metalloprotease family and show preference for cleavage
of ET-1 over ET-2 or ET-3 [30]. While ECE-1 is predominantly expressed on the cell
surface and has broader tissue distribution, ECE-2 exhibits primarily neuroendocrine
distribution [31] [32]. In addition, Nakano et al reported that conversion of pro-ET-1 by
chymase cleavage of the Tyr31-Gly32 bond to generate a novel 31 amino acid ET
peptide, that causes constriction of smooth muscle cells [33] [34]. ECE-1 is comprised of
a short cytoplasmic N terminal tail, is localized to chromosome 1 and has four isoforms
(ECE-1a-d) derived from single gene from differential gene splicing [35] [36] [37]. The
ECE-1a isoform is mainly responsible for generating the functional secreted ET-1 after
cleavage of pro-ET-1 [35]. All these isoforms differ in their N-terminal amino acid
sequences and reveal different subcellular localization [38]. ECE-1c is the predominant
isoform expressed on the cell surface, with ECE-1a and ECE-1d, whereas ECE-1b is
found intercellular [36]. In addition, Kuruppu and co-workers reported that the expression
and localization of the ECE1 is the rate-limiting step in the generation of ET-1 [39].
Further insights in the biology of ECE-1 come from the study of Muller et al who
demonstrated

different

subcellular

localizations

of

ECE-1

isoforms

[40].

In

neuroendocrine AtT-20 cells, ECE-1b and ECE-1d are present in late endosomes and
early recycling compartments respectively. Additionally, in human endothelial cells, both
ECE-1a and ECE1c isoforms are present, however ECE-1a shows nuclear
immunoreactivity and co-localization with nucleolin [41]. Interestingly, difference in the
sub-cellular localization of these isoforms has opposing effects on cellular behavior.
ECE-1a

and

ECE-1c

promote

and

suppress

invasion

respectively,

whereas

overexpression of ECE-1a abolishing the activity of ECE-1c in prostate cancer cells [42].
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The other two isoforms ET-2 (EDN2) and ET-3 (EDN3) are present on chromosome 1
and chromosome 2 respectively [43]. The kidney and the intestine primarily express ET2, ET-3 is found in brain, intestine, lung and kidney [12]. ET-2 differs from ET-1 by two
amino acids and both isoforms has equal affinity for both ETAR and ETBR. In contrast,
ET-3 differs from ET-1 by six amino acids and is selective for ETBR compared to ETAR
[10]. Interactions of all three isopeptides with receptor controls several fundamental
processes of cell growth, tissue differentiation and repair. The gene for ETAR and ETBR
is located on chromosome 4 and 13 respectively and shows a high degree of
conservation between human and animal species. Both receptors share 63% sequence
homology with each other over a 420-residue match length. The EDNRA gene contains
427 amino acids and has eight exons and seven introns while EDNRB gene contains
442 amino acids and has 7 exons and 6 introns [10] [44]. The differences in the Cterminal sequences of two ET receptors allow G-protein coupling and results in divergent
effects following ligand activation [45]. Both receptors are present in variety of cell types
including vascular smooth muscle cells, endocrine cells and reproductive cells whereas
the ETBR is also abundantly expressed in endothelial cells [46] [47] [48]. The
vasoconstriction response is through ET-1/ETAR interaction in the vascular smooth
muscle cells. In the absence of smooth muscle, binding of ET-1 to ETBR causes
vasodilation by the release of vasodilator such as nitric oxide (NO) [49]. In addition,
Karne et al reported the presence of a third ET receptor subtype (ETCR) specific for ET3, in Xenopus laevis. ETCR is comprised of a 424 amino acids and shares 47% and 52%
sequence similarity to ETAR and ETBR respectively [50]. Receptor activation is complex
exhibiting diverse cellular outcomes by interaction with different G-protein coupled cells
surface receptors. Extracellular binding of ET-1 to ETAR induces activation and coupling
to Gαq/11 and stimulation of phospholipase C. This in turn leads to increase inositol
triphosphate and diacylglycerol levels and enhance protein kinase C expression with
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rapid elevation in Ca2+ levels which are responsible for vasoconstriction. On the
contrary; engagement of ETBR with ET-1 stimulates vasodilation by Gαq/11 to induce
phosphoinositide hydrolysis [35]. In the context of cancer, ET-1 and its receptors are deregulated in many solid tumors and melanoma which contribute to tumor growth and
progression. Studies have also indicated that autocrine signaling across the ET-1 axis
plays a vital role in tumor cell proliferation. The interaction of the ET-1 ligand to its
cognate receptor in turn activates a sequence of intracellular events that act in a
synergistic fashion to foster cell proliferation [15]. Interestingly, ET-1 also promotes cell
proliferation and act as a protective factor by inhibiting apoptosis in different cell types. In
ovarian and prostate carcinoma cells, ET-1 modulates phosphatidyinositol 3-kinase
activation and protects cells against paclitaxel-induced apoptosis by significantly
inhibiting the levels of pro-apoptotic proteins such as Bad and Bax [51] [52]. In addition
to contributing in tumorigenic potential, ET-1 also regulates the tumor microenvironment
interactions that are important in maintenance and metastatic spread of the disease.
Through autocrine and paracrine signaling across the axis and amplification of the cross
talk between different components of microenvironment, ET-1 facilitates tumor-stroma
interactions, angiogenesis and lymphangiogenesis, epithelial to mesenchymal transition,
stemness and therapy resistance [10]. In contrast, the role of other two isoforms in
human cancer is not much explored and few studies have attempted to define their
possible role in cancer biology. In basal cell carcinoma aberrant activation of Hedhehog
(HH) signaling is associated with ET-2 over-expression and the presence of Gli-1
binding sites at the 3’ promoter of EDN2 gene indicate that the expression is under the
influence of HH signaling pathway [53]. Moreover, in human breast cancer
pathogenesis, EDN2 is overexpressed and co-localizes with the hypoxic areas within the
tumors [54]. Both ET-1 and ET-2 enhance the invasive and metastatic potential of tumor
cells when co-cultured in presence of macrophages, suggesting ET-2 would mimic the
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actions of ET-1 [55]. In addition, ET-2 is a potent chemo-attractant for macrophages and
leads to increased activation dependent on ETBR signaling [56]. Interestingly, in breast
and cervical cancers, epigenetic inactivation of the EDN3 gene is associated with
reduced expression and gene silencing [57] [58] [59]. Also, hyper-methylation of both
ET-2 and ET-3 is reported in human colon cancer suggesting that silencing of these
genes is essential step and pre-requisite for cancer development to evade competition
with ET-1 for both receptors [60] [61]. Recent evidence indicates that a reciprocal
relationship exists in expression of ET-1 and ET-3 in glioblastoma stem cells and
glioblastoma tumors [62] inferring different isoforms are expressed in distinct cell
populations. Evidence indicates that ET-3 (expressed by the metastatic melanoma cells)
promotes survival, proliferation and invasion via ETBR signaling and interaction with HIF1α dependent machinery [63] [64].

4. Endothelin in Inflammation
Rudolf Virchow first observed the presence of leukocytes within tumors and
indicated a possible association between inflammation and cancer [65]. To date, several
lines of evidence support this notion that inflammatory insults are a trigger and are prerequisite for cancer initiation In physiological conditions, in response to tissue damage or
attack by pathogens, neutrophils first infiltrate the inflamed site, followed by
macrophages and mast cells via activation of diverse array of signaling pathways and
various soluble and insoluble mediators. The orchestrated actions of inflammatory cells
strengthen the host defense, participate in tissue repair and pathogen elimination to
decrease inflammation and regain normal tissue homeostasis. However, if the
inflammation continues or it is not decreased, the cellular response changes to chronic
inflammation, which leads to dysplasia and metaplastic changes thereby promoting the
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risk of cancer initiation and progression. Epidemiological and clinical studies suggest
that 15-20% of all cancer deaths are correlated with chronic inflammation and infection
[66]. In the gastrointestinal tract, prolonged infection by Helicobacter pylori is coupled
with gastric cancer and mucosa-associated lymphoid tissue with lymphoma. In the liver,
chronic infection caused by Hepatitis C and B viruses increases the risk of hepatocellular
carcinoma. Infection with Schistosoma haematobium and human herpes virus type 8
induces chronic inflammation and increases the risk in urinary bladder and Kaposi’s
sarcoma respectively [67] [68]. Also, cholangiocarcinoma and nasopharyngeal
carcinoma are preceded by chronic inflammatory infiltrate stimulated by Clonorchis
sinensis and Epstein Barr virus infection respectively [69]. In addition to microbial
infection, some chemical irritant or immune deregulation and autoimmunity can also
contribute to chronic inflammation and contribute significantly to tumor development. For
example, in inflammatory bowel disease (IBD) the pro-tumorigenic niche created by
effector CD4+ T cells and IL-6 increases the risk of colorectal cancer [70]. Similarly,
inflammatory diseases such as chronic pancreatitis, barrett’s metaplasia, chronic
cholecystitis, chronic asthma and endometriosis may increase the risk of pancreatic
cancer, esophageal cancer, gall bladder cancer, bronchial cancer and endometrial
carcinoma respectively [69] [71] signifying the critical role of inflammation in cancer
growth. In contrast, a chronic cutaneous inflammatory condition, psoriasis depicts an
inflammatory state that is rarely associated with cancer risk [72]. On the other hand,
exposure to environmental cues can also potentiate chronic inflammation. Long-term
exposure to cigarette smoke can cause chronic obstructive pulmonary disease (COPD),
a potential risk factor for lung cancer by activating IKK-β/NF-κB and JNK-1 dependent
inflammation [73] [74]. Dostert et al demonstrated that the Nalp3 inflammasome present
in asbestos/silica particulate matter contribute to hepatic fibrosis and lung cancer by
release of pro-inflammatory cytokine IL-1β [75]. Also, obesity can play a role in
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development of hepatocellular carcinoma by release of inflammatory mediators like IL-6
and TNF-α [76].
Several studies showed the pro-inflammatory role of ET-1 in the pathogenesis of many
infectious diseases like bacterial meningitis, cerebral malaria, HIV encephalitis, sepsis
and chagas disease in addition to its function as a potent vasoconstrictor [77]. ET-1 is
ubiquitously expressed by the endothelium throughout the body in normal physiological
conditions, however, in response to external stimuli such as hypoxia, cytokines, reactive
oxygen species, angiotensin II or shear stress exerted on the endothelium facilitate
increase secretion of ET-1 [78]. Elevated levels of ET-1 is found in macrophages [79],
fibroblasts [80], mesenchymal stem cells [81] neutrophils and leukocytes [82].
Interactions of these cell types with each other and with the tumor cells is believed to
drive inflammation associated cancers. The cellular cascade of events mediated by ET-1
within the tumor microenvironment releases various cytokines and chemokines,
promotes trafficking of immune cells and play a crucial role in tumor growth and
progression.
4.1. ET in fibroblasts
The strength and elasticity provided by the extracellular matrix components play
a major role in maintenance of cellular architecture and tissue homeostasis. In normal
wound healing, inflammatory cells are recruited to the site of injury to remove necrotic
and apoptotic cells followed by limited deposition of ECM. In pathological conditions, due
to excessive scarring or repeated injury, the conditions persist and inflammation fails to
decrease and eventually contribute to development of fibrosis, which is commonly
observed in idiopathic pulmonary fibrosis, hepatic fibrosis and systemic sclerosis [83]
[84]. An increasing body of evidence indicate the induction to various cell types such as
resident fibroblast, stellate cells, vascular pericytes, circulating bone marrow derived
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monocyte to a myofibroblast like phenotype upon ET-1 stimulation [85]. The role of ET-1
as a pro-fibrogenic factor in the pathologies of various organs has gained considerable
attention and interest as witnessed during the last decade. Mechanistic and
experimental evidences implicate the regulation of ET-1 at the transcriptional level.
Several factors such as shear stress, hypoxia, TGF-β, IFN-γ, angiotensin II and thrombin
up-regulate; whereas, nitric oxide down regulate the expression of ET-1 mRNA [86] [87].
The involvement of ET-1 in diverse biological processes can be attributed to its
interaction with various transcription factors such as GATA, Smad, TGF-β and activator
protein-1 (AP-1) [23] [88].
The pro-fibrotic role of ET-1 in lung pathology is well studied. Elevated levels of
ET-1 peptide and ET receptors are associated with scleroderma associated lung
disease.

In addition, increased concentrations

of

ET-1 in the plasma and

bronchoalveolar lavage (BAL) fluids of patients with scleroderma and idiopathic
pulmonary fibrosis is reported [89] [90]. Fibroblasts isolated from the lungs of systemic
sclerosis patients showed elevated levels of ET-1; and ET-1 applied to lung fibroblasts
induced a contractile phenotype with enhanced expression of alpha smooth muscle actin
(α-SMA) that could be reversed by antagonizing ET-1 signaling [91]. In a lung fibroblast
cell line, ET-1 via ETA receptor showed a dose and time-dependent increase in the
CTGF and α-SMA by a JNK-AP1 dependent pathway [92] or by acting downstream of
TGF-β

signaling

pathway

[93].

In

vivo

evidence

suggests

increased

ET-1

immunoreactivity in the epithelium surface and inflammatory cells of bleomycin-induced
lung fibrosis has a significant effect on collagen deposition upon treatment with dual ET
receptor antagonist, Bosentan [94] [95], suggesting the ET-1/ET receptor axis an
attractive target for treatment of lung fibrosis. The first large, multinational, double blind
clinical study to test the efficacy of Bosentan in IPF patients was BUILD-1 (Bosentan
Use in Interstitial Lung Disease). Pharmacologial inhibition of the axis in patients with
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IPF did not show superiority over placebo [96]. Compare to BUILD-1, a second clinical
trial BUILD-3 failed to provide any improvement in the length of life using the primary
end point analysis in IPF patients [97]. In context of liver fibrosis, activation of hepatic
stellate cells is a central event, which subsequently progresses to cirrhosis from
prolonged injury, results in excessive scarring. ET-1 is constantly produced by liver
parenchymal cells and stellate cells in response to injury and induces a pro-fibrogenic
response in an autocrine and paracrine manner [98]. ET-1/ET receptors signaling in
stellate cells promotes proliferation, enhanced contraction, increase hepatic resistance
and blood flow, which is abrogated by the mixed ETA/ETB antagonist Bosentan and
ROCK inhibitor [99] [100] [101] [102]. In fact, ET-1 increases TGF-β expression and
collagen synthesis by eliciting Ca2+ release, however selective blockade of ETAR
inhibits collagen deposition [103] [104] [105]. Further, pre-clinical studies also indicate
the anti-fibrotic effects of ETAR antagonism by ambrisentan and darusentan by inhibiting
the activation of stellate cells, extracellular matrix synthesis and ischemia respectively in
animal models [106] [107]. The pro-fibrotic actions of ET-1 and its ability to promote
major phenotypic transformation in hepatic fibrosis are regulated by many factors. Tumor
necrosis factor-α (TNF- α) has shown to increase ET-1 levels in rat hepatic stellate cells
through an IKK-JNK dependent signaling [108]. In human stellate cells, treatment with
angiotensin II and TGF-β stimulate ET-1 release by stabilization of ET-1 mRNA by a
PI3K/AKT dependent pathway which was abolished by ETAR (BQ123) and Ang-II
(losartan) blockers [109] [110]. In addition, studies by Zhan and co-workers
demonstrated the effects of ECM protein fibronectin in enhanced ET-1 release from
activated stellate cells in an integrin and ERK dependent fashion [111]. The beneficial
effects of ET axis antagonism encourage the use of testing of antagonists in clinical
settings; however liver toxicity observed in patients with pulmonary hypertension limits
it’s use [112]. In a double-blind randomized study, treatment with BQ123 and BQ788 on

15
hemodynamics in liver cirrhosis patients fails to provide significant benefit over palcebo
control; suggesting the use in clinical settings warrants further investigation [113].
All three ET isoforms and both receptors are present in the kidney and the
expression of ET-1 and ETAR progressively increase with nephritis [114]. The podocytes
cells present in the Bowman’s capsule, and mesangial cells express increased levels
ET-1 and receptors in response to cytoskeletal remodeling and glomerular permeability
[115] [116] [117] [118]. In renal physiology and pathophysiology, ET-1 plays a pleiotropic
role in cell proliferation, podocyte dysfunction, inflammation, fibrosis and pathobiology of
the chronic kidney disease [119]. Enhanced expression of ET-1 and the ETBR is
reported in glomerular endothelial cells in patients with renal disease, with no difference
in ETA receptor expression [120] [121]. From the perspective of fibrosis, over expression
of ET-1 and ET-2 in transgenic mice and rats respectively is associated with kidney
pathophysiology,

pronounced

renal

fibrosis,

collagen

accumulation

and

glomerulosclerosis [122] [123]. Increased production of ET-1 in renal vessels is
correlated with increase resistance and collagen I formation in hypertensive rats [124].
Treatment with recombinant TGF-β2 increase tissue ET-1 levels and fibrosis, however,
systemic treatment with TGF-β2 neutralizing antibody, CAT-152 ameliorates the disease
[125] [126]. Inhibition of ET signaling has pronounced effects in various renal injury
models; with attenuation of fibrosis, hypo cellularity, a decrease in the ECM matrix
components, and regression of vascular fibrosis. [127] [128] [129]. Compare to hepatic
fibrosis, the pro-fibrogenic outcomes of ET-1 are mediated by Ang II where increased
accumulation of collagen I is observed, and treatment with either ET receptor or Ang II
inhibitors reduces the renal fibrogenic response by blocking TGF-β signaling [130] [131].
Despite of their encouraging results in pre-clinical settings, ET axis antagonists achieved
moderate success in clinical trials. In diabetic nephropathy patient treatment with ETAR
inhibitor Avosentan was associated with congestive heart failure, although a reduction in
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proteinuria was observed [132]. In a randomized double blind study, a protective effect
of avosentan in combination with sitaxsentan (ETAR selective) was observed in kidney
and hearts in patients [133]. In a separate study, another ETAR antagonist, Atrasentan in
combination with a renin-angiotensin system blocker reduces albuminuria and provided
better renal outcome than Atrasentan alone [134] [135].
4.2. ET in Immune System
The biological role of ET-1 in immune response and regulation of the immune
microenvironment is well documented. The classic antigen presenting cells, dendritic
cells (DC), which are responsible for anti-tumor immunity, also produce ET-1 ligand and
express both functional ET receptors, at significantly increased levels during DC
maturation. However, in the context of DC maturation, both receptors display reciprocal
effects, posing a unique target for immunotherapy [136]. Guruli et al. showed that
selective targeting of ETAR using Atrasentan promotes DC apoptosis, decrease
expression of DC marker CD83 and cytokine IL-12, and abrogates the ability of DCs to
stimulate T cells. However, ETBR blockade by A192621 counteracted the effects of
ETAR antagonism and promoted DC survival, implicating the involvement of autocrine
and paracrine loops in DC function and maturation. Additionally, stimulation of human
monocyte derived DCs with TLR2 and TLR4 agonists enhanced ET-1 production in a
dose and time dependent manner, which could subsequently be inhibited by a HIF-1α
inhibitor [137]. In addition to DCs, both ET receptors are present in B-lymphocytes, a
subset of T cells (CD4 and CD8), monocytes and neutrophils isolated from normal and
systemic sclerotic patients [138] [139]. Compared to normal B cells, over expression of
ET-1 and ETAR is reported in circulating chronic lymphocytic leukemia B cells. Moreover,
ET-1 mediated survival; proliferation and drug resistance was abolished by ETA receptor
antagonism [140]. In addition, B cell depletion with rituximab blunted ET-1 mRNA levels
in response to placental ischemia [141]. In human ovarian tumors, transcriptional
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profiling of endothelial cells suggests over expression of ETBR and is correlated with
poor prognosis and absence of T infiltrating lymphocytes (TILs). Moreover, blockade of
ETBR by BQ788 leads to an increase in intercellular adhesion molecule-1 (ICAM-1)
expression, increased T cell homing and adhesion to tumors [142]. In contrast, selective
ETAR inhibition prevents the stimulation of ICAM-1 and recruitment of anti-tumor immune
cells [142]. Altogether, these studies suggests the potential of ET axis in cancer
immunotherapy and underscore an inverse association of ETAR and ETBR where dual
ET receptors antagonism target tumor cells and enhance T cell infiltration by ETAR and
ETBR respectively. Recently, study in malignant gliomas demonstrated an increased
expression of ETBR with tumor grade correlated with fewer infiltrations of cytotoxic T
cells (CTLs), signifying the critical role of ETBR signaling in the homing of T cell
population to tumors [143] [144]. In contrast, ETBR expression correlated with microvessel density and tumor angiogenesis in oesophageal squamous cell carcinoma and
not with TILs [145]. In hemolysis-elevated liver enzymes-low platelet (HELLP) syndrome,
ETAR antagonism decreased ET-1 and IL-17 levels and was accompanied by paucity of
CD4+ and CD8+ T lymphocytes [146]. Additionally, in multiple sclerosis signaling
through ETAR induced IL-17 secretion from CD+T cells and was significantly inhibited by
BQ123 [147]. Also, in granulomatosis polyangiitis (GPA) patients, ETBR expression in
the lesions T lymphocytes predominates the ETAR expression [148]. Further,
characterization of ET-1 promoter identified two binding sites for nuclear factors of
activated T cells (NFAT) [149], which is a key regulator of T cell development and
function [150]. In both pulmonary arteries and osteoblasts, ET-1 activates calcineurin
and promotes nuclear transport of NFAT, which indicates a potential interaction within
the immune microenvironment [151] [152]. In transgenic mice, over expression of ET-1
significantly increased the density of CD4+ T cells compared to age matched controls
[153].
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Several observations have also linked the orchestrated actions of ETs in
neutrophils, monocytes and macrophages within the complex host microenvironment.
Previous studies have indicated contradictory roles of ETs as chemoattractant for
monocytes and neutrophils. ET-1 ligand has been earlier shown to be strong chemo
attractant [154] or non-chemo attractant for blood monocytes [155]. Interestingly, a 31
amino acid bioactive peptide exhibited significant chemotactic activity towards
monocytes and neutrophils compared to 21 amino acid ET-1 peptide and big ET-1. The
enhanced chemo taxis is complemented by increase in intracellular calcium levels and
was inhibited by selective A receptor antagonism (BQ123), and not by selective B
receptor inhibition (BQ788) [156]. Also, ET-1 induced a chemo kinetic migration of rabbit
peritoneal monocytes dependent on ETA receptor [157]. In addition to ET-1, interaction
of ET-2 and ET-3 with both ETAR and ETBR stimulated migration of neutrophils in a
concentration dependent manner [158] [159]. Grimshaw et al. reported that hypoxia
induced increase in ET-2 production act as a chemo attractant for macrophages and
monocytes dependent on ETBR, indicating a possible role of ET-2 in facilitating the
recruitment of inflammatory cells [56] [160]. In human monocytes, ET-1 has been shown
to stimulate pro-inflammatory NF-κB pathway and drive the expression of CD40 but not
IL-6 in an ETAR dependent manner [161] [162]. Moreover, infection of the U937
monocytic cell line with Chlamydia pneumonia increased expression of ET-1, further
indicating its possible involvement in acute and chronic inflammation [163] [164]. Also,
Trypanosoma cruzi infection in cardiac myocytes induces pro-inflammatory mediators
and ET-1 release and subsequent activation of NFAT signaling pathway [165]. More
recently, in apolipoprotein E knockout transgenic mice, ET-1 over expression in the
endothelium increases oxidative stress, inflammation and monocyte/macrophage
accumulation [166]. However, reduction in macrophage dependent inflammation in Csf1
mutant mice with over expressing ET-1 diminishes vascular injury and the inflammatory
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cell population [167]. Within the tumor microenvironment, autocrine and paracrine
signaling between the cancer cells and macrophages accelerate the infiltration towards
the inflamed sites. In bladder cancer, ET-1/ETAR interaction increases migration of both
tumor cells and tumor-associated macrophages (TAMs) with enhance production of IL-6,
MMPs and CCL2, accompanied by increase in metastatic colonization in the lung via
ruptured vascular integrity. Interestingly, dissemination of tumor cells and diminution of
TAMs is blocked by ETAR antagonist, zibotentan [168].In an experimental breast cancer
model, ET axis mediates lung metastasis and trans-endothelial migration of breast
cancer cells stimulated by macrophages [169]. Additionally in a rat model, stromal
deficiency of the ETBR was correlated with reduced metastatic spread, infiltration of
TAMs and production of TNF-α, suggesting a pivotal role of the ETBR in tumor
progression [170].
4.3. ET in endothelial cells
In addition to its potent mitogenic effect on fibroblasts, smooth muscles and
tumor cells, ETs also control the proliferation of blood and lymphatic endothelial cells.
Interaction of ET-1 and ET-3 with ETBR stimulate the proliferation and migration of
endothelial cells in a dose dependent manner [171] [172] [173]. In endothelial cells, ET-1
modulates the angiogenesis process and exhibits a potent effect in combination with
VEGF. ET-1 stimulates release of MMP-2, which allows sprouting and migration of
endothelial cells and formation of vascular cord-like structures indicating that ET-1/ETBR
interaction favors neovascularization in concert with VEGF [174] [175]. Previous
observations demonstrated that both VEGF and ET-1 stimulate each other’s expression.
In bovine aortic endothelial cells, VEGF induces ET-1 mRNA expression and ET-1
secretion while in vascular smooth muscle cells, ET-1 acts on ETAR to stimulate VEGF
mRNA and VEGF secretion [176], showing a coordinated role of VEGF and ET-1 in a
physiological conditions. In pathological conditions, including angiogenesis and lymph
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angiogenesis, the levels of VEGF and ET-1 are influenced by various environmental
cues, including hypoxia. Some of the earliest evidence about the role hypoxia in
influencing endothelin expression comes from the studies by Kourembanas et al. who
demonstrated that oxygen tension increases ET-1 transcription and secretion in
endothelial cells [177] by induction of the AP-1 transcription factor [178]. Under normal
oxygen conditions, HIF-1α is subjected to proteasomal degradation by E3 ubiquitin
ligase complex, catalyzed by the prolyl hydroxylase domain (PHD), which acts as an
oxygen sensor [179]. However, during oxygen tension conditions, HIF-1α is stabilized
and binds to hypoxia responsive elements (HREs) to induce transcription of angiogenic
genes such as ET-1, VEGF and erythropoietin [180] [181] [182]. In cancer cells, ET-1
stabilizes HIF-1α in normoxic and hypoxic conditions by inhibiting PHD2 expression and
promoter activity by acting on the ETAR and ETBR, indicating that a reciprocal
relationship exists between ET-1 and HIF-1α [183] [184]. In chondrosarcoma cells as
well, ET-1/ ETAR interaction promotes tumor growth and angiogenesis by inducing HIF1α and VEGF levels [185]. Also, in human lymphatic endothelial cells, ET-1 control the
stability of both HIF-1α and HIF-2α by promoting its nuclear accumulation and by down
regulating PHD2 hydroxylation [186]. Once stabilized, the ET axis promotes and
interacts with the HIF-1α dependent machinery to drive the expression of VEGF family of
proteins VEGFA, VEGFB, VEGFC and VEGFR3 receptor [64] [175]. Indeed a reciprocal
interplay exists within the hypoxic microenvironment mediated by HIF-1α/HIF-2α in
melanoma and endothelial cells linking ET-1/ETBR to VEGF A/C accelerating
neovascularization and tumor growth, signifying the presence of autocrine/paracrine
circuit [187]. Within the tumor microenvironment, β-arrestin controls ET-1 and VEGF
activity epigenetically by interacting with HIF-1α, and ET-1 itself to modify the
microenvironment by driving the expression of chemokine receptors dependent on ETAR
and hypoxic machinery [188] [189]. In many solid malignancies, increased ET-1 and ET
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receptors expression is coupled with increase VEGF expression. In ovarian carcinoma,
increase expression of ET-1 and both GPCRs is significantly correlated with VEGF
expression and micro vessel density implying a mutual relationship between ET-1 and
VEGF during neovascularization, as this angiogenic response can be altered by ET
receptor blockade [190]. In addition to ET-1, HIF-1α also modulates and stabilizes ET-2
and acts as a survival factor in breast tumor cells via ETBR signaling [54]. In breast
carcinoma, a significant relationship exists between HIF-1α and the pro-angiogenic
genes, ET-1 and VEGF-C, where enhanced invasion of MCF-7 mediated by ET-1 is
counteracted by the ETAR antagonist atrasentan [191] [192]. Expression of ET-1, ETAR
and ETBR has been correlated with VEGF expression, intratumoral vascularization,
increased lymphatic dissemination, and the elevated levels of ETAR in primary breast
cancer are associated with decreased overall diseased free survival [193]. Furthermore,
studies have shown that ET-1 induces lymphatic vessels to grow and invade. ETBR and
ET-1 were significantly upregulated in lymphatic endothelial cells derived from metastatic
lymph nodes, suggesting the role of ET-1/ETBR signaling in angiogenesis and lymph
angiogenesis [175] [194] [195]. Interestingly, mathematical modeling and global
transcript analysis of melanoma cell lines identified ETBR as one of the genes linked with
aggressive phenotype and the ability to form tubular networks in the absence of
endothelial cells thus mimicking a true vascular endothelium [196]. The de novo
generation of capillary like channels is known as vasculogenic mimicry [197]. Very
recently research in melanoma cells, showed ET-1 induced phosphorylation of VEGFR3,
MAPK and AKT formed tubular capillary network via ETBR signaling. Moreover, in
combination with VEGF-C, a synergistic effect was observed in fostering vasculogenic
mimicry [198].
In addition, in ovarian carcinoma ET-1/ETAR interaction stimulated downstream
activation of cyclooxygenase (COX) 1/2 and production of prostaglandin E2. COX
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inhibitors inhibit the angiogenic effect mediated by ET-1 to stimulate VEGF levels,
specifying its role neovascularization [199]. Also, elevated levels of COX1 is reported in
ovarian cancer and enhanced expression is associated with tumor regions undergoing
extensive angiogenesis that have pro-angiogenic VEGF and HIF-1α levels [200].
Exposure of endothelial cells to hypoxic conditions induces expression of COX1 and
COX2, however treatment with the non-selective COX inhibitor, indomethacin reversed
the hypoxic effects and ameliorate endothelial cell injury [201]. ET-1 significantly
increases COX-1 and COX-2 by increasing their promoter activity; and pharmacological
inhibition of COX-2 using NS-398 significantly impaired the levels of ET-1, PEG2 and
VEGF [202]. Selective ETAR inhibition by atrasentan and ZD-4054 drastically reduced
the expression of angiogenic and invasive mediators such as COX 1/2, VEGF and
MMPs, thus implicating that the VEGF and COX genes acts downstream of the ET-1
gene and aid in neoangiogeneis [203] [202].

5. Endothelin in Normal Pancreas
5.1. Role in pancreatic islet cells
The effect of endothelium derived vasoactive peptide ET-1 on the islet cells of
the pancreas has been well studied and been shown to support the pancreatic beta cell
function (Figure 2). Co-immunostaining studies performed in human and rat tissues
using islet specific hormones suggest the presence of the ET-1 and endothelin receptors
[204]. In both human and rat islet beta cells, positive staining for the components of
endothelin axis was observed. In addition, alpha cells of the human islets show
colocalization only with ET-1; however, rat islet shows weak immunoreactivity for
receptor A and positive staining for receptor B and ET-1. As opposed to beta and islet
cells, somatostatin-expressing delta cells show no expression with ET-1 and ET
receptors in human pancreas. The presence of ET-1 and its receptors were also
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confirmed in rat beta cell lines INS-1 and RINm5f by radiolabel binding studies with ET-1
using selective inhibitors for ETAR and ETBR respectively. Kakugawa et al. also reported
the presence of ET-1 like immunoreactivity in the normal pancreatic islets and it was
shown to co-exist with insulin and glucagon but not with somatostatin [205], indicating an
insulinotropic role for ET-1. The ET-1 stimulated glucose induced insulin release by
direct action on mice islets was also observed by Gregerson et al. [206] and involved
calcium ions influx indicating direct involvement in glucose homeostasis. The
insulinotropic effect of ET-1 is mediated by the endothelin A receptor involving PKC
activation, as the specific inhibitor BQ123 attenuated the secretion while specific ETBR
antagonist BQ3020 did not alter the glucose stimulated release [207]. In contrast, Brock
et al. suggested that the mechanism of insulin release is an indirect effect due to
paracrine activation from the alpha cells of pancreatic islets. Using purified beta cells
from normal rat islet and three beta cell lines (INS-1, MIN6 and βTC3), exogenous
administration of ET-1 failed to elicit insulin secretion. In addition, competitive receptor
binding studies on βTC3 cells displayed no specific binding, with only ETAR expression
in rat islet and alpha cell line αTC1.9. Alternatively, ET-1 potentiated the release of
insulin when both purified beta and non-beta cells were mixed in presence of glucose
[208]. In a rat experimental model, Zimmerman and Maymind described a decrease in
the blood glucose levels and enhanced insulin release within 15 minutes after infusion of
ET-1 in anesthetized rats. This increase in the insulin level was associated with a
decrease in the glucagon hormone levels suggesting a possible impact on the endocrine
pancreas [209]. Another possibility is that nitric oxide (NO) release, due to ET-1
stimulation contributes to insulin secretion, as the nitric oxide inhibitor N-monomethyl-Larginine (NMLA) abrogated insulin release; signifying the involvement of endothelium in
the pancreatic islet contributes to ET-1 induced insulin secretion [210]. In healthy human
subjects, pharmacological infusion of ET-1 intravenously reduced the splanchnic blood
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flow. Interestingly, this decrease is shadowed by a significant reduction in glucose
concentration, splanchnic glucose production, and a transient decrease in insulin and
glucagon levels [211] [212]. The inconsistency observed in both human and rat
experimental model system can be accredited to species specific differences, structural
differences and distribution of the receptors [204].
In addition to ET-1, Carlo and his colleagues also evaluated the insulinotropic
role of ET-3 in isolated rat islets. Both ET isoforms stimulated insulin release in rat islets
when cultured in presence in medium containing a physiological concentration of
glucose and calcium, indicating a direct interaction with the islets. Alternatively,
incubation in glucose and calcium deprived medium abrogated the release. The
difference in insulin secretion mediated by ET-1 and ET-3 can be explained on the basis
of the structural disparities and their binding affinities towards the ET receptors [213].
Additionally, evidence for insulin stimulated ET-1 release is also reported in in vitro
studies. In bovine endothelial cells insulin stimulates the secretion and production of ET1 in a dose related fashion through a PKC dependent mechanism [214] [215] [216]. This
insulin-mediated release of ET-1 was also reported in human endothelial cells when
cultured in presence of glucose [217]. In contrast, exposure of porcine endothelial cells
to hyperglycemic conditions resulted in reduction of immunoreactive ET-1 secretion
[218]. Interestingly, studies have demonstrated elevated levels of ET-1 are positively
associated with both Type I (insulin dependent) and Type II (non-insulin dependent)
diabetes mellitus. Haak et al. observed increase plasma endothelin levels in 69 patients
and 83 patients of Type II and I respectively as compared to 152 controls patients [219].
Additionally, in patients with non-insulin dependent diabetes mellitus (NIDMM) and
insulin dependent diabetes mellitus (IDMM) circulating levels of ET-1 are higher as
compared to controls [220]. Using radioimmunoassay analysis Takahaski and his
colleagues demonstrated significant increase in the levels of ET-1 as compared to
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healthy controls [221] with no change in the ET-2 and ET-3, signifying the crucial role of
ET-1 peptide on the endocrine pancreas. Examination of the circulating peptide
concentrations in diabetic patients and obese hypertensive patients indicate that
hypersinsulinemia is a potent inducer of ET-1 in humans [222] [223]. On the contrary,
Bertello et al. did not observe any changes in the plasma ET-1 levels in patients with
NIDMM compared to healthy human subjects [224]. Despite its role in enhanced insulin
production, studies also indicate that the ET-1 peptide modulates glucose metabolism by
inducing insulin resistance by inhibiting beta cell function. In a rat model, intraperitoneal
administration of ET-1 increased plasma glucose level in dose dependent fashion by
lowering the insulin sensitivity [225]. Additionally, in healthy human subjects
exogenously administered ET-1 reduces the glucose uptake in skeletal muscle causing
insulin resistance with no effect on its vasoactive role [226]. In a randomized study
involving healthy men, pharmacological elevation of ET-1 following intravenous
administration abolished insulin release with simultaneous reduction in C-peptide
secretion but did not alter insulin sensitivity [227]. Further evidence of a role for ET-1 in
reducing the insulin sensitivity, comes from hyperinsulinemic NIDMM patients, where a
negative correlation exists with total uptake of glucose and circulating plasma ET-1
peptide levels [228]. Measurement of insulin sensitivity in response to intravenous
glucose using minimal modeling technique indicates that the association between insulin
release and beta cell is linked via close loop feedback system involving mutual
alterations in insulin release and sensitivity [229] [230]. Kahn et al further strengthen this
close coordinated relationship in healthy human subjects and suggested the relationship
between beta cells and insulin sensitive tissues is dictated in a hyperbolic manner and
alterations in insulin release have a minuscule effects on insulin sensitivity [231].
5.2. Role in pancreatic acinar cells
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Similar to islet cells, pancreatic acinar cells also express endothelin receptors
(Figure 2). Using radiolabeled binding studies in rat model; high specific affinity
receptors for all three forms of endothelins were identified, with ETA subtype present in
higher numbers compared to ETBR. Additionally, further studies from the same group
also indicate that ET isoform 1 and 2 bind to the ETA subtype whereas ET-3 binds only to
the ETBR. Indirect interaction of ET receptors with phospholipase C pancreatic
secretagogues favors internalization of the receptors and reduces the binding of ET
peptides by activation of protein kinase C without altering the intracellular calcium levels
[232]. In contrast, Yule et al. demonstrated that exposure of acini cultured in calcium free
medium to ET-1 induces the release of intracellular calcium levels similar to
cholecystokinin (CCK) although with less potency. Interestingly, as opposed to CCK or
other PI-PLC like agonists, ET-1 failed to stimulate amylase secretion [233]. Similar to
previous reports, the presence of receptor B was also seen in the rat acinar cells using
anti-serum against the specific amino residues of the ETBR [234].
5.3. Role in pancreatic microcirculation
The impact of potent vasoconstrictor, ET-1, on pancreatic microcirculation is well
studied in many species due to its significance in regulating blood flow under
physiological conditions. Takaori and his colleagues utilized anesthetized mongrel dogs
and evaluated the effect of all three ET isoforms on pancreatic blood flow. Both ET-1
and ET-3 decrease the pancreatic blood flow in a dose dependent fashion, with more
potency than the effects observed with ET-2, without significantly alerting systemic blood
pressure. Interestingly, no effect in the liver was reported indicating the specific effect of
ETs on pancreas vasculature [235]. Similarly, in an experimental rat system, topical
superfusion of 100 pmol ET-1 in exteriozed pancreas significantly reduced the blood flow
velocity accompanied by stasis of red blood cells (RBCs) as compared to control
animals. In addition, administration of ET-2 and ET-3 also diminished blood flow velocity
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in a dose dependent manner although with less prominent effects as compared to ET-1.
This decrease in pancreatic microcirculation is paralleled by reduced functional capillary
density, with ET-1 being more potent followed by ET-3 and ET-2 [236] [237]. Using a
microsphere technique Lai et al. characterized the effects of exogenous ET-1 on the
vasculature of pancreatic islets [238]. A few minutes after administration, 5nmol/kg dose
of ET-1 significantly decrease perfusion in pancreas islets with minuscule effects on the
blood pressure. Interestingly, islets were more responsive to the vasoconstrictive effects
caused by ET-1 as compared to exocrine pancreas blood vessels. However, this
decrease was not attenuated either in presence of selective A receptor antagonist
(BQ123) or selective B receptor antagonist (BQ788) when used alone or in combination.
The inability of selective A and B receptor antagonists to reverse the ET-1 mediated
effects indicate the involvement of a third ET receptor subtype. Cloning and
characterization of ETC receptor form Xenopus laevis dermal melanophores suggest
high affinity for ET-3 peptide and a 47% and 52% sequence similarity with ETAR and
ETBR respectively that could possibly explain persistent vasoconstriction. However, the
mammalian complement is yet to be recognized [50]. Analogous to the effects observed
with exogenous ET-1, the vasoconstriction caused by endogenous ET-1 in rat pancreas
was also not hindered by BQ123, however surprisingly BQ788 diminished the total
pancreatic and islet blood flow. Selective antagonism of B receptor impedes the release
of nitric oxide (NO) responsible for vasodilation, which explains the reduced blood flow.
Another possibility is that, in addition to its role as a vasodilator, ETB receptors also act
as “clearance” receptors for endothelins [239]. Fukuroda et al. demonstrated that
intravenous infusion of BQ788 but not BQ123 reduced the uptake of
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I-ET-1 in the

lungs and significantly inhibited the clearance of ET-1 from circulation [240]. Also, in
transgenic ETBR deficient mice, increased circulating levels of ET-1 is reported provides
further support for the role of ETBR in clearance [241]. Additionally, ex vivo, perfusion
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caused by ET-1 in isolated mice islets is reversed by ETAR and ETBR antagonism;
indicating the presence of both receptors on the islets.

6. Endothelins in Pancreas Pathophysiology
6.1. Role in Pancreatitis and Inflammation
The deregulation of pancreatic microcirculation and capillary leakage plays a
major role in the pathogenesis and is hallmark of severe pancreatitis. A growing body of
literature suggests that these microcirculatory disorders facilitate necrosis of acinar cells,
release of proteases, activation of pro-inflammatory cytokines, the infiltration of
neutrophils, and are believed to contribute to organ dysfunction [242] [243] [244].
Alterations in the pancreatic blood flow may include activation of endothelial cells and
release of endothelin peptides, which are important mediators in the determining the
pathophysiology of pancreatitis [245] [246]. Plasma endothelin-1 levels correlate with
pancreatitis severity and are a useful indicator for diagnosis. Using enzymoimmunological analysis Milnerowicsz et al. demonstrated that the plasma ET-1
concentration in patients with severe acute pancreatitis with necrosis was 6.37± 1.9
pg/ml as compared to control 1.37 pg/ml. Additionally, patients with severe acute
pancreatitis without necrosis, mild acute pancreatitis and chronic pancreatitis had
increased levels of ET-1 [247]. Additionally, immunohistochemical localization of ET-1
shows a significant correlation of ET-1 immunostaining and the degree of severity in
patients with chronic pancreatitis [205]. Further, a marked increase in the plasma ET-1
levels and strong immunohistochemical reaction for ET-1 is reported in individuals who
smoke and in patients with chronic pancreatitis compared to non-smoking healthy
subjects [248]. Additionally, Borissova et al. and Goerre et al. also demonstrated a
significant increase in plasma ET-1 levels after exposure to cigarette smoke [249] [250]
suggesting a direct effect of tobacco smoke on the peptide release. The elevated levels
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of ET-1 exhibit positive correlation with orocecal transit time (OCTT) indicating a close
association with gastrointestinal dysmotility in patients with acute pancreatitis [251].
Moreover, elevated serum concentration of ET-1 in circulation is associated with
leukocytosis and correlates with AP and multi-organ dysfunction syndrome [252].
Though well studied in context of acute pancreatitis (AP) and in experimental
disease systems, doses, time of application, and the effects of endothelin-1 and its
antagonists are controversial, as ET-1 has been shown to play dual role in both
protection and disease aggravation. Gene expression profiling of dibutyltin dichloride
(DBTC) induced pancreatitis in Lewis rats revealed upregulation of ET-1 as the
candidate gene associated with pancreatic inflammation. In addition, treatment with
selective ETAR (BQ123) and ETBR (BQ788) inhibitors reverses the inflammatory
response [253]. Zhang et al. observed in a severe acute pancreatitis model that therapy
with the anti-inflammatory dexamethasone drug significantly reduced levels of ET-1 and
NO compared to sham operated animals [254] [255]. Zhang et al. also reported that
retrograde infusion of sodium taurocholate in a multiple injury model of pancreatitis
showed a remarkable increase in serum ET-1 levels [256]. Assessment of early
pathological abnormalities included evident edema and necrosis in the pancreas and
multiple organ injury accompanied by prominent increase in levels of ET-1, NO, IL-6,
TNF-α and PLA2 in severe AP induced by sodium taurocholate [257].
Similar to sodium taurocholate induced pancreatitis, histological examination
after topical ET-1 administration induces alterations in tissue integrity, profound edema,
focal acinar cell necrosis and a marginal increase in serum amylase levels compared to
control group [237]. Liu et al. observed that in presence of ET-1 cerulean-stimulated
acute pancreatitis exhibit remarkable changes in pancreas morphology. This was
followed by hemorrhage and an increase in serum amylase and elastase levels.
Interestingly, intra-aortal infusion of ET-1 alone failed to alter the pancreas integrity
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[258]. Foitzik et al. also observed similar results where ET-1 superimposed on mild acute
necrotizing pancreatitis (ANP) favored acinar and peripancreatic fat necrosis with
prophylactic treatment of ETAR antagonist LU-135252 ameliorating the disease. Also, a
synergistic effect is witnessed in capillary blood flow reduction in rats infused with
alcohol and ET-1 and was subsequently reversed by ETAR antagonist LU-135252 [259].
In addition, transgenic mice with ET-2 over-expression develop severe pancreatitis and
significant increase in acinar cell necrosis with mild increase in trypsinogen activated
peptides (TAP) levels compared with non-transgenic littermates controls [260]. Further,
studies from the same group also suggest a significant decrease in mortality in ANP
induced rats exposed to pharmacological ETAR inhibitor LU-135252 compared to the
untreated group. Pharmacological inhibition using LU-135252 is paralleled by improved
capillary blood flow, stabilized capillary permeability, reduced extravascular fluid
sequestration and intravascular fluid loss, and a decrease in hematocrit concentration
without mitigating signature of disease severity such as acinar cell necrosis [261] [262]
[263]. Activation of trypsinogen and its presence in the plasma is an accurate indicator of
AP and correlates with necrosis, disease severity and hemorrhage [264] [265]. Ultrastructural examination of Wistar rats with AP induced by intra-peritoneal injection of
sodium taurocholate treated with either selective ETAR (LU-302146) or dual ETAR and
ETBR (LU-302872) antagonists reveal a 2-3 fold reduction of trypsinogen activation
index in pancreas tissue, mainly by blockade of ETAR. In addition, pharmacological
inhibition of both the ETA and ETB receptors showed necrosis in a few acinar cells, and
enhanced auto phagocytosis with insignificant effects in recruitment of inflammatory cells
[266]. Additionally, Dlugosz et al. identified similar degree of trypsinogen attenuation and
reduced score of necrosis using either mixed ETA/ETB or ETA inhibitors in AP [267].
Contrasting results were reported by the same group in cerulean induced rat AP treated
with either selective ETAR (LU-302146) or non-selective ETA/ ETB receptor (LU-302872)
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antagonists [268]. Electron microscopy visualization of cellular organelles reveals a
slight increase in vacuolization of acinar cells, with disorganized endoplasmic reticulum,
and total cytoplasm degradation with no alteration in pancreatic edema and necrotic
score upon therapy. Surprisingly, treatment displayed no effects on the trypsinogen
activation index as compared to untreated AP, although infiltration of inflammatory cells
was decreased. The authors rationalize that the difference in the outcomes of ET
receptor antagonism in different models of AP can be explained by discrepancies in the
pancreatic microcirculation. Also, the divergences of potency, dosing of ET inhibitors and
the pancreatitis experimental model system used can explain the contradiction in both
the studies. The decrease in the inflammatory cell population is in harmony with previous
findings as well. Plusczyk et al. demonstrated that pre-treatment with low dose (4mg/kg
body weight) and not high dose (10mg/kg body weight) of ET antagonist Tenzostan (Ro61-0612) is effective in abrogation of pancreatitis induced parenchymal tissue injury,
microcirculatory disorders, improve perfusion and infiltration of leukocytes in the tissue
[269]. An increasing body of evidence indicates that coupling of ET-1 to the ETAR is
responsible for chemotaxis, migration and adhesion of leukocytes and selective targeting
of ETA and not ETB receptor diminish the migration [156] [270] [271] [272]. The high
concentration of the inhibitor used in this particular study mediates simultaneous
inhibition of both receptors while at low dose inhibits only ETAR. The involvement of the
ETB receptor in clearance of ET-1 isoform from circulation and release of vasodilator
nitric oxide (NO) to counteract the release of ET-1 and mediate vasoconstriction is well
studied [240] [273] [274]. Thus, synchronized blockade of both receptors using high
dose of antagonist abolishes the clearance mechanism thereby maintaining high levels
of ET-1, which masks the favorable outcomes of ETAR inhibition indicating that the
coupling of ET peptide with ETAR is associated with pathogenesis of pancreatitis. These
findings were confirmed and extended in a bile salt induced rat pancreatitis model where
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mixed therapy using dual ETA and ETB antagonist Bosentan failed to provide survival
benefit [275].
Contrary to the previous findings, Todd et al. investigated first the consequences
of ET receptors blockade in a murine model of acute hemorrhagic pancreatitis.
Treatment with mixed ETA/ETB antagonist PD145065 decreased the severity of
pancreatitis with no effects in the mortality. Additionally, reduction in serum amylase
levels,

markers

of

systemic

inflammation

(IL-6

and

IL-10)

and

diminished

myeloperoxidase activity was also noted upon treatment [276]. In addition, further
studies by Eibl and co-workers also support the favorable outcomes of ETAR antagonism
over ETBR using LU-135252 which blocks receptor A and B at low (50mg/kg body
weight) and high doses (100mg/kg body weight) respectively. After induction of AP by
retrograde infusion of glycodeoxycholic acid, blockade of ETAR and not ETBR was
effective in stabilizing the capillary permeability; decrease fluid loss and leukocyte rolling
[277]. In addition, an increase in capillary permeability after exogenous administration of
ET-1 in AP is reversed by ETAR antagonism thereby improving the capillary blood flow
and reduced leukocyte rolling. However, simultaneous inhibition of both receptors
displays comparable effects than that ETAR inhibition alone [263] [278]. In a separate
approach to evaluate the efficacy of different therapeutic regimens, Eibl and his coworkers utilized ETAR, platelet receptor activating receptor (PAF) antagonists, and
intercellular cell adhesion molecule-1 antibody (ICAM-1) either alone or in combination in
rats after 6 hours of administration of bile salt and cerulein to induced pancreatitis. In
harmony with previous reports, ETAR antagonist LU-135252 was found to be more
effective than PAF antagonist and ICAM-1 antibody in improving or reducing capillary
leakage. Also, combination therapy of ETAR antagonist either with PAF or ICAM-1 was
found to be more beneficial than the combination of PAF antagonist and ICAM-1
antibody in stabilizing capillary permeability [279]. Similar to previous observation, ETAR
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antagonist LU-135252 was found be more advantageous in enhancing capillary blood
flow and reducing leukocyte rolling than ICAM-1 antibody in a delayed model of AP after
12 hours infusion of glycodeoxycholic acid and cerulein [280].
Despite its role in promoting damage to pancreatic parenchyma and deterioration of
acinar cells, some conflicting reports also suggests the protective role of ET-1 in context
of AP. Kogire and colleagues witnessed decrease in pancreatic edema, acinar cell
vacuolization and inflammatory cells infiltration in pancreas tissue after intravenous
infusion of ET-1 plus cerulein compared to cerulein alone in a rat model system.
Surprisingly, this ET-1 mediated amelioration of experimental pancreatitis was
neutralized by selective ETAR antagonist BQ123 [281]. Martignoni and coworkers
examined the influence of selective ETAR (LU135252 and BSF208075) and nonselective, ETA/ETB (BSF420627) antagonists in three severity groups of AP (4%, 5% and
6% sodium taurocholate). Prophylactic application of both selective and non-selective
antagonists failed to provide survival benefit and restoration of pancreatic damage [282].
Besides its involvement in maintaining the vascular tone, ET-1 also participates in the
synthesis of prostaglandins [283] [284] and beneficial results seen could be dependent
on secondary production of prostaglandins. The cytoprotection offered by prostaglandins
(type A, E or F) in response to noxious agents and anti-inflammatory compounds is
reported in gastric mucosa [285] [286], small intestine [287], kidney [288] and liver [289].
An increasing body of evidence also suggests the protective role of prostaglandins and
its analogs in cerulein and sodium taurocholate induced AP by hindering the activation of
pancreatic digestive enzymes [290] [291] [292] [293]. On a similar note, Dlugosz and coworkers demonstrated the favorable role of all three ET isoforms on the histology and
ultrastructure of the pancreas. Exogenous application is followed by diminution of
trypsinogen activation and reduced polymorphonuclear cells migration in the pancreas;
however aggravating results was seen with ETAR antagonist [294] [295]. In addition,

34
using NF-kB inhibitor (pyrrolidine dithiocarbonate, PDTC) in combination with ET-1 and
ET-3 a synergistic effect was observed in attenuation of trypsinogen activation in
cerulein-induced pancreatitis [296].
Hypovascularity of the pancreas makes it vulnerable to ischemia/re-perfusion
injury and is a major complication associated with graft pancreatitis. Given the
involvement of ET-1 in microcirculatory disturbances of the ischemia/re-perfusion, recent
studies have indicated a beneficial role of ET inhibitors in attenuating disorders in the
liver [297] [298] [299], kidney [300] and small intestine [301]. Recently the blockade of
ET receptors and its impact on the pancreatic transplantation is being addressed in few
studies. In a pig model, selective antagonism of ETAR using BSF 208075 reduces
ischemia/re-perfusion induced injury accompanied by significant reduction in injury to
pancreatic parenchyma and tissue edema. The prophylactic treatment is also paralleled
by decrease in inflammatory cell infiltration and pro-inflammatory cytokine IL-6 and ET-1
levels [302] [303] [304]. Also in a rat experimental model, systemic oxygen perfusion
using nitric oxide gas followed by orthotropic liver transplant reduced ET-1 levels,
neutrophil infiltration and production of prostacyclin [305] [306]. Findings by Marada et
al. suggested the promising effects of cold storage conditions in a pancreas
transplantation model and showed significant reduction in TGF-β and ET-1 levels [307].
Figure 2 describes the sequence of ET-1 mediated events in inflammation.
6.2. Role in Pancreatic Stellate cells and Pancreatic Cancer
Pancreatic stellate cells (PSCs) are the resident cells of the pancreas located in
the peri-acinar region and are characterized by the presence of vitamin A droplets in the
cytoplasm in quiescent state [308]. Once activated in response to external stimuli,
inflammation or injury, PSCs acquire a myofibroblasts like phenotype and secrete
increase amount of extracellular matrix (ECM) proteins rich in collagen. The excess
deposition of this fibrous tissue rich in collagen is termed as fibrosis or desmoplasia,
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regarded as a hallmark for pancreatitis and pancreatic cancer [309] [310] [311].
Literature reports have suggested several extracellular mediators and intracellular
pathways in PSCs activation. The external stimuli include soluble mediators, cytokines,
oxidative stress, hypoxia, TNF-α; platelet derived growth factor (PDGF), ethanol and its
metabolites and TGF-β. Accumulating evidence reveal PDGF as mitogen for PSCs and
TGF-β1 as a main stimulator to induce collagen and α-SMA (smooth muscle actin) to
maintain the pro-fibrotic phenotype of PSCs [312] [313] [314]. In the context of acute
pancreatitis in response to necro-inflammation where the injury is limited, PSC
proliferation occurs at an early stage and is believed to play a role in repair or
regeneration of the pancreas tissue and maintenance of the tissue architecture by
maintaining the ECM turnover. In contrast, in chronic pancreatitis the PSCs are activated
due to repeated inflammatory insults resulting in fibrosis and aggravation of disease
[315]. Additionally, this aggravation results in sustained increase expression of α-SMA
and confers augmented contractile potential. Masumune et al. observed that this
contraction is caused by ET-1 via the ETBR as selective inhibition abolished the
contractility. Additionally, both receptors are involved in enhanced migration of PSCs
isolated from male Wistar rats, revealing the varied role of receptors in response to ET-1
peptide [316]. Further, studies by Stumpe and coworkers implied that excess secretion
of ET-1 from activated but not quiescent PSCs possibly impacts the pathogenesis of
pancreatitis through an autocrine and paracrine loop [317]. To gain mechanistic insights
in the induction and maintenance PSCs activation in pancreatitis, Jonitz and coworkers
observed that treatment of PSCs with TGF-β1 and TNF-α stimulated the secretion of ET1 peptide by increased binding to smad3 and NF-kB respectively. Also, treatment with
ET-1 induced the phosphorylation of ERK1/2 and p38, a marker of PSCs activation (αSMA) and pro-inflammatory cytokines (IL-1β and IL-6) [318]. Nevertheless, dual ETA/ETB
antagonist Bosentan displays an anti-tumor effect in PC cells and anti-fibrotic effects in
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PSCs by marked reduction in the expression of CTGF (connective tissue growth factor)
and α-SMA [319] indicating a pro-fibrogenic role of ET-1 in PC. Previous investigations
have suggested the inhibitory role of interferons in the activation of PSCs and
extracellular matrix deposition in pancreatic and hepatic fibrosis [320] [321] [322]. Using
gene expression analysis in IFN-γ treated PSCs, Fitzner and his group showed down
regulation of the ET-1 isoform and CTGF in a STAT-1 dependent manner [323]. Further,
proteomic analysis of the conditionally generated immortalized human non-tumor
(NPSC) and tumor derived (TPSC) pancreatic stellate cells showed differential
expression of ET-1 with a significant p value in TPSC compared to NPSC cells [324].
Soon after the discovery of ET-1 in 1988 from porcine endothelial cells earlier
reports have also revealed the secretion of all three ET isoforms from pancreatic cancer
cell lines. With specific ET-1 radioimmunoassay, production and concentration of
immuno-reactive ET-1 was detected in PC cell lines, more commonly than CA19-9, CEA
and DUPAN-2 tumor markers. In contrast, ET-2 and ET-3 were detected in only one cell
line tested [325] [326]. Further in vitro and in vivo evidence of ET-1/ET receptor system
in PC comes from the study by Bhargava and his colleagues. Using selective ETA
antagonist LU-302146, the proliferations of three PC cell lines was prominently
decreased. In addition, LU-302146-treated orthotropic tumors displayed reduced tumor
burden and metastatic spread of the disease, reduction in micro-vessel density and
increase in overall survival [327]. In an experimental model of PC, treatment with the
angiotensin inhibitor losartan target pro-fibrotic gene signatures ET-1 and CTGF thereby
enhancing drug delivery and potentiating chemotherapy [328]. Recently, Fukuda et al.
reported the diagnostic method to detect ETBR expression in cell lines and tissues using
an ETBR transfected cells. Immunostaining and immunoblot analysis suggested no
biologically specific staining in PC cells, xenograft tumors and human pancreatic cancer
tissues; however, mild staining in acinar and islet cells was reported [329]. Contrary to
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previous reports, a recent study stated the expression of ET-1 axis in human PC cases.
Cook and his co-workers determined the immuno-histochemical expression of ET-1 and
ETBR in surgically resected human PC specimens and found no expression of ETAR
Additionally, this increase in expression of ET-1/ETBR axis was found to be correlative to
micro-vessel density and VEGF expression [330].

7. Conclusions and Future perspective
The endothelin axis is a critical regulator of various physiological and
pathophysiological processes extending from maintaining vasomotor tone to cancer
progression. The central involvement of this axis in promoting cellular cross talk and
signaling within the human microenvironment holds promise for the future clinical trials.
Given the extensive fibrosis and hypo-vascular nature of pancreatic tumors and its
involvement in fostering the stromal-tumor cell interaction this axis represents a new and
yet unexplored target for pancreatic cancer targeted therapies. Pre-clinical and
experimental studies in different cancer settings with either selective or dual ET receptor
antagonists used as monotherapy or in combination with cytotoxic drugs can provide
considerable therapeutic benefit. Additionally, the favorable effects of ET axis
antagonism observed in fibrosis and vascular disorders further represents a potential
target for cancer treatment. However, systematic targeting of the axis with ET
antagonists in combination with conventional chemotherapy or radiotherapy in PC need
to be evaluated.
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Figure 1: Endothelin axis: molecular components and physiological roles.
Schematic representation of the synthesis of the three isoforms of endothelins. The
primary translational product is a pre-proendothelin form, which is 203 amino acid
polypeptide. This peptide is cleaved by furin like proteases to yield biologically active big
ET-1. Big ET-1 is further cleaved by endothelin converting enzyme (ECEs) to produce
mature ET-1. Amino acids that differ between ET-1 and ET-2 and ET-3 are shown in
yellow. ECEs have four isoforms, ECE-1, ECE-2, ECE-3, and ECE-4 and have different
cellular localization. Once formed the mature peptides can bind to either endothelin A
receptor (ETAR) or endothelin B receptor (ETBR). ET-1 has an equal binding affinity for
both the ETAR and ETBR receptors; however, there is difference in binding affinity for
other two ET isoforms. Both ET receptors belong to G-protein–coupled receptors and
are differentially expressed according to cell type. ETAR is expressed predominantly on
smooth muscle cells whereas ETBR is expressed on endothelial cells. Both receptors are
expressed in various other cell types and regulate diverse functions.
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Figure 2: Role of Endothelin(s) in pancreas physiology. In normal pancreas, infusion
of endothelin-1 (ET-1) stimulates insulin secretion and decreases the blood glucose
levels by acting on the islet cells expressing endothelin A receptor (ETAR) and
endothelin B receptor (ETBR). The insulinotropic action mediated by the ET-1 indicates a
direct involvement in regulating the glucose homeostasis by glucagon release involving
influx of Ca2+ influx and protein kinase C activation. Additionally, in pancreatic acini,
interaction of ET-1 with both ETAR and ETBR induces internalization involving increase in
intracellular calcium with no effects on amylase secretion. Vascular smooth muscle cells
express both ET receptors whereas endothelial cells express only ETBR. In the pancreas
microcirculation, ET-1 acting on the blood vessels induces vasoconstriction, however,
nitric oxide release by ET-1/ETBR interactions favors vasodilation. Administration of ET-1
decreases pancreatic blood flow and perfusion with minuscule effects on blood pressure.
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Figure 3: Role of endothelin(s) in pancreas pathophysiology. In response to stress
due to hypoxia, acute, or chronic insults elevated production of ET-1 induces alterations
in pancreas integrity, promotes acinar cell necrosis, increases in serum amylase and
elastase levels and promotes inflammation. However, the prolonged inflammatory insult
and damage to pancreatic parenchyma and gain of mutations such as Kras can lead to
trans-differentiation of acinar cells to ductal phenotype. The tumor cells expressing ETAR
and ETBR also secrete ET-1, which can interact with different cellular components within
the microenvironment, and promote tumor progression and metastasis. Interaction of
ET-1 with receptors present on the cancer associated fibroblasts and stellate cells
promote proliferation and modulate tumor stroma by increase expression of extracellular
matrix proteins (α-SMA, collagen, fibronectin) thereby promoting fibrosis. In response to
ET-1/ETBR interaction, endothelial cells promote angiogenesis and neo-vascularization
in a VEGF dependent manner. Within in the immune microenvironment, ET-1 signaling
can facilitate chemotactic migration of monocytes and macrophages at the inflamed sites
and homing of T cell population within the tumors.
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1. Background and Rationale
Endothelins (ETs) are family of three 21 amino acid vasoactive peptides; ET-1,
ET-2 and ET-3 that exerts their effects via two G-protein couple receptors ETAR and
ETBR expressed on various cell types. Endothelin-1 (ET-1) is an important signal
messenger in various pathological malignancies including cancer [1] [2]. The peptide
regulates and control different aspects in the cancer progression such as proliferation,
angiogenesis, epithelial to mesenchymal transition (EMT), immune modulation and
metastasis [3] indicating its potential impact on multitude processes in the tumor
microenvironment (TME) of cancer.
Several studies have hinted the involvement of ET-1, ETAR and ETBR in
pancreatic inflammations and are important mediators in the determining the
pathophysiology of pancreatitis [4] [5] [6]. The autocrine and paracrine effects mediated
by endothelin (ET) axis induce the pro-inflammatory cytokines, exacerbating the
inflammatory process [7]. Recent evidence indicates the role of endothelin(s) in TME in
few scattered studies, however the comprehensive representation of the overall axis in
any given cancer type is unknown and expression pattern in human PC is not well
studied.
PC is characterized by extensive desmoplasia and heterogeneous blood flow,
which is a major cause for the poor sensitivity of PC to chemo-and radiation therapy.
Once activated in response to stimuli or injury, pancreatic stellate cells (PSCs) acquire a
myofibroblasts like phenotype and secrete increase amount of extracellular matrix
(ECM) proteins rich in collagen [8] [9]. Treatment with ET-1 induces enhance contraction
and migration of PSCs in ERK and MAPK dependent manner. Additionally, it also
stimulates marker of PSCs activation, αSMA and CTGF and enhance secretion of proinflammatory cytokines, IL-1 and IL-6 [10] [11] [7]
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While a number of studies have suggested that ET-1 levels are enhanced in
pancreatic inflammations, it has also been claimed that the levels are correlated with the
disease severity and inflammation [12] [13]. This notion has been substantiated to a
degree by recent studies that demonstrated that marked increase in the plasma ET-1
levels in patients with severe acute pancreatitis and chronic pancreatitis [14] [15] [16].

2. Hypothesis
Autocrine and paracrine signaling along the ET axis promotes pancreatic cancer
initiation and progression and contributes to pathophysiological characteristics and
aggressiveness of PC

3. Objectives
Aim 1: To determine the expression pattern of ET axis in human PC and mice model
with disease progression as well as in various components of tumor microenvironment.

Aim 2: To determine the impact of targeting the ET axis in in vivo (autochthonous
tumors in KPC model of PC) and in vitro (murine pancreatic stellate cells ad human
cancer associated fibroblasts) and investigate the molecular mechanisms responsible for
ET-1 mediated induction of pro-fibrotic genes.

Aim 3: To analyze the expression pattern of ET axis in the pancreatic inflammations
(acute and chronic) in presence of oncogenic Kras and in pre-neoplastic lesions.
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CHAPTER 2
Materials and Methods
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1. Cell lines and culture conditions
The expression of ET-1, ETAR and ETBR was analyzed in panel of 13 human PC
cell lines (Capan1, MiaPaca, HCG25, Suit2, QGP1, SW1990, Panc1, AsPC1,
CD18/HPAF, BxPC3, Colo357, T3M4 and HPAC), human pancreatic duct epithelial cells
(HPDE), murine PC cell line (UN-KPC-961) and mouse pancreatic stellate cells
(ImPSC.c2). These human PC cell lines were obtained from ATCC and grown in 10%
DMEM supplemented with fetal calf serum (FCS) and 100ug/ml of antibiotics (Penicillin
and Streptomycin). Human promonocytic cell line, U937 was cultured in 10% RPMI
supplemented with FCS, 10mM HEPES buffer, 1mM pyruvate and 100ug/ml of
antibiotics. All cell lines were maintained at 370C under 5% CO2. Human fibroblasts cell
lines derived from normal, chronic pancreatitis and cancer patients were cultured in 10
% RPMI supplemented with fetal calf serum (FCS) 100ug/ml of antibiotics (Penicillin and
Streptomycin) and maintained in either Puromycin (5µg/ml) or Blasticidin (5µg/ml) as a
selection agent. Normal fibroblasts, chronic pancreatitis fibroblasts (Patient 1 and Patient
2) and cancer associated fibroblasts (CAFs) (10-32, 10-15, 10-03, E6.E7) were cultured
in puromycin while the 10-11 CAFs were maintained in blasticidin. Murine ImPSC.c2 and
10-03 human CAFs were serum starved for 24 hours and stimulated with 100nm of ET-1
for 30 mins, 1hr, 4hr, 8hr and 16hr in either DMEM or RPMI containing 1 % FCS. The
antagonists BQ123 (100μM) (Peptides International, PED-3512-PI), BQ788 (20μM)
(American peptide, 88-255), Bosentan (25μm) (Key organics, KS1231) were dissolved
according to the manufacturer’s instructions and added 45 min prior to the addition to the
recombinant ET-1.
2. Tissue specimens
Formalin fixed and paraffin embedded pancreatic tissue samples from 38 Whipple
resected PC patients were procured from University of Nebraska Medical Centre and
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were analyzed for expression of ECE-1, ET-1, ETAR and ETBR. These samples were
obtained from the UNMC tissue bank following approval from the Institutional regulatory
board (IRB # 186-14). Additionally, tissue samples from PC patients from University of
Nebraska Medical Centre’s Rapid Autopsy Program (RAP) (IRB approved) comprising of
normal pancreas, primary tumor, lung metastasis, liver metastasis, lymph node
metastasis, omentum/diaphragm metastasis were also evaluated for expression of ET-1,
ETAR and ETBR for PC metastasis. In this Rapid Autopsy Program, after three hours of
death, tissues are harvested from donor patients and are put in liquid nitrogen or
formalin for fixation. Microarrays made from these embedded tissues were analyzed for
expression after mounting on charged slides. Within the tissue microarray (TMA), control
specimen from normal kidney, colon in addition to tumor tissues is also present.
3. Immunohistochemistry and Immunofluorescence
Slides were baked overnight at 560C and deparaffinised with xylene followed by
rehydration with increasing concentration of ethanol. The slides were then treated for 1
hour with 3% H2O2 in methanol to quench the peroxidase activity. 0.01M preheated
citrate buffer (pH 6, 950C) in microwave for 15 mins was used for antigen retrieval. After
cooling at room temperature (RT), the non-specific reaction was blocked using 2.5%
horse serum (ImmPress Universal antibody kit; Vector Laboratories, Burlingame,
California, USA) for 2h. The sections were then incubated overnight at 40C with
respective primary antibodies diluted in PBS (anti- ETAR, 1:1000, ab117521; anti-ETBR,
1:2000, ab117529; anti-ET-1,1:2000, ab117521; anti ECE-1,1:750, ab189843 antiF4/80, 1:80, e-Biosciences, 14-4801-82; anti-α-SMA,1:100, ab7817; anti-CTGF, 1:500,
ab ab6992; anti-fibronectin, 1:400, ab 2413; anti-Collagen I, 1:500, ab34710; anti
cleaved caspase-3, 1:300, cell signaling 9661,). The slides were washed with PBST (4
washes for 10 mins each) followed by anti-rabbit secondary antibody (ImmPress
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Universal antibody kit; Vector Laboratories, Burlingame, California, USA) incubation for
30 min at RT. The slides were washed with PBST (4 washes for 10 mins each) and color
was developed using 3-3’ diaminobenzidine solution (DAB substrate kit, Vector
Laboratories). After washing with distilled water, slides were counterstained with Gill’s
hematoxylin for 5 mins (Vector Laboratories) and dehydrated with graded ethanol and
then mounted with Permount solution (Fischer Scientific, Pittsburg, Pennsylvania, USA).
All stained slides were scored by a pathologist at UNMC using a Nikon light Microscope
and images of the particular area were taken. The staining intensity for ECE-1, ET-1
ETAR, and ETBR were graded on a scale of 0-3, 0 being negative and 3 strongly positive.
The proportion positive of cell for each of the molecule in a given specimen were scored
between 1-4 indicating 0-25% for intensity 1, 26-50% for intensity 2, 51-75% for intensity
3 and 76-100% for intensity 4. Composite score was then calculated by multiplying the
staining intensity and proportion positivity in a range between 0-12. Quantification of
F4/80 and CD206 positive macrophages and cleaved caspase 3 positive cells were
performed by counting cells in 15-20 high-powered fields from each mouse.
For immunofluorescence, the tissues were blocked with 10% goat serum at room
temperature for 2h followed by overnight incubation at 40C with respective primary
antibodies diluted in PBS (anti- ETAR, 1:300, AER-001; anti-ETBR, 1:300, AER-002; anti
CK19, 1:200, TROMA III, anti- CD31, 1:300, ab32457, anti CD68, 1:100, 14-0688-82,
anti-F4/80,

1:80,

e-Biosciences,

14-4801-82;

anti-α-SMA,1:200,

ab7817,

anti

FSP1,1:300, ab27957, anti-FAP, 1:300, ab53066, anti CD206, 1:300, bs4727R, anti
CD4, 1:100, ebioscience, 14-9766-80, anti-CD8, 1:100, ebioscience, 14-0808-82, AntiFOXP3, 1:100, ab20034, anti CD4, 1:100, ab133616). After overnight incubation the
slides were washed with 1X PBS thrice for 10 mins and incubated for 30 mins at room
temperature with secondary antibody (FITC conjugated anti-rat, Texas Red conjugated
anti-rabbit and FITC conjugated anti-mouse). The slides were washed with 1X PBS

80
thrice for 10 mins, mounted by DAPI containing Vectashield mounting solution and
analyzed using Zeiss (Carl Zeiss Microimaging, Thornwood, NY) confocal laserscanning microscope, and representative images were captured digitally using the 710
LSM software.
4. RNA isolation, reverse transcription and RT- PCR analysis
QIAGEN RNeasy kit (QIAGEN, Valencia, CA, USA) was used to isolate RNA and
cell lines according to manufacturer’s protocol. The isolated RNA was converted to
cDNA after hybridization with oligodT using Superscript II Reverse Transcriptase
(Invitrogen). The cDNA was amplified by PCR using Taq Polymerase in reaction volume
of 50ul. For human endothelin -1 and receptors following primer pairs were used: ET-1
(GTC AAC ACT CCC GAC GAC GTT/ CTG GTT TGT CTT AGG TGT TCC TC), ETAR
(CAC TGG TTG GAT GTG TAA TC/ GGA GAT CAA TGA CCA CAT AG), ETBR (TCA
ACA CGG TTG TGT CCT GC/ ACT GAA TAG CCA CCA ATC TT,). For Mouse ECE-1,
ET-1 and receptors following primers were used: ECE-1 (GTG GCA TTG GTG TCG
TAG TG/ GGA AGA AGA GCT GGT TGC TG), ET-1 (CTT CCC AAT AAG GCC ACA
GAC CAG/ AGC CAC ACA GAT GGT CTT GCT AAG), ETAR (ACC GCC ATT GAA ATC
GTC TCC ATC/ TTA GCA AGA AGC TGA GCA GTT), ETBR (TGA CGC CAC CCA CTA
AGA CCT CC/ GCC TTC TGT ATG AAG GGC ACC AG). Obtained PCR products were
run on 2% Agarose gel containing ethidium bromide. Human β actin and Mouse GAPDH
was co-amplified using β actin and GAPDH primers respectively to ensure the quality of
cDNA for PCR in every case.
5. In vitro assays of cell migration
To assess migration of ImPSC.c2 in presence of ET inhibitors, ImPSC.c2 (1x106)
were seeded at in a 6 well plate in DMEM supplemented with 10% FBS and incubated
overnight. After obtaining approximately 90% confluency, the cells were serum starved
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for another 24 hours and an artificial wound is made using 200μl pipette tip. The detach
cells were washed with PBS and remaining cells were treated with either ET-1 or
antagonists for 45 mins prior to addition of ET-1 in DMEM containing 1% FBS while the
control cells were left untreated. Representative phase contrast images were taken at 0
and 24 hours at 10X magnification using Accu-scope microscope attached with Moticam
580 digital camera. The wound closure was measured by calculating the distance
between the two edges and ten independent areas in the wound per image was counted
using a straight line tool in the Image J software. The mean distance of the ten
independent areas at 0 and 24 hours of control and treatment sets was calculated and
the percentage of wound closure was measured as mean area at 24 hour/mean area at
0 hour multiplied by 100. The migratory potential of murine macrophages (RAW 264.7)
and human monocytes (U937) towards UN-KPC-961 and Panc1 cells respectively was
assessed using boyden chamber consisting of a 0.8 μm transwell membrane. Briefly,
1x106 UN-KPC-961 and Panc1 cells were seeded in six well plates in DMEM containing
10% FBS. After overnight incubation the cells were treated with ET antagonists and the
macrophage/monocyte cell suspension (0.5x106 cells) in serum free medium was
seeded in the upper chamber of the insert. The migration of these cells was allowed for
24 hours in a humidified atmosphere at 37°C with 5% CO2. The migratory cells on the
lower chamber that invaded through the pores were fixed and stained with Diff-quick
staining kit (Dade Behring, Inc). For each membrane the number of cells migrated was
counted in 10 random fields at 10X magnification.
6. In vitro 2D co-culture using tumor and stellate cells
In cell-cell non-contacted coculture system using boyden chamber the murine
stellate cells (ImPSC.c2) were separated from murine tumor cells (UN-KPC-961) derived
from KPC mice tumors using a 0.8 μm transwell membrane. 0.5x106 ImPSC.c2 were
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seeded in a 6 well plate in DMEM supplemented with 10% FBS. After 24 hours the cells
were washed with PBS and treated with either specific ETAR inhibitor (BQ123), specific
ETBR inhibitor (BQ788), or dual inhibitor (Bosentan) and cultured in presence and
absence of same numbers of UN-KPC-961cells cultured in serum free DMEM on the
inner chamber of transwell membrane and allowed to interact with ImPSC.c2 for another
24 hours. After the end of the treatment period, ImPSC.c2 were harvested and
processed for western blot analysis.
7. In vitro assays of cell proliferation
Cell proliferation was measured by the WST-1 assay according to the
manufacturer’s instructions (Roche). Briefly, 3x103cells were seeded into 96 well plates
in triplicates for each cell type. Following 24hr of seeding, the cells were changed to 1%
DMEM and treated with ET-1 (1nm, 10nm, 100nm an 1000nm) for 24hr, 48 hr and 72 hr.
The absorbance was measured at 440 nm using a SpectraMax 190 (Molecular Devices)
microplate reader.
8. Cell cycle analysis
Briefly, 1x106cells were seeded in 60 mm petri dishes in 10% DMEM and allowed
to grow for 24 hrs. Cells were serum starved for 48 hr and treated with BQ123 (100μM),
BQ788 (20μM) and Bosentan (50μM) for 24 hr. Following treatment cells were
trypsinized and fixed in 70% ice-cold methanol for 60 mins, washed in PBS and
incubated for 30 min at 40C in Telford reagent (90 mM EDTA, 0.1% Triton-X-100,
50μg/ml propidium iodide, 25μg/ml RNase-A in PBS). The total DNA content was
measured by fluorescence activated cell sorting method.
9. Annexin V staining and flow cytometry
A total of 1x106cells were seeded in 60 mm petri dishes in 10% DMEM and
allowed to grow for 48 hrs. Following treatment with BQ123 (100μM), BQ788 (20μM)
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and Bosentan (50μM) for 24 hr, the early and late apoptotic cells were detected using
annexin V-FLUOS staining kit (Roche) according to the manufacturer’s instructions.
Cells were collected and resuspended in the HEPES buffer containing annexin-V –
fluorescein and propidium iodide in the dark for 15 mins, and the data were acquired by
the flow cytometry
10. Cytotoxicity assay using MTT
Briefly, cells were seeded in 96 well plates in triplicates in DMEM supplemented
with 10% FCS and after 24 hours the cells were treated with indicated concentrations of
BQ123, BQ788 and Bosentan and incubated at 370C for 24, 48 and 72 hours. At the end
of

each

time

point

100

μl

5mg/

ml

MTT

(3-4,5

dimethylthiazol-2yl)-2,5

diphenyltetrazolium bromide was added and the plates were incubated for an additional
4hours at 370C. Post incubation, the solution was removed and 100μl of DMSO was
added and absorbance was measured at 490nm using microplate reader.
11. Western blotting
Cell lines were processed for protein extraction followed by Immunoblot analysis.
Cells were washed with PBS twice and then lysed using Radioimmunoprecipation assay
buffer (RIPA) containing 50mM Tris, 5mM EDTA, 150 mM NaCl, 1% NP40, 0.25%
sodium deoxycholate,1mM Na3VO4. 200mM sodium fluoride and Protease Inhibitor
(Roche diagnostics) and kept at 40C for 20 min under mild shaking. Cell lysates were
incubated in -700C for at least 1hr and subjected to freeze thaw and pass through
syringe to disrupt the cell membrane. Lysates were then centrifuged at 14000 rpm for 30
min at 40C and the supernatant were collected and protein quantification was done using
Bio-Rad protein estimation kit. Immunoprecipitates were then resolve on 12%
Polyacrylamide gel under reducing conditions, transferred to polyvinylidene fluoride
membrane (PVDF) and blocked with 5% nonfat dry milk in PBS for 2h at RT. The
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membranes were then incubated overnight at 40C with respective primary antibodies
diluted in PBS (anti- ETAR, 1:5000, ab117521; anti-ETBR, 1:5000, ab117529; anti-ET1,1:5000, ab117521; anti-α-SMA,1:200, ab7817; anti-CTGF, 1:2000, ab ab6992; antifibronectin, 1:3000, ab 2413; anti-Collagen I, 1:5000, ab34710; anti-desmin,1;10000,
ab32632; anti FSP1,1:3000, ab27957, anti-CK19,1:3000, TROMA III, anti-pERK,1;1000,
cell signaling 9101, anti-t-ERK, 1:1000, cell signaling 9102; anti-p-AKT, 1:1000, cell
signaling, 4060S; anti-t-AKT, 1:1000, cell signaling 4691S; anti-β actin, 1:5000, Sigma
A1978). Membranes were washed with Tris buffer saline (TBS) containing 0.1% Tween
followed by incubation at RT in HRP (Horse Radish Peroxidase) conjugated anti rabbit,
anti-mouse or anti-goat secondary antibodies in 3% nonfat dry milk in PBS at 1:5000
dilutions. The signal was detected using ECL western blotting detection reagents
(Amersham, Biosciences, and Buckinghamshire, UK).
For treatment of monocytes, U937 cells were differentiated into macrophages in
six well plate containing 10nM/ml phorbol myristate acetate (PMA) for 72 hours. The
supernatant was collected and the attached cells were washed with PBS and lysed
using RIPA buffer for immunoblot analysis. For IL-4 or IL-13 or IL-10 treatments, the
macrophages differentiated using PMA were washed with PBS and incubated with
10ng/ml of each of IL-4, IL-13 and IL-10 for 24 hours. The supernatant was collected and
the attached cells are lysed using RIPA buffer. Lysates collected were further analyzed
for the expression of ET-1, ETAR and ETBR using specific antibodies through Western
blot.
12. In vivo endothelin axis antagonism using Bosentan
20 weeks old KPC mice (n=4 control group and n=5 mice in the Bosentan group)
were housed under specific pathogen-free conditions. All mouse experiments were
performed in compliance with protocols approved by the Institutional Animal Care and
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Use Committees of the University of Nebraska Medical Center. The dual ET receptor
antagonist, Bosentan (Key Organics) was administered daily for continuous 10 days by
intraperitoneal injection at a dose of 1 mg/kg whereas the control group received saline.
Throughout the course study, mice were monitored for weight loss and others signs of
abnormalities. Mice were sacrificed at the end of the treatment period and the weight of
pancreas was recorded. Tissues were then fixed in 10% formalin and embedded in
paraffin for histopathological analysis and RNA analysis.
13. RNA extraction from mouse tissues, reverse transcription and real time PCR
analysis
RNA was extracted from the tumors removed from KPC (Pdx1-Cre, p53

(R172H)

KrasG12D) mice (saline or Bosentan treated), KC (Pdx1-Cre, KrasG12D) mice (LSL-KrasG12D and K-rasG12D; Pdx-1cre referred as unfloxed and floxed, respectively exposed to
cigarette smoke and KC (Pdx1-Cre, KrasG12D) mice exposed to cerulein day 0, 2, 7 and
21 post treatment using mirVANA isolation kit (Ambion, Foster city, CA, USA) by a
standard protocol. All animal experiments were reviewed and approved by the University
of Nebraska Medical Center Institutional Animal Care and Use Committee (IACUC). The
animals were exposed to cigarette smoke or cerulein treatment as previously described
[1] [2]. Genomic DNA contamination was removed by Dnase treatment using RNeasy
mini kit (Qiagen) and RNA integrity was measured spectrophotometrically. The isolated
RNA was converted to cDNA after hybridization using random hexamers using
Superscript II Reverse Transcriptase (Invitrogen). Following primer pairs were used:
ECE-1 (TCA CGC TTT CGA TGA TCA AG/GTA TTG CTG CAC CAT GCA CT), ET-1
(GCT GGT GGA AGG AAG GAA AC/TTG TGC GTC AAC TTC TGG TC), ET-2 (AGA
CTG GCA AGA TGT GGA CT/ TTC TTG TCA CCT CTG GCT GT), ET-3 (TGC GTT
GTA CTT GTA TGG GG/ AGT CTC CCG CAT CTC TTC TG), ETAR (CGG CAT TAA
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CCT GGC AAC/ATG AGG CTT TTG GAC TGG TG), ETBR (TCG CTC TGT ATT TGG
TGA GC/ TTC AGG CAG GAC TGC TTC TC). Real time PCR was performed using
Light Cycler 480 SYBR green I master mix (Roche Diagnostics, Indianapolis, IN, USA) in
the Light Cycler 480II (Roche Diagnostics). The relative amount of expression was
calculated using 2ΔΔCT method. Statistical comparisons were made using student’s t-test
and P<0.05 was considered statistically significant. The average of the three
independent analysis for each gene was calculated and normalized to Gapdh.
14. Microarray analysis
Mouse fibrosis RT2 Profiler PCR Array (PAMM-120ZF, Qiagen) was used to
evaluate the differential gene expression. The array evaluated the expression of 84
genes involved in facets of fibrosis, like extracellular matrix and cell adhesion, growth
factor production and signal transduction. Real time PCR detection was carried out
according to manufacturer’s instructions. The PCR components cocktail was prepared
by adding 1350µl real time PCR SYBR green master mix and 1350µl of nuclease free
water to 20µl of cDNA. For the real time PCR detection 25 µl of the PCR cocktail was
added to each well of 96 well RT2 Profiler PCR Array. The array was then cycled on a
Roche Light Cycler 480. The thermocycler parameters were 950C for 10 min, followed by
45 cycles of 950C for 15 s and 600C for 1 min. The experiment was performed in
triplicates. For data analysis, the delta-delta CT method was used and the values
obtained were exported to template excel sheet containing the algorithms provided by
the manufacturer. The fold changes were calculated as the difference in gene
expression between the treated and the control tumors. A positive value indicates gene
upregulation whereas a negative value indicate downregulation.
15. Perfusion analysis using BQ123
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Mice bearing T3M4 (tumor1) and Colo 357 (tumor 2) xenografts were
administered with interaperitoneal injection of BQ123 (2 mg/kg) [3]. Perfusion mapping
was done by flow sensitive alternating inversion recovery (FAIR) with a rapid acquisition
by refocused echo (RARE) readout (RARE factor = 16). Perfusion was measured prior to
administration of BQ123 (0 min) to establish baseline and subsequently imaged for 120
min post-administration to monitor the change in perfusion. Anatomic MRI scan was
used to indicate the position of tumors and the regions of interest (ROI) in the tumors
and muscle used for perfusion analysis. Perfusion maps were captured before and 120
min after injection of BQ123 and were windowed between 0 to 500 ml/(100g tissue per
min). Blood flow values were determined from the serial perfusion maps between 0-120
min and plotted as a function of time. Tumor bearing animals were treated with saline
(left) or BQ123 (right). 90 min after treatment animals were injected with pimonidazole
HCl (Hypoxyprobe), which forms stable adducts with proteins in hypoxic cells. Animals
were euthanized 45 mins thereafter and tumors were harvested and processed for
immunohistochemistry. Hypoxy-probe-Plus kit was used to detect hypoxia using
manufacturer’s instructions.
16. Procurement of Animals
The ET-1flox/flox mice were obtained as a kind gift from Dr. Donald Kohan at
University of Utah Health Sciences Center [4]. These mice have the exon 2 of the ET-1
gene flanked by loxP sites. The ET-1 mice were crossed with the KPC mice (Pdx1-Cre,
p53

(R172H)

KrasG12D). These KPC mice express localized Cre recombinase regulated by

Pdx1 promoter and are on C57BL/6 background. This promoter is expressed in
pancreas. Here the Kras gene contains a point mutation G12D and is followed by LoxStop-Lox codon. In the presence of Cre, the stop codon is excised and the mutant
protein is expressed. The ET-1flox/flox mice were crossed with KPC mice to generate the
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intermediate crosses, which were intercrossed in order to generate the ET-1-/- Pdx1-Cre,
p53 (R172H) KrasG12Dfinal genotype.
17. DNA isolation, genotyping and maintenance of animals
Animals were maintained in accordance with guidelines and protocols approved
by the Institutional Animal care and Use Committees (IACUC) of the University of
Nebraska Medical Center. The animals were exposed to 12-hour light/dark cycle and
were allowed access to food and water ad libitum. The tails of mice were clipped at the
age of 8 days and the DNA isolated using Maxwell 16 mouse-tail DNA purification kit,
Promega, Madison, WI, USA. Following DNA isolation, genotyping was performed using
following primers: Wild-type ET-1 (gct gcc caa ttc tga att ctg / gat gat gtc cag gtg gca
gaa g), Flox ET-1 (ccc aaa gat tct gaa ttg ata act tcg/ gat gat gtc cag gtg gca gaa g),
Kras (cct tta caa gcg cac gca gac tgt aga/ agc tag cca cca tgg ctt gag taa gtc tgc a), p53
(ctt gga gac ata gcc aca ctg/ agc tag cca cca tgg ctt gag taa gtc tgc a), Pdx-Cre (ctg gac
tac atc ttg agt tgc/ ggt gta cgg tca gta aat ttg). The reaction for ET-1 primers is cycled 35
times (1 minute at 94°C, 2 minutes at 60°C, and3 minutes at 72°C), which amplifies an
approximately 900-bp fragment for both the wild type and flox ET-1 alleles. Mice were
observed daily and anal prolapse or any other signs of distress were carefully recorded.
18. Statistical Analysis
Student t test was used to determine the statistical significance between control
and treatment group in all the experiments and p value less than 0.05 was considered to
be statistically significant. Error bars were given on the basis of calculated standard error
values. To measure colocalization using confocal microscopy the images were assessed
using ImageJ (National Institute of Health, Bethesda, MD) with Manders colocalization
using JaCoP plug-in.
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1. Synopsis
Overexpression of Endothelin-1 (ET-1) and its receptors (Endothelin A receptor,
ETAR and Endothelin B receptor, ETBR) is observed in many solid cancers and is
associated with poor prognosis. However, their expression pattern in pancreatic cancer
(PC) and its tumor microenvironment (TME) have not been well studied. We have
analyzed the expression pattern of Endothelin- converting enzyme (ECE-1), ET-1, ETAR
and ETBR in both Whipple resected human PC patients and patient tissue microarray,
which have both the primary and metastatic sites harvested. Immunohistochemical
analysis indicated that expression of the ET axis is restricted to the acinar compartment
and islet cells of the normal pancreas whereas a predominant expression of all four
molecules is seen the duct cells of the PC. In addition to the primary site, expression
was also seen in various metastatic sites. Careful observation suggests that in addition
to tumor cells, the expression is observed in tumor blood vessels and immune cells and
the expression on tumor blood vessels is correlated with the poor prognosis of the PC
patients. Additionally, expression of the axis was also determined in a genetically
engineered mouse model of PC (K-rasG12D; Trp53R172H/+; Pdx-1-Cre). RT-PCR and
immunohistochemical analysis suggested that expression increases gradually with
disease progression in both pancreatic ducts and the stromal compartment of PC. The
expression on various cellular components was analyzed in both murine and human PC
tissues using dual confocal microscopy with markers for blood vessels (CD31), tumor
cells (CK19), stellate cells (α-SMA) and macrophages (F4/80 & CD68). Further,
bioinformatics analysis with the TCGA database revealed positive correlation of ET axis
expression with advance tumor grade and stage; and a significant association of fibrotic
associated genes and the pathways regulating fibrosis seen upregulated in tumors
exhibiting over expression of the ET axis. We show for the first time components of the
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ET axis are over-expressed not only in PC cells but also in various cellular
compartments of the surrounding microenvironment.
2. Background and Rationale
Pancreatic cancer (PC) is the 10th most commonly diagnosed cancer and the
fourth leading cause of cancer-related deaths in the United States [1]. Due to the lack of
early diagnostic and therapeutic modalities, PC has an extremely poor prognosis with a
dismal five years survival rate of only 2-5% [2]. At the time of diagnosis, the disease has
usually metastasized locally to the lymph nodes and to distant organs. While numerous
studies have focused on the genetic abnormalities that underpin this disease, much
remains unknown regarding this complex, intractable malignancy that unfortunately often
only manifest symptoms in patients at advanced, metastatic stages [3]. Most prominent
among the mutations driving PC is the Kras oncogene, which is mutated into a
constitutively active form (KrasG12D) in around 70% of PC patients [4]. Morphologically PC
is characterized by a highly complex stromal compartment consisting of cellular
components that include pancreatic stellate cells, endothelial cells, immune cells,
neuronal cells, endocrine cells and extracellular matrix [5, 6]. These cellular components
of tumor microenvironment (TME), have complex interactions with each other and with
the cancer cells. The intricate autocrine and paracrine signaling between these cellular
components is believed to orchestrate the initiation, progression and metastasis of PC
and contribute to the pathophysiological hallmarks like hypoxia, desmoplasia, perineural
invasion and resistance to therapy that define this lethal malignancy.
Endothelins (ETs) are a family of three 21 amino-acid vasoactive peptides ET-1,
ET-2 and ET-3 that mediate their effects via two G-protein couple receptors, ETAR and
ETBR that are expressed on various cell types. While under normal physiological
conditions, the ET system is involved primarily in the regulation of basal vascular tone [7],
there is emerging evidence demonstrating its expression and role in tumor progression of
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several malignancies including melanoma [8], glioblastoma [9], prostate, ovarian,
hepatocellular, breast and colorectal carcinomas thus making it a potential therapeutic
target [10-14]. Elevated ET-1 levels are observed in many tumors where it is produced
both by tumor and stromal cells [15]. Further, overexpression of the two endothelin
receptors is observed on tumor cells, endothelial cells, infiltrating immune cells and tumor
associated fibroblasts in various malignancies. Activation of the ETAR in tumor cells
promotes proliferation, migration, invasion and cell survival (anti-apoptotic signals) by
activating different signaling pathways including MAPK, PKC, EGFR and Akt [15]. The ET
axis also plays a critical role in tumor neovascularization by regulating HIF-1α, VEGF,
COX2 and prostaglandin E2 and induces proliferative signaling in endothelial cells,
pericytes and vascular smooth muscle cells. ET-1 potentiates hypoxia signaling via
regulation of hypoxic inducible factor-1α (HIF-1α). Indeed, a reciprocal relationship has
been proposed in which ET-1 stabilizes HIF-1α resulting in the activation of HIF-1αregulated angiogenic genes, including HIF-1α- mediated transcription of ET-1 itself. Thus,
ET expression can be influenced by the tumor microenvironment, and ETs then modify
that environment through the actions of HIF-1α [16, 17]. These interactions are generally
amplified under conditions of hypoxia as compared with normoxic conditions. Due to the
high expression of ETAR on osteoblasts, the ET-1/ETAR axis promotes osteoblast
proliferation and facilitates bone metastasis in prostate and breast cancer. ETAR
antagonism reduces bone metastasis in experimental models and several clinical trials
have evaluated the role of ETAR antagonists in patients with advanced bone metastatic
breast and prostate cancer [18-22]. While most of the studies center on the ETARmediated pro-tumorigenic effects, emerging evidence also suggests the critical
involvement of ETBR. In ovarian cancer, high expression of ETBR on tumor blood vessels
is associated with poor infiltration of anti-tumor T-lymphocytes and the ETBR antagonist,
BQ788, enhanced the efficacy of immunotherapy [23]. In contrast, ETAR activation was

94
associated with enhanced T-cell infiltration in ovarian tumors [24]. In breast cancer ET-2
is involved in the recruitment of macrophages via ETBR expressed on macrophages [25].
Very recently, the role of endothelins in the TME has come up in a few scattered
studies, however the comprehensive picture in any given cancer type still remains
unknown [26]. Tumor cells secreting ET-1 peptide also expresses both ETAR and ETBR
thereby activating autocrine and paracrine interactions with the tumor stroma [27].
Further, the remodeling of tumor stroma can occur due to ET-1 mediated interactions
with ETAR and ETBR expressed on stellate cells, and cancer associated fibroblasts . The
signals or cues coming from stromal cells facilitate reprogramming of the tumor cells and
favor epithelial-to-mesenchymal phenotypic transition or acquisition of stem cell like
phenotype [28, 29]. Alternatively, blood and lymphatic endothelial cells increase
angiogenesis and lymphangiogenesis in response to ET-1-ETBR activation. In parallel,
the tumor secretes vascular endothelial growth factor (VEGF) in an ET1-dependent
manner, inducing sprouting and branching of new vessels from existing vessels [30, 31].
Recently, Cook et al. demonstrated overexpression of ET-1 and ETBR in human
PC [32], however the expression pattern of the overall axis (ECE-1, ET-1, ETAR and
ETBR) in PC and its complex microenvironment is still under explored. The study here in
provides for the first time the expression pattern of the entire ET axis in PC, and in
various cellular compartments using both a genetically engineered mouse model and
human PC cases. Importantly, TCGA database analysis indicated a positive correlation
of pro-fibrogenic genes with the ET axis over expression giving further impetus to our
hypothesis that the axis possible plays a pleotropic role in the tumor microenvironment
of PC.
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3. Results
A. Endothelin-1 and its receptors are expressed in human pancreatic cancer cells
The expression pattern of enodthelin-1 and its receptors was determined in 13
human pancreatic cancer cells and ductal epithelial cells (HPDE) using immunoblot and
RT-PCR analysis (Figure 1A and 1B). The colon cancer cell line, SW480 and human
melanoma cell line SKMEL28 were taken as positive controls for ET-1/ETAR and ETBR
respectively [33, 34]. Interestingly our results indicate the ubiquitous expression of ET-1
expression in the majority of cell lines tested. The ductal epithelial cell line,HPDE,
showed expression of ET-1 and ETAR with no expression of ETBR. In majority of cell
lines, expression of endothelin receptors (ETAR and ETBR) showed an inverse
relationship, with either one or the other expressing in a cell line one at a time. In
SW1990, a low level of endothelin A receptor was observed however no expression of
endothelin B receptor was seen. High levels of both ETAR and ETBR were present in
poorly differentiated (AsPC1), moderately differentiated (BxPC3) and well differentiated
(Colo357, HPAF II and Capan-1) PC cell lines as indicated by RT-PCR and immunblot
analysis -indicating the differential expression pattern of ETAR and ETBR in these cells,
suggesting a potential association between receptors expression and differentiation of
PC cells. Actin was used as an internal control to normalize transcript levels.
B. ET axis components are overexpressed in PC tissues
To further delineate the expression and investigate the clinical significance of
ECE-1, ET-1, ETAR and ETBR in human PC we first performed immunohistochemistry on
formalin fixed paraffin embedded tissue samples from 38 pancreatic cancer patients who
underwent

Whipple

procedure

and

on

five

normal

pancreas

samples.

Immunohistochemistry (IHC) analysis revealed that within the axis the expression in
tumors was found to be higher for ECE-1 and was expressed in 34 cases (89%). The
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expression of ET-1 was observed in 33 cases (86%), whereas the expression of ETAR
and ETBR were seen in 29 (75%) and 24 (68%) cases respectively (Figure 2A). In
normal human pancreas, low immunoreactivity of ECE-1, ET-1, ETAR and ETBR was
seen in the pancreatic acini, however islet cell were found to be strongly positive for all
four molecules. Figure 2B and 2C shows the quantification of composite
immunohistochemistry score and a heat map representation respectively of the
expression pattern on case-to-case basis. Interestingly, in the normal pancreatic ducts
weak immunostaining can be seen for ECE-1 compared to ET-1, ETAR and ETBR. To
evaluate the clinical significance of ET axis expression in PC, the expression was
correlated with the clinicopathological characteristics. The expression was correlated
with the age, gender, tumor stage, tumor grade, lymph node metastasis and distant
metastasis (Table I). The incidence (positivity) of ET-1, ETAR and ETBR was correlated
with patient characteristics using the chi-square test for the categorical variables and the
t-test for age. For both ETAR and ETBR no patient characteristics were associated with
marker positivity. Interestingly, ET-1 positivity was associated with a higher proportion of
moderate grade patients and was negatively associated with a higher proportion of poor
and well differentiated patients with a significant p value (p=0.04).
To study the expression of ET-1 and its receptors during PC metastasis
immunohistochemical staining was performed using tissue microarrays (TMA) from
UNMCs unique rapid autopsy program (RAP), which included patient samples from both
primary and metastatic sites. We examined pancreatic cancer tissue samples from the
primary and metastatic sites to measure the incidence of ET axis proteins and the
average composite scores. Generalized estimating equations (GEE) was used to
calculate the proportion with the positive staining results for each of the molecules
examined for each tissue type as well as the mean composite score for each. The
expression

was

compared

between

non-neoplastic

ducts

and

pancreatic
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adenocarcinoma having normal pancreas and tissues from primary PC. Figure 3
represents the immunohistochemical analysis and heat map representation of ET-1 and
both the receptors respectively in primary and metastatic tissues. We next determine the
change ET axis expression with progression of PC on the basis of tumor grade and
differentiation. Table II shows the expression of ET-1, ETAR and ETBR in primary tissues
of 44 patients on the basis of loss of tumor differentiation. A progressive increase in the
expression of ET-1 and receptors was observed from poorly differentiated to well
differentiated carcinoma. Further, within the axis ETAR was found to be highly expressed
in all three histologic grades and was higher than ET-1 and ETBR. In addition, patients
who express all three of the molecules in primary sites also expressed the same in
various metastatic sites suggesting the role of ET-1 and the receptors in metastatic
spread of disease. Table III shows the distribution of TMA utilized in this study and the
number of tissue specimens analyzed for ET-1, ETAR and ETBR. The expression of ET1, ETAR and ETBR was seen in 37.1% (13/35), 74.3% (29/39), 31.5% (12/30) and 73%
(27/37) of the primary cases. We then determined the incidence rate (proportion
positive) for each of the molecules in each of the tissue, using GEE methods to take into
account multiple tissue samples per patient. As shown in table IV, compared to
metastatic tissue the incidence rate in primary tumor was found to be significantly higher
for ET-1 (p=0.0020), ETAR (p=0.022) and ETBR (p=0.020). In addition, the incidence for
ETAR on blood vessels was found to be significant in metastatic tissues, however no
significant difference for ETBR was observed in these tissues.
C. Elevated expression of ETBR on tumor blood vessels is correlated with patient
survival
Very interestingly, in addition to tumor cells where the expression of ET axis
components was identified in the cytoplasm, a strong immunostaining was also seen in
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the stromal compartment of these patients particularly infiltrating immune cells and blood
vessels, suggesting a potential involvement in the pancreas microenvironment (Figure
4A). To further confirm the expression in the stromal compartment, the expression was
scored by a pathologist in a double blinded condition in Whipple resected PC tissues. Of
all the cases analyzed the expression in blood vessels was seen in 60.5 % (23/38) and
31.5% (12/38) for ETAR and ETBR respectively. Additionally, expression in the immune
cells indicate the expression of ET-1 in 31.5% (12/38), ETAR in 34.1% (13/38) and ETBR
in 39.4 (15/38) of the cases (Figure 4B). Importantly, analysis of survival data from 33
patients showed that elevated ETBR positivity on blood vessels is correlated with poor
prognosis of the PC patients. Representative immunohistochemistry images of the low
ETBR expression on normal pancreas and elevated expression on tumor blood vessels
in PC patients are shown in (Figure 6). The median survival of the patients with low
ETBR expression on blood vessels was 14.7 months as compared to 10.3 months in
patients with high ETBR blood vessel positivity (Figure 5E). However, no significant
correlation of ET-1, ETAR and ETBR expression on tumor cells was seen with survival of
these patients. Even in the small sample size this was a significant finding suggesting
that analyzing the expression in the context of microenvironment in addition to tumor
cells is equally important to determine the pathobiological significance of the pathway.
D. Expression of ET axis in mouse progression model of PC
Genetically engineered mouse (GEM) models are potential alternatives to
xenograft subcutaneous models to study the tumor microenvironment and evaluate
therapeutic strategies in vivo. We have procured the most widely used mouse model in
pancreatic cancer, which expresses constitutively activated KrasG12D in the pancreas.
This double transgenic line was developed by Dr. David Tuveson by crossing LSLKrasG12D with Pdx-1-Cre. The resultant double transgenic animals (KrasG12D; Pdx-1-Cre)
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develop PanIN lesions at age of 9 weeks, advanced PanINs at 30 weeks and few
animals developed PC with metastasis at 50 weeks of age [35]. However, this model
does do not develop aggressive nor metastatic tumors. We have utilized widely used
KPC model which consists of a triple transgenic animal (K-rasG12D; Trp53R172H/+; Pdx-1Cre). The KPC model involves targeted expression of an endogenous KrasG12D allele
and Trp53R172H/+ in murine pancreatic progenitor cells and closely recapitulates many of
the genetic alterations, histopathology and metastatic features of human pancreatic
cancer. The KPC mice develop pre-neoplastic lesions at 4-6 weeks after birth and
invasive PDAC at 22 weeks of age with a median survival of 5 months and 100%
mortality by 12 months of age. We studied the expression of ECE-1, ET-1, ETAR and
ETBR in the autochthonous tumors of KPC mice. The expression was analyzed at the
mRNA levels form tissues obtained from 5wk, 7 wk, 10wk, 15wk, 20 wk and 25wk
animals. Low expression of ECE-1, ET-1 and both receptors was seen in animals of 5
wk age and a progressive increase was observed to 25 wk KPC animals (Figure 7A). In
contrast, low expression of ET axis components was seen in the control animals, which
have WT Kras in the pancreas. The expression was also evaluated by tissue IHC where
the onset of expression of ECE-1, ET-1, ETAR and ETBR was observed in early PanIN
lesions in 5 wk animals (Figure 7B). In the advanced lesions of 25 week animals,
significant expression was seen both in cancer cells and tumor microenvironment
components similar to human PC. In the 25 wk control animals having WT Kras, low
expression was seen in the acinar compartment whereas the strong immunoreactivity
was seen in the islet cells, which is similar to the normal human pancreas. In addition, in
the

normal

pancreatic

duct

similar

to

normal

human

pancreas

prominent

immunostaininig of ECE-1 was seen. The progressive increase in the expression of ET-1
axis components with increase tumor grade and stage similar to human PC suggests the
therapeutic potential of targeting this axis and study thereof using the KPC model.
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E. Expression of ET axis in tumor microenvironment of human PC and mice KPC
tissues
PC represents one of the most complex tumor microenvironments (TME) and
consists of pancreatic stellate cells, endothelial cells, immune cells, neuronal cells,
endocrine cells, and highly obstructive extracellular matrix. These cellular components of
the TME have complex interactions with each other and with the cancer cells. To confirm
the expression on components of PC microenvironment the expression was determined
using dual confocal microscopy utilizing markers for blood vessels, tumor cells and
stellate cells and macrophages. In both human PC and mouse KPC tissues, we
observed that epithelial marker CK19 positivity is associated with both ETAR and ETBR
(Figure 8A & 8B). Additionally, we found that both ETAR and ETBR are associated with
CD31 (Figure 9A & 9B). In contrast, α-SMA positive stellate cells display low expression
of ETAR and high expression of ETBR (Figure 10A & 10B). As macrophages are an
integral part of TME and play a key role in its establishment, we analyzed the expression
on tumor infiltrating macrophages. Using CD68 specific antibody we found that
expression of ETBR is mainly associated with CD68 positive macrophages, whereas low
expression of ETAR was seen (Figure 11A). In addition, dual immunofluorescence
analysis on the F4/80 positive murine infiltrating macrophages in the stromal
compartment of KPC mouse tissue suggests low expression of ETAR and predominant
expression of ETBR (Figure 11B). We have analyzed the expression of both ET
receptors in cancer stem cells (CSCs) in KPC mice tissues. Expression of both ET
receptors was observed in CD133 positive CSCs (Figure 12A & 12B). In addition to the
ET receptors, the expression of ECE-1 and ligand ET-1 was also studied in these
tissues using triple co-immunofluorescence analysis. Examination revealed expression
of ECE-1 and ET-1 on tumor cells and stellate cells that displayed co-expression with
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the CK19 (Figure 13A & 13B) and α-SMA (Figure 14A & 14B) respectively in both PC
and KPC tissues. Furthermore, co-immunostaining using ECE-1 and ET-1 specific
antibodies showed extensive co-expression with CD68 and F4/80 positive macrophage
populations in human PC and mice KPC tissues (Figure 15A & 15B). An overall
summary of the ET axis expression profile on various cellular compartments of
microenvironment is given in Table V.
F. ET-1 and receptors correlate with tumor grade and stage in human TCGA
database
With the limitation in sample size in these two data sets (Whipple resected and
RAP cases), we conducted a TCGA analysis on 162 PC patients (Table VI i). The total
number of patients in stage 1 is 20 whereas stage 2 has the information on 126 patients.
In addition, the sample size of the patients in stage 3 and 4 has information on 3 patients
each. We correlated the expression of ET-1 and its receptors on the basis of tumor
grade and stage (Table VI ii). The expression of ET-1 and both receptors correlated with
advanced tumor grade and stage. Higher expression of the ET-1 was observed in stage
3 & 4 patients (p=0.05) and stage 2 patients (p=0.05) compared to stage 1 patients.
Similarly, expression of ETAR (p=0.01) and ETBR (p=0.03) showed higher expression in
stage 2 compared to stage 1 with increase in tumor stage, suggesting a positive
correlation with advance tumor stage. To further determine the functional implication and
pathobiological significance of this overexpression in PC tissues, we looked for genes in
the TCGA database which has high correlation coefficients with overexpression of both
ETAR and ETBR. To further determine the consequences of the overexpression of the
axis in these PC patients we utilized bioinformatics approach to screen for the genes
which correlate with the tumors with overexpression of ET-1 and its receptors. Using
Pearson correlation coefficient ‘r’ the strength of the linear relationship between two
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variables is determined. An ‘r’ value of 0 indicates no association between the two
variables whereas ‘r’ value of +1 and -1 indicates the perfect positive and negative
association respectively between the variables. Bioinformatics analysis of the TCGA
database cases revealed high positive correlation of the genes associated with both
ETAR and ETBR. Interestingly, significant association of pro-fibrotic genes were found to
be correlated with ETAR expression particularly Collagen I (Col1A2, Col3A1, Col5A2,
Col6A3), Platelet derived growth factor receptor-beta (PDGFRβ), Fibroblast activation
protein (FAP), Lumican (LUM) and Fibrillin 1 (FBN1), Sulfatase 1 (SULF1), Fibrillin 1
(FBN1), Follistatin like 1 (FSTL1), Secreted protein acidic and cysteine rich (SPARC),
Chondroitin sulfate synthase (CHSY3). Table VII lists the top 30 genes that were found
to correlative on patient-to-patient basis with both ETAR and ETBR. Figure 16 shows the
association of PDGFRβ with ETAR expression (r=0.93), indicating a stronger association
of the two variables. Additionally, pathways regulating hepatic fibrosis, SHH signaling,
and tumor growth and metastasis, were also upregulated in tumors exhibiting
overexpression of the ET axis (Figure 17). These findings indicate that over expression
of ET-1 axis particularly ETAR correlates with a pro-fibrotic gene signatures suggesting
an active involvement of the ET-1 axis in the stromal compartment of PC.

Discussion
The ET system is comprised of a strong vasoactive peptide and receptors that
play a crucial role in physiological events. In addition, a link has been suggested
between the axis components and various pathological malignancies including cancer.
Although a few studies have also reported a potential role of ET-1 in human pancreatic
cancer, the data are very limited. Kushuhara et al first witnessed and reported evidence
for the presence of ET-1 peptide in the pancreatic cancer cell lines using
radioimmunoassay. However, no ET-1 receptors were detected in a panel of PC cell
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lines tested [36]. Oikawa et al further confirmed these findings and analyzed the
expression of all three ET isoforms in human PC cell lines postulating that the
expression pattern of all three isoforms is similar to endothelial cells [37]. Inconsistent
with the previous finding, Bhargava et al reported the presence of ET receptors in
pancreatic cancer cell lines and suggested that mRNA expression of ETAR is limited to
some cell lines (MiaCaPa-2 and AsPC-1, not Panc-1) with no detectable expression of
ETBR [38]. In this study, we delineate the expression of ET-1, ETAR and ETBR in a panel
of 13 PC cell lines using SW480 cells and SKMel 28 as positive controls for ET-1/ETAR
and ETBR respectively. Similar to previous observations, ET-1 was detected in all PC
cell lines, with the receptors showing inverse association with the exception of AsPC1,
BxPC3, Colo357 and Capan-1. Inconsistent with the previous findings we observed
expression of ETAR and ETBR in Panc1 and MiaPaCa respectively, whereas detectable
expression of both receptors is observed in AsPC-1 cells.
Using islet specific antibodies, previous studies have demonstrated the presence
of ET-1 and receptors in human and rat pancreas tissues thus suggesting the
involvement of ET axis in supporting the beta cell function [39]. Using radiolabeled
binding experiments; the presence of ET-1 and its receptors was also demonstrated in
rat beta cell lines INS-1 and RINm5f. Similar to pancreatic islets, radiolabeled binding
studies also indicate the presence the higher of ETAR than ETBR in the pancreatic acini
[40]. Cook et al recently reported the higher expression of ET-1 and ETBR in 45
pancreatic cancer samples compared to normal pancreas, however no positive staining
for ETAR was detected in the epithelium of tissues studied [41]. Our study to investigate
the expression pattern of ET axis components, ECE-1, ET-1 and both receptors in tumor
samples from Whipple resected PC cases and microarray from UNMC rapid autopsy
program suggests over expression of the axis as compared to normal pancreas. We
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have demonstrated that in normal pancreas, the expression is limited to acinar region
and low immunoreactivity for all four molecules is seen with prominent expression is
seen in pancreatic islets. In contrast, minimal immuno-staining is seen in the normal
pancreatic ducts. We observed that in Whipple resected PC cases, within the axis ECE1 has highest incidence and expressed in 89% cases (34/38). Analysis of the PC
specimens in the tumor samples further indicates that ET-1, ETAR and ETBR are
expressed in 86% (33/38), 76% (29/38) and 63% (24/38) of cases. The discrepancy in
the ETAR staining can be explained on the basis of antibody use in the study. Our
immunohistochemical analysis in human PC samples used a polyclonal antibody (used
by Cook et al) and demonstrated low staining intensity in the ductal cells of the
pancreas. We further confirmed our findings by immunostaining the serial sections to
compare the reactivity and intensity of the both the antibodies. Figure 18 shows clear
differences in the staining intensities in the three PC cases used; suggesting the low
ETAR incidence observed can be attributed to the selection of the antibody in the study.
We also investigated the expression pattern in different tumor samples (obtained from
the UNMC rapid autopsy program, RAP that included those with both the primary and
metastatic sites harvested). Similar to our previous analysis, overexpression of axis
components is seen compared to normal pancreas. The incidence of ET-1, ETAR and
ETBR is seen in 37.1% (13/35), 74.3% (29/39) and 31.5% (27/37) of the cases
respectively. The higher expression of ETAR specific antibody in both primary and
metastatic lesions of RAP tumor samples further strengthen our findings obtained in
Whipple resected tumor samples.
The tumor microenvironment of the PC is of particular interest, as the primary
tumor

possesses

an

extensive

and

obstructive

stromal

compartment.

This

microenvironment is comprised of endothelial cells, fibroblasts, immune cells and
vascular smooth muscle cells. ET-1 acts as a modulator of stromal response and
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facilitates tumor progression either in autocrine signaling on tumor cells or by paracrine
effect on nearby stromal cells [42]. Studies have shown that an elevated level of the ET
axis is correlated with tumor progression, intra-tumoral vascularization and tumor
angiogenesis [43] [44]. In breast cancer, increased ET-1, ETAR and ETBR expression is
associated with tumor progression, disease free survival and overall survival [45]. Also,
in bladder cancer overexpression of the axis is correlated with tumor grade and longer
disease free survival [46] [47]. In endothelial cells, ET-1 modulates the angiogenesis
process and exhibits a potent effect in combination with VEGF. ET-1 stimulates the
release of MMP-2, which allows sprouting and migration of endothelial cells and
formation of vascular cord-like structures indicating that ET-1/ETBR interaction favors
neovascularization in concert with VEGF [31] [30]. Previous observations have
demonstrated that both VEGF and ET-1 stimulate each other’s expression. In bovine
aortic endothelial cells, VEGF induces ET-1 mRNA expression and ET-1 secretion while
in vascular smooth muscle cells, ET-1 acts on ETAR to stimulate VEGF mRNA and
VEGF secretion showing a coordinated role of VEGF and ET-1 [48]. According to our
data, in addition to the expression on tumor cells, expression of ET axis is also observed
in the stroma of PC, particularly on immune cells and tumor blood vessels. We also
observed that an association between the elevated levels of ETBR on blood vessels with
poor overall survival. Our findings indicate that overexpression of ET axis proteins on
tumor cells is not correlated with patients overall survival. Importantly, our main finding is
that investigation of the tumor microenvironment components is necessary to establish
prognostic significance of the pathway and ETBR expression on blood vessels is an
independent prognostic factor for patient survival. To our knowledge, this is the first
report to demonstrate that ETBR is an independent prognostic marker for human
pancreatic cancer. It may follow from our data that even in a small data set, this is a
significant finding and further characterization of the different microenvironment
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components can add significant prognostic information
To further investigate the pathobiological significance of the pathway, we also
analyzed the expression of ET axis proteins in the TCGA database and their correlation
with tumor grade. Next, we investigated the implications of overexpression of ET axis
proteins in PC. In this study, we found significant positive correlation of ETAR and ETBR
with pro-fibrotic genes (Collagen I/III/VI, PDGFRβ, FAP) and pathways using a
bioinformatics approach. Pancreatic stellate cells (PSCs) are the resident cells of the
pancreas and are the principal source of fibrosis in the stroma that interact closely with
the surrounding tumor cells and stimulate tumor growth and metastasis [49]. Once these
cells are activated in response to external stimuli, inflammation (pancreatitis) or cancer,
PSCs acquire a myofibroblast like phenotype and secrete increase amount of
extracellular matrix (ECM) [50]. Tumor cells secreting ET-1 participate in the recruitment
and activation of PSCs. Alternatively, ET-1 is released from PSCs in an autocrine
manner and can also perpetuate their activation [51]. In the context of PC, Jonitz and
coworkers observed that treatment of PSCs with TGF-β1 and TNF-α stimulated the
secretion of ET-1 peptide by increased binding to smad3 and NF-kB respectively. Also,
treatment with ET-1 induced the phosphorylation of ERK1/2 and p38, a marker of PSCs
activation (α-SMA) and pro-inflammatory cytokines (IL-1β and IL-6) [52]. This ET-1
induced effect was abrogated by the dual ETAR and ETBR inhibitor, Bosentan and
displays anti-fibrotic effects in PSCs by marked reduction in the expression of CTGF
(connective tissue growth factor) and α-SMA [53] indicating a pro-fibrogenic role of ET-1
in PC. Our present study suggests that ET receptors are expressed in PC and in the
TME exhibit a significant correlation with fibrosis associated genes. This knowledge,
may provide a rationale for developing a novel cancer therapy for targeting the ET axis
to combat this fatal malignant disease. However, more experimental and clinical
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evidence are needed to prove the significance of this axis a therapeutic target. To
determine the clinical significance of targeting this axis in vivo, we have utilized the
widely used genetically engineered KPC mouse model (K-rasG12D; Trp53R172H/+; Pdx-1Cre) that harbors a Kras and p53 mutation in the pancreas.[54] [55]. We observed the
expression of ECE-1, ET-1; and both receptors increase gradually with the disease
progression in these mice. Our data also infers that in addition to tumor cells, a
prominent expression is seen in the stromal region (an observation similar to what we
witnessed in human PC cases indicating the potential of targeting this axis). Because the
main goal of the present study was to define and characterize the expression pattern in
various cell types in the microenvironment of PC, we utilized the -markers specific for
fibroblasts (α-SMA), endothelial cells (CD31), tumor-associated macrophages (CD68 &
F4/80), tumor cells (CK19) and stem cells (CD133). In this study, we found that CD31+
blood vessels and CD133+ stem cells show co-expression with both ETAR and ETBR. In
contrast, α-SMA+ fibroblasts, CD68+ and F4/80+ macrophages show predominant
expression of ECE-1, ET-1 and ETBR, however, low expression of ETAR was observed
in both KPC mouse and human PC tissues.
In conclusion, we have shown that, ET axis components are over-expressed in
pancreatic cancer cells, human PC tissues and in the KPC mouse progression model of
PC. Further, the proteins associated with this axis plays a pleotropic role in the TME and
are expressed in various cellular compartments. This study establishes the prognostic
significance of the ET axis in lethal PC indicating that TME components can also be of
prognostic significant. Importantly, positive correlation of extracellular matrix associated
genes further sheds light on the therapeutic potential of the axis and can be exploited for
improving the delivery and efficacy of existing drugs.
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Figure 1: Expression of ET-1, ETAR and ETBR in pancreatic cancer cell lines. A.
Protein lysates from a panel of PC cell lines and normal pancreatic ductal epithelial cells,
HPDE were resolved on 10% SDS-PAGE gel using western blot analysis. The
expression of ET-1, ETAR and ETBR was observed in these cell lines when incubated
with anti- ET-1, anti- ETAR and anti- ETBR antibody. Colon cancer (SW480) and
melanoma cell line (SKMel28) were used as positive control for ET-1/ETAR and ETBR
respectively. β-actin was used as an internal control. B. RT-PCR using ET-1, ETAR and
ETBR gene specific primers in PC cell lines. β-actin was used as an internal control.
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Figure 2: Expression of ECE-1, ET-1, ETAR and ETBR in pancreatic cancer tissues.
A. Immunohistochemical analysis of ECE-1, ET-1, ETAR and ETBR in the pancreatic
acini and ducts of normal pancreas (magnified image) with strong staining observed in
islet cells for all four molecules (black arrow). There is a significant increase in
expression of ECE-1, ET-1, ETAR and ETBR in the PC tissues when compared to normal
pancreas. The magnified image shows over-expression in the pancreatic ducts. B. The
staining score and intensity score were multiplied to obtain the composite scores.
Composite scores of ECE-1, ET-1, ETAR and ETBR in normal pancreas ducts and PC
tissues are shown as box plots. C. Heat map representation of ET axis expression in
normal pancreas and PC patients on case to case basis.
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Table I: Clinicopathological characteristics of Whipple resected PC patients. ET-1
positivity was significantly associated with a higher proportion of moderate grade
patients (p=0.04) and was negatively associated with a higher proportion of poor and
well grade patients.
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Table I

Primary Tumor (T): T1, T2, T3, T4: Size and/or extent of the primary tumor
Distant Metastasis: MX: Distant metastasis cannot be evaluated
M0: No distant metastasis
M1: Distant metastasis is present
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Figure 3: Expression of ET-1, ETAR and ETBR in pancreatic cancer tissues from
Rapid Autopsy Program (RAP). The staining score and intensity score were multiplied
to obtain composite scores and are represented in the heat map with a scale from 0 to12
from low expression to high expression respectively. Heat map representation of
immunohistochemical analysis of ET-1, ETAR and ETBR in metastatic sites in the primary
tumor (A), and metastatic sites of liver (B), lung (C), lymph node (D), omentum/
diaphragm (E) from tissue microarray obtained from rapid autopsy program. F.
Immunohistochemical representation of ET-1, ETAR and ETBR expression and incidence
in metastatic sites.
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Table II: Expression of ET-1, ETAR and ETBR with tumor grade in tissue microarray
(TMA)
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Table II
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Table III: Distribution of tissue microarray (TMA) indicating number of cases analyzed for
primary and metastatic sites for ET-1, ETAR and ETBR expression.
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Table III
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Table IV: Incidence of ET-1, ETAR and ETBR in TMA. The incidence rate (the
proportion positive) for each of the molecules for each of the tissues, using GEE
methods to take into account multiple tissue samples per patient with significant p value.
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Table IV

p=p= 0.022

p= 0.020

p= p=0.024

p= p=0.0020

p= 0.67
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Figure 4: Expression of ETAR and ETBR in the stromal compartment of human PC.
A. Immunohistochemical analysis of ETAR and ETBR in tumor blood vessels (red arrows)
and immune cells (green arrows). B. Grid map representing immunohistochemical
analysis of ECE-1, ET-1, ETAR and ETBR in immune cells and tumor blood vessels
along with the overall incidence in whipple resected PC patients. Red and black squares
represents the positive and negative cases respectively. C. Table represents the
incidence of ETAR and ETBR on blood vessels and immune cells
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Figure 5: Comparison of survival curves associated with ET axis expression in PC.
Kaplan Meier curves showing the overall survival in 33 whipple resected PC patients.
Tumor positivity for ET-1 (A), ETAR (B) and ETBR (C) are not significant independent
predictors of overall survival. Kaplan Meier curves showing ETAR (D) and ETBR (E)
expression on tumor blood vessels (BV). Survival curve indicate that the poor prognosis
of PC patients is associated with elevated expression of ETBR expression on BV
(p=0.024). Negative and Positive indicates low and high expression respectively.
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Figure 6: Comparison of ETBR expression on blood vessels. Immunohistochemical
analysis of ETBR in blood vessels (BV) in normal pancreas and in PC patients. In the
normal pancreas, ETBR expression can be seen in blood vessels with enlarged lumen
and restored architecture. Similar, in the PC (patient 3 and patient 4) comparable
expression can be seen in tumor blood vessels, however heterogeneous vascular
structure is seen. In contrast, in patient 5 and patient 6, elevated expression of ETBR on
BV can be seen and the expression is correlated with poor prognosis of the patients.
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Figure 7: Expression of ECE-1, ET-1, ETAR and ETBR in triple transgenic mouse
model of PC. A. RT-PCR analysis of ECE-1, ET-1, ETAR and ETBR mRNA expression
in various ages of mice from KrasG12D P53; Pdx-1-Cre (KPC) mice compared to
corresponding age-matched normal mice. A progressive increase in the expression of
ECE-1, ET-1 and both receptors is observed in KPC mice compared to healthy age
matched controls. GAPDH was used as a loading control. B. Immunohistochemical
analysis of ECE-1, ET-1, ETAR and ETBR in pancreatic tissues from normal wild type 25
week animals versus KPC mice at ages 5, 10 and 25 weeks. Control mice showed low
expression in the acinar compartment with predominant expression in the islet cells for
ECE-1, ET-1, ETAR and ETBR as indicated by black arrowheads. On the other hand,
increased expression was observed in the ductal compartment with advanced age in
KPC mice.
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Figure 8: Expression of ETAR and ETBR in tumor cells in human and mouse PC
tissues. Dual confocal microscopy images show co-expression of ETAR (red) and ETBR
(red) with epithelial marker CK19 (green) in human PC (A) and in 25 week KPC mouse
(B) tissue. Scale bar = 50µm.
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Figure 9: Expression of ETAR and ETBR in blood vessels in human and mouse PC
tissues. Dual confocal microscopy images show co-expression of ETAR (green) and
ETBR (green) with endothelial marker CD31 (red) in human PC (A) and in 25 week KPC
mouse (B) tissue. Scale bar = 50µm.
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Figure 10: Expression of ETAR and ETBR in pancreatic stellate cells in human and
mouse PC tissues. Dual confocal microscopy images show co-expression of ETAR
(red) and ETBR (red) with stellate cell marker α-SMA (green) in human PC (A) and in 25
week KPC mouse (B) tissue. As compared to ETBR, low expression of ETAR is seen in
α-SMA positive cells. Scale bar = 50µm.
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Figure 11: Expression of ETAR and ETBR in macrophages in human and mouse PC
tissues. Dual confocal microscopy images show co-expression of ETAR (red) and ETBR
(red) with macrophage marker, CD68 and F4/80 (green) in human PC (A) and in 25
week KPC mouse (B) tissue. As compared to ETBR, low expression of ETAR is seen in
CD68 and F4/80 positive macrophages. Scale bar = 50µm.
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Figure 12: Expression of ETAR and ETBR in stem cells in mouse KPC tissues. Dual
confocal microscopy images show co-expression of ETAR (red) (A) and ETBR (red) (B)
with stem cell marker CD133 (green) in 25 week KPC mouse tissue and control. As
compared to age-matched control, increase co-expression is seen for both ETAR and
ETBR is seen in CD133 positive stem cells. Scale bar=50µm.
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Figure 13: Expression of ECE-1, ET-1 in tumor cells in human and mouse PC
tissues. Three color immunofluorescence analysis show co-expression of ECE-1 (red),
ET-1 (purple) with epithelial marker CK19 (green) in human PC (A) and in 25 week KPC
mouse (B) tissue. Both ECE-1 and ET-1 showed predominant co-expression with CK19
positive tumor cells. Scale bar= 20µm.
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Figure 14: Expression of ECE-1, ET-1 in pancreatic stellate cells in human and
mouse PC tissues. Three color immunofluorescence analysis show co-expression of
ECE-1 (red), ET-1 (purple) with stellate cell marker α-SMA (green) in human PC (A) and
in 25 week KPC mouse (B) tissue. Both ECE-1 and ET-1 showed predominant coexpression with α-SMA positive stellate cells. Scale bar= 20µm.
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Figure 15: Expression of ECE-1, ET-1 in macrophages in human and mouse PC
tissues. Three color immunofluorescence analysis showing co-expression of ECE-1
(red), ET-1 (purple) with macrophage marker CK19 (green) in human PC (A) and in 25
week KPC mouse (B) tissue. Both ECE-1 and ET-1 showed predominant co-expression
with CD68 and F4/80 positive macrophages. Scale bar= 20µm.
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Table V: Expression profile of ET axis in TME of PC. Summary of the ET axis
components (ECE-1, ET-1, ETAR and ETBR) expression in tumor cells, stellate cells,
blood vessels, macrophages and stem cells. (NA= not analyzed).
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Table VI: Expression of ET 1, ETAR and ETBR in TCGA databse. i. Representation of
the number of TCGA cases on the basis of tumor stage. ii. Correlation of ET-1 (EDN1),
ETAR (EDNRA) and ETBR (EDNRB) with disease stage in the TCGA sample set showed
higher expression is significantly correlated with disease stage.
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Table VII: Bioinformatics analysis of TCGA database identified pro-fibrotic gene
signatures associated with ETAR and ETBR over expression. The top 30 genes
exhibiting strongest positive correlation with ET-axis included signaling receptor
(PDGFRβ), extracellular matrix (ECM) proteins [collagens (COL1A2, COL6A3, COL5A2;
fibro-nectin (FBN1), SPARC, lumican (LUM)], ECM modifying enzymes [sulfatase 1
(SULF1); chondritin sulfate synthase 3 (CHSY3)], basement membrane proteins [Nidogen 2 (NID2)] and marker of fibroblast activation (FAP).
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153
Figure 16: Correlation of pro-fibrotic gene PDGFR-β with ETAR over expression.
Example of one gene showing positive correlation with ETAR over-expression. Pearson
correlation coefficient ‘r’ indicates the strength of the linear relationship between two
variables. An ‘r’ value of 0 indicates no association between the two variables whereas
an ‘r’ of +1 and -1 indicates the perfect positive and negative association respectively
between the variables. Every dot indicates one patient. The association of PDGFR-β
with ETAR expression (r=0.93), indicates a stronger association of the two variables.
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Figure 17: Correlation of pathways associated with ET axis over expression.
Significant pathways were identified by Ingenuity pathway analysis that are upregulated
and positively correlated with ET axis over expression.
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Figure

18:

Comparison

of

ETAR

staining

in

human

PC

tissues.

Immmunohistochemical analysis of ETAR in serial sections of three human PC cases
was compared to assess the immuno-reactivity of two different antibodies. A prominent
increase in the ETAR expression was seen in pancreatic ducts with Abcam antibody as
compared to the Novus biologicals antibody.
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Chapter 4
Targeting endothelin axis in pancreatic cancer using selective
and dual receptor inhibitors under in vivo (KPC, K-rasG12D;
Trp53R172H/+; Pdx-1-Cre) and in vitro (pancreatic stellate cells and
cancer associated fibroblasts) system
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Synopsis
One of the hallmarks of pancreatic cancer (PC) is extensive and dense fibrous
stroma that makes up 60-70% of the total tumor volume. Interaction of stromal cells with
the cancer cells further modulates the malignant properties and favor metastasis of
cancer cells. The cross talks between the stromal cells with each other and also with the
tumor cells contribute to tumor growth and aggressiveness. The role of Endothelin(s) in
the context of PC is not well studied and provides indirect evidence in fibrosis. In this
study, we have evaluated the impact of targeting this axis using dual endothelin receptor
antagonist, Bosentan using in vitro (murine stellate cells and human cancer associated
fibroblasts) and in vivo mouse (KrasG12D, Trp53R172H+/-, Pdx-1-Cre) model. Bosentan
treatment resulted in decrease in desmoplasia accompanied by decrease expression of
extracellular matrix proteins. Further, the treatment induced direct killing of tumor cells
as indicated by increase in cleaved caspase-3 positive cells. In vitro, pre-treatment of
murine pancreatic stellate cells and human cancer associated fibroblasts with ETs
inhibitors abrogated ET-1 mediated up regulation of fibrotic genes and suggested that
ET-1 primarily induces pro-fibrotic gene signatures by both ET receptors. Further, ET-1
stimulation in PSCs induced a significant increase in the p-ERK and p-AKT in a time
dependent manner. This ET-1 induced increase was inhibited by selective ETBR
antagonist BQ788 and to a lesser extent by selective ETAR antagonist BQ123, however
dual receptor antagonist Bosentan significantly attenuated the ET-1 mediated induction.
Our studies suggest that signaling through ET-1 axis regulates pro-fibrogenic genes
through ERK and AKT dependent pathway in PSCs. In addition, pharmacological
inhibition of the ET axis reduces the infiltration of tumor-associated macrophages and
increases infiltration of cytotoxic T cells in the PC stroma. Altogether, our studies also
demonstrate

that

targeting

ET

axis

can

modulate

the

obstructive

and
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immunosuppressive TME and make it potentially more amenable for chemotherapy and
immunotherapy.
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Background and Rationale
PC is the 4th leading cause of cancer-related deaths in the United States
accounting for nearly 37,390 deaths annually [1]. Due to the lack of early diagnostic and
therapeutic modalities, PC has extremely poor prognosis with a dismal five year survival
rate of <8%. Despite notable advances in surgical technique and postoperative care,
and the use of adjuvant chemical and radiotherapies, virtually all early-stage patients
who undergo resection also eventually succumb to recurrence and/or metastasis [2] that
account for lethality of the disease. One contributing factor to the failure of systemic
therapies may be the abundant tumor stromal contents forming the physical barrier and
thereby impeding the drug delivery [3]. The stromal microenvironment is a complex
structure composed of an extracellular matrix (ECM), cancer associated fibroblasts
(CAFs), inflammatory cells and blood and lymphatic vessels that distort the normal
architecture of pancreatic tissue. A major source of CAFs in PC is pancreatic stellate
cells (PSCs), which are resident cells of the pancreas that store lipid droplets and
express fibroblast activation protein-α (FAP α) [4]. Once activated in response to
external stimuli, inflammation or injury, PSCs express the myofibroblast protein αsmooth muscle actin (α-SMA) and secrete factors that stimulate tumor growth and
metastasis.
Recently, activation of sonic hedgehog (SHh) pathway has been identified to
promote stromal desmoplasia [5, 6]. Inhibition of SHh by neutralizing antibody or small
molecule inhibitor has been shown to decrease desmoplasia [7] and improve small
molecule drug uptake in pancreatic tumors in KPC mice. However, most of the tumors in
KPC mice resumed growth after a transient response [8]. Another microenvironment
targeting strategy, utilizes CD40 agonist to drive antitumor T cell response-facilitating
depletion of tumor stroma [9], making PC stroma as an attractive therapeutic target for
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drug development. However, controversy exists and recent evidence has questioned the
role of stroma in PC progression. Transgenic mice with αSMA(+) myofibroblasts
depletion in the tumor stroma induces immune suppression and accelerates cancer
progression [10]. Also, genetic ablation or prolonged inhibition of sonic hedgehog ligand
led to non-invasive and poorly differentiated tumors and decreased survival in mice [11].
These findings demonstrate the need to use caution when targeting stroma in PC and
highlight the importance of selective modulation of stroma is prerequisite to achieve
considerable therapeutic benefit and improve the effectiveness of stroma- targeting
drugs.
Endothelins (ETs) are a family of three peptides, ET-1, ET-2 and ET-3, which
mediate pleotropic effects via two G-protein coupled receptors ETAR and ETBR and have
key physiological functions in normal tissue, and act as modulator of vasomotor tone [12]
Accumulating evidences indicate the pro-fibrogenic role of ET-1 in the various
pathological malignancies including cancer and have gain considerable interest and
attention[13] Mechanistic and experimental evidences implicate the regulation of ET-1 at
the transcriptional level. Several factors such as shear stress, hypoxia, TGF-β, IFN-γ,
angiotensin II and thrombin up-regulate; whereas, nitric oxide down regulate the
expression of ET-1 mRNA [14] [15]. The involvement of ET-1 in diverse biological
processes can be attributed to its interaction with various transcription factors such as
GATA, Smad, TGF-β and activator protein-1 (AP-1) [12]. The role of ETs in the context
of pathogenesis of PC and fibrosis is not well studied and provides incomplete evidence.
The effect of targeting ET axis and its impact on fibrotic genes was evaluated using dual
ET receptor inhibitor, Bosentan in rat model. Bosentan treatment was found to inhibit the
proliferation of PSCs and the genes involved in PSC activation like α-SMA and CTGF
[16]. In addition, ET-1 induced phosphorylation of ERK and MLC promotes migration and
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contraction of stellate cells. This ET-1 induced migration and contraction was inhibited
by selective ETA and ETB antagonist[17]. In addition to contraction and migration caused
by ET-1, stimulation led to the activation of PKCs, MAPK and ERK pathway. Further, it
also enhances the production of pro inflammatory cytokines like IL-1 and IL-6 and
expression of α-SMA and CTGF (connective tissue growth factor) suggesting an
autocrine and paracrine loop mediated by ET-1 which acts on activated stellate cells[18].
In this study, we have evaluated the impact of ET axis inhibition using
autochthonous tumors that develop in genetically engineered mouse model (KPC) of
PC. The study here in provides for the first time the anti-tumor and anti-fibrotic effects of
ET axis antagonism in lethal PC in vivo. Importantly, we also examine the effect of
selective and dual receptor antagonists on the proliferation of murine PSCs and human
CAFs and investigated the molecular mechanisms responsible for ET-1 mediated
induction of the pro-fibrotic gene signatures. Our results also suggest that
pharmacological targeting of the ET axis in KPC mice reduces the infiltration of tumorassociated macrophages and increases recruitment of cytotoxic T lymphocytes (CTLs).
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Results
A. Inhibition of ET axis in vivo using Bosentan increases apoptosis and reduces
fibrosis in KPC autochthonous tumors
We evaluated the impact of ET-axis inhibition in autochthonous tumors that develop
in genetically engineered mouse model (KPC) of PC that is driven by pancreas-specific
expression of mutant K-ras and p53. Dual endothelin receptor antagonist, Bosentan
(1mg/kg body weight) was administered for a period of 10 days in 20 wk KPC mice
(n=5) having high stromal content whereas the control animals (n=5) received saline. At
the end of the treatment period the primary tumors were harvested and analyzed for
various histopathological features such as fibrosis and apoptosis. No difference in the
weight and volume of pancreas was observed. Bosentan treatment resulted in a
significant increase in the number of apoptotic cells (p=0.01) compared to saline treated
control group as indicated by immunohistochemical staining against cleaved-caspase 3
and TUNEL staining (Figure 1A). Using Trichrome-Masson staining we observed that
Bosentan treatment reduces stromal growth in KPC derived tumors compared to control
group (Figure 1B). The Trichrome-Masson staining for fibrosis/desmoplasia was
evaluated in mouse pancreatic tissue sections in a semi-quantitative fashion. Moderate
to strong staining was seen in areas with control mice with 51-75 and 76-100 percent
positivity respectively. In treated group, the staining shows variability with areas having
poor to moderate staining with 0-25 and 26-50 percent positivity. The composite score
is obtained by multiplying the numerical value and staining intensity for both the groups.
To further determine the impact on fibrosis following Bosentan treatment we sought
to investigate the effect on matrix associated genes using RT2 profiler fibrosis PCR
array. Following 10-day treatment the tumors were harvested and used in the array as
described in the materials and methods section. Data were normalized to six house

171
keeping genes in the array. Heat map represents the expression of 84 genes involved
in the PCR array (Table I). The array contains the genes encoding ECM remodeling
enzymes, TGFβ signaling molecules and inflammatory cytokines, as well as additional
genes important for fibrosis. The volcano plot in Figure 2A was used to identify genes
that are 2-fold differential expressed upon treatment with ET antagonist as compared to
control. We observed that Bosentan treatment has a significant impact and down
regulated the pro-fibrotic gene signatures such as CTGF (5.22 fold), α-SMA (1.51 fold).
In addition, we also found that a reduction in the extracellular matrix proteins such as
Col3a1 (5.12 fold), Col1a2 (4.54 fold) with significant p value (Figure 2B).
Pharmacological inhibition of the ET axis using Bosentan also decreased the levels of
matrix remodeling enzymes such as Lysyl oxidase (Lox) (2,87 fold), Mmp2 (3.57 fold),
Mmp14 (3.58 fold) and cellular adhesion proteins such as Integrin alpha V (Itgav) (2.55
fold), Integrin subunit beta 1 (Itgb1) (2.31 fold) and Integrin subunit beta 1 (Itgb5) (2.30
fold) with significant p value (Table I). Further we also observed that Bosentan treated
KPC mice displayed reduce levels of members of TGFβ superfamily such as Tgfb3
(2.45 fold), Tgfbr1 (1.64 fold), Smad 3 (1.75 fold), serine/threonine kinase AKT 1 (1.93
fold) and growth factors such as Pdgfa (1.39 fold) and Pdgfb (2.25 fold). Table II
represents the overall summary of the gene expression profile. The pro-fibrotic
associated gene signatures identified through TCGA database displayed significant
association with ET axis overexpression and the gene signature targeted by Bosentan
in fibrosis array is in concordant with ET axis association as predicted by TCGA
analysis. These findings indicate that Inhibition of ET-axis by dual-specificity inhibitor
Bosentan resulted in significant decrease in desmoplasia and increase in apoptosis in
autochthonous tumors in KPC mice, suggesting a possible a possible impact on fibrosis
on targeting ET axis. The decrease in the expression of these genes was confirmed by
western blot analysis using tumor lysates and there was significant reduction in the
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expression of CTGF, αSMA, fibronectin and FSP1 (Figure 3A). These findings were
further confirmed through immunohistochemistry analysis as well. Bosentan treatment
reduces the extracellular matrix proteins mainly collagen and αSMA which is associated
with stellate cells activation and also fibronectin and CTGF, suggesting a possible
impact on fibrosis on targeting this axis.

B. Bosentan treatment decreases the FSP1 positive but not FAP positive
fibroblasts in PC tumor stroma
To further determine the impact on various populations of stromal fibroblasts
following Bosentan treatment triple immunofluorescence analysis was done using CK19,
αSMA and FSP1 specific antibodies (Figure 4A). Bosentan treatment reduces both FSP
1 positive and αSMA positive fibroblasts in the PC tumor stroma with significant p value.
Interestingly, α-SMA expressing fibroblasts surround the CK19 positive ducts whereas
the FSP1 staining is present in different sub population and exhibits no overlap with αSMA (Figure 4B). In addition, Bosentan treatment has no significant effect on FAP
positive fibroblasts cells however co-localization with α-SMA was seen (Figure 4C).

C. ET-1 promotes proliferation and migration of pancreatic stellate cells
(ImPSCc2)

As pancreatic stellate cells are predominantly responsible for desmoplastic
reaction in PC, the effect on growth on immortalized pancreatic stellate cell line
(ImPSC.c2) was evaluated by MTT assay. Treatment of ImPSCc2 cells with recombinant
ET-1 increased their proliferation in a time and dose dependent manner, with significant
effects at 100nm (Figure 5A). ETAR specific antagonist (BQ123) has negligible effect on
growth of these ImPSC.c2 (Figure 5B) however; both ETBR specific (BQ788) (Figure
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5C) and dual receptor antagonists (Bosentan) (Figure 5D) reduced the growth in time
and dose dependent manner. To further assess the mechanism of underlying cause of
the growth inhibition of ImPSCc2 following treatment with endothelin antagonists we
performed cell cycle analysis and Annexin V staining of the control and treated cells by
fluorescence activated cell sorting analysis. Increase apoptosis in stellate cells
compared to control was seen following treatment with receptor B antagonist BQ788 and
dual receptor antagonist Bosentan (Figure 6A & 6B). Also, treatment with BQ788
induced G1/S cell cycle arrest. The percentage of cells increased from 48.2% to 54.5%
and 32.9% to 35.7% in G1 and S phase respectively. Treatment with endothelin A/B
receptor antagonist arrest cells in S phase of the cycle. The percentage of cells
increased from 32.9 % to 48.2 % and decreased from 48.2 % to 37.8% in the S phase
G1 phases respectively (Figure 6C). We then investigated the effect of ET-1 and
inhibitors on the migratory potential of ImPSCc2 using wound healing assay (Figure 7).
The cells were seeded in a 6 well plate and after the cells reached approximately 90%
confluency an artificial wound was made using 200μl pipette. The cells were then
washed with PBS and were then incubated for 24 hr in presence of endothelin
antagonists after pretreatment for 45 mins before addition of 100nm of ET-1. Phase
contrast images were obtained at 0h, and 24hr time points. As compared to the control
group, treatment with recombinant ET-1 displayed a higher migration rate of ImPSCc2 in
a time dependent manner with significant effects observed at 24 hr (p<0.01). In contrast,
selective A receptor (p<0.01) and B receptor (p<0.01) inhibitor treated cells resulted in
significant decrease in the cellular migration compared to rET-1 group. This observation
of decreased cellular migration was further strengthened using dual ET axis antagonism
as it also demonstrated a significant decrease in migration of PSCs (p<0.01).
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D. ET-1 stimulates expression of pro-fibrotic genes predominantly through ETBR
and to lesser extent by ETAR in murine pancreatic stellate cells in vitro
We also evaluated the anti-fibrotic effects of ET axis antagonism in vitro and
investigated the expression of ET axis in immortalized mouse pancreatic stellate cells
(ImPSCc2) and tumor cell line derived from KPC model of PC. We have successfully
derived and characterized aggressive cell line UN-KPC-961, from the primary tumors
that developed in KPC mice [19]. To study the cellular cross talk between tumor and
stellate cells along ET axis in vitro, 2D co-culture using Boyden chamber was utilized
where immortalized mouse stellate cells are cultured in presence of tumor cells alone or
in the presence of selective ETAR (BQ123), selective ETBR (BQ788) and dual
(Bosentan) ET receptor antagonists. Our results indicated that tumor cells express
receptor A whereas stellate cells predominantly express receptor B and low levels of
receptor A (Figure 8A). The co-culture of ImPSCc2 with UN-KPC-961 cells did not alter
the matrix-associated markers. Co-culture of ImPSCc2 treated with BQ123 did not
influence expression of stromal genes. ET axis antagonism resulted in inhibition of
genes associated with PSC activation (α-SMA) predominantly through ET-1/ETBR
signaling however, dual receptor inhibition using Bosentan significantly inhibit the
expression of α-SMA, CTGF fibronectin and Collagen-1 in these cells (Figure 8b).
Additionally, serum starved stellate cells were pre-treated with endothelin inhibitors,
which is not toxic to cells for 45 mins prior to addition of recombinant ET-1. Exogenous
administration of ET-1 caused timely dependent increase in expression of αSMA,
CTGF, fibronectin and collagen I in stellate cells (Figure 8c).This ET-1 induced
expression was inhibited by selective ETBR antagonist BQ788 and not by selective
ETAR antagonist, BQ123. Moreover, ET-1 induced expression was significantly
abrogated by dual receptor antagonist Bosentan, suggesting that ET-1 stimulates
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expression of matrix-associated genes mainly through ETBR and to less extent by
ETAR.

E. Expression of ET-1 and receptors in patients derived fibroblasts
We further extended our studies in fibroblasts derived from the pancreas of
healthy individuals, chronic pancreatitis and cancer associated fibroblasts. These cell
lines were developed and immortalized in our lab. We first characterized the purity of
these cell lines using immunoblot analysis against specific myo-fibroblast marker αSMA and epithelial marker CK19. The HEK 293 and Panc1 cells were used as positive
controls for α-SMA and CK19 respectively (Figure 9A). As compared to normal
fibroblasts, a robust expression of α-SMA was observed in these cell lines whereas no
expression of CK19 was evident. In addition to α-SMA, the expression of other profibrotic genes like collagen I, fibronectin, CTGF was analyzed. Desmin, which is
supposed to be a marker for quiescent fibroblasts, is expressed at very low levels in
these cells (Figure 9B). The expression pattern of ET-1 and its receptors in fibroblasts
isolated from chronic pancreatitis and cancer patients were also studied by RT-PCR
analysis using PC3 as a positive control. Expression of ET-1 and ETAR was seen in all
cell lines tested except 10-32 fibroblasts. However, the expression of ETBR is mainly
observed in cell lines derived from cancer-associated fibroblasts (Figure 9C).
F. Inhibition of ET-1 axis inhibits fibrosis in human CAFs in vitro
The effect of selective ETAR antagonist, BQ123, selective ETBR antagonist,
BQ788 and dual receptor antagonist, Bosentan on proliferation of 10-03 CAFs (express
both ETAR and ETBR) was also determined by MTT assay. Similar to the effects
observed on ImPSCc2 cells, BQ123 has negligible effect on growth of these cells
(Figure 10A), however both BQ788 (Figure 10B) and Bosentan (Figure 10C) reduce
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the growth in a dose and time dependent manner. We also evaluated the anti-fibrotic
effects of ET axis antagonism in vitro using 10-03 CAFs. These serum CAFs were pretreated with endothelin inhibitors, which is not toxic to cells for 45 mins prior to addition
of recombinant ET-1. The ET-1 treatment caused time dependent increase in the
expression of α-SMA, fibronectin and collagen I (Figure 11A & 11B), an effect similar
as observed in ImPSCc2 cells. Both selective ETAR and ETAR inhibitors abrogated the
ET-1 induced expression in pro-fibrotic gene signatures after 4 hr of treatment.
However, a synergistic effect was observed with dual receptor antagonism, Bosentan
(Figure 11A & 11B).

G. ET-1 promotes the expression of pro-fibrotic genes through a p42/44 MAPK
and AKT dependent pathway
To probe the signaling mechanism through which ET-1 induces the expression of
pro-fibrotic genes we perform the western blot analysis. We found that treatment with
recombinant ET-1 in murine ImPSCc2 induces a robust expression in the p-ERK and pAKT in a time dependent manner with a peak observed at 1hr of treatment (Figure 12A
& 12B). Pretreatment of selective A and B inhibitors decrease the ET-1 mediated
increase in the p-ERK levels, however no significant effect was observed in p-AKT
levels. In addition, a 45-min pre-incubation with the dual specificity ETAR and ETBR
antagonist Bosentan blocked the ability of ET-1 to induce phosphorylation of p-AKT and
p-ERK levels, suggesting that ET-1 induces the expression of pro-fibrotic genes through
ERK and AKT dependent mechanism (Figure 12A & 12B). Similar to murine stellate
cells, we found that treatment with recombinant ET-1 in 10-03 CAFs induces a robust
expression in the p-AKT in a time dependent manner and persistent activationwas seen
up to 16 hrs (Figure 13A & 13B). Pretreatment with both selective ETA and ETB
receptors inhibitors decrease the ET-1 mediated increase in the p-AKT levels after 4 hrs
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of treatment. In contrast, Bosentan abrogated the ET-1 mediated increase after 30 mins
of treatment. Additionally, ET-1 also induces the expression of p-ERK with a peak
observed after 1 hr of treatment and sustained increase in the p-ERK levels was seen up
to 16 hrs. Both BQ123 and BQ788 reduces the phosphorylation of ERK at 16 hrs of
treatment, however, dual receptor inhibition abrogated the ET-1 induces increase after 8
hrs of treatment (Figure 13A & 13B), suggesting that both p-AKT and p-ERK signaling
are inhibited at different time points.

To summarize the overall findings,endothelin-1 release from the tumor cells act on
the nearby pancreatic stellate cells in a paracrine manner expressing endothelin
receptors and activate the downstream signaling which in turn induces the expression of
pro-fibrotic genes through ERK/AKT dependent manner. However, in presence of
Bosentan the binding of ligand to the receptor is inhibited resulting in the decrease
expression of pro-fibrotic genes (Figure 14).

H. ET axis antagonism reduces infiltration of macrophages and increases
cytotoxic T cell populations
We further determine the impact on recruitment of macrophages and T cells
population in PC stroma following Bosentan treatment in autochthonous tumors (in KPC
mouse model of PC). Dual specificity ET axis antagonist Bosentan reduces the number
of tumor associated macrophages (TAMs) in KPC mice compared to age matched
controls with significant p value (p<0.008) (Figure 15A). In addition, we also observed
that pharmacological inhibition of ET axis reduces M2 marker (CD206) in KPC tumors
with significant p value (Figure 15B). Interestingly, Bosentan treatment enhance
recruitment of CD3 positive T cells in the stromal compartment of KPC tumors (Figure
16). Importantly, our immunofluorescence analysis also suggests increased infiltration
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of cytotoxic T cells (CTLs) in the treated KPC tumors. Quantitative examination of the
mice tumor tissues infers infiltration of CD8+ T cells with significant p value (p=0.007)
(Figure 17C &17D) compared to age matched controls, whereas no significant
difference in CD4+ T cells was observed (Figure 17A & 17B).
Expression of ET receptors in human macrophage-like U937 cells was also
determined using Immunoblot analysis using Colo357 and T3M4 PC cells as postive
controls for ETAR and ETBR. The U937 cells predominantly express ETBR, which was
not impacted by the differentiation status of the macrophages following treatments with
PMA and cytokines (Figure 18A). The effect of ET antagonism using seletive and dual
inhibitor on migration of human monocytes U937 (Figure 18B) and murine
macrophages RAW264.7 (Figure 18C) towards tumor cells was analyzed using Boyden
chamber assay. Monocytes and macrophage were cultured in serum free media and
their migration towards Panc 1 and UN-KPC-961 cells in presence and absence of
inhibitors was evaluated. In both U937 and RAW cells increased migration was seen
towards tumor cells. Importantly, both specific and dual inhibitors significantly reduce
the tumor cell induced migration of U937 cells. In addition, ETBR-specific inhibitor,
BQ788 and dual ET receptor antagonist, Bosentan significantly inhibited tumor cell
induced migration of murine macrophage-like RAW 264.7 line while minimal effects with
ETAR-specific inhibitor, BQ123 was observed.

I.

Selective ETAR antagonism increases tumor perfusion and decreases tumor
hypoxia in xenografts tumors
Selective ETAR antagonism using BQ123 has been demonstrated to specifically

induce dilation of tumor vessels and improve perfusion in low-perfused tumor areas [20]
We evaluated the effect of ETAR antagonist BQ123 in xenograft murine model derived
from pancreatic cancer cell lines. The change in perfusion was studied by MRI using
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flow sensitive alternating inversion recovery (FAIR) (Figure 19A). Perfusion was
measured prior to adminsitrationof BQ123 to establish base line and subsequently
imaged for 120 mins post adminsitration. Left panel shows the anatomic MRI scan to
indicate the postion of the tumor and the region of interest in the tumor and muscle for
perfusion analysis. Changes in perfusion in response to BQ123 were more pronounced
in tumors than in the muscle. Further, we observed that the kinetics of perfusion
changes were notably different in the T3M4 and Colo 357 tumors(Figure 19B). We also
found that enhanced perfusion induced by BQ123 resulted in decreased hypoxia in
T3M4 tumors (Figure 19C).

Discussion
An intense stromal desmoplastic reaction surrounding the tumor cells is the
typical histological hallmark feature in PC and pancreatic stellate cells (PSCs), one of
the major components of the TME are most important cellular source of CAFs in PC [21].
Evidences indicate that ET-1 mediate recruitment of various cell types such as resident
fibroblast, stellate cells, vascular pericytes, circulating bone marrow derived monocyte
responsible for pro-fibrotic potential of ET-1 [22]. Studied have indicated that ET-1
mediate the contraction, migration and expression of matrix associated genes in PSCs
are abolished by dual receptor ETAR and ETBR inhibitor, Bosentan [23], however the
data is very limited and provide inconclusive role of ET axis in generating the stromal
reaction in PC. Our preliminary investigation suggests the direct correlation of stromal
associated genes with ET axis in lethal PC. Bioinformatics analysis of the TCGA
database infers that over expression of ET-1, ETAR and ETBR in PC has significant
correlation with the fibrosis associated genes and pathways demonstrating the
therapeutic potential of the axis. Our more recent data from the animal experiments
confirm the pro-fibrogenic effect of ET-1 in vivo. We evaluated the impact of ET axis
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antagonism using spontaneous KPC mice model treated with Bosentan. Bosentan is
currently used in clinics to treat pulmonary hypertension and the formation of new digital
ulcers in scleroderma patients [24] [25]. Our data show that Bosentan treatment of 20week KPC mice, which has abundant tumor stroma, has global impact on the pro-fibrotic
gene signatures compared to control mice. Further visualization of treated tumor tissues
indicates decrease in the IHC and Immunoblotting signals for Collagen I, fibronectin, αSMA and CTGF. Additionally, inhibition of the ET axis using FDA approved drug,
Bosentan induces significant increase in the TUNEL positive cells and increased
positivity of cleaved caspase 3. To our knowledge this is the first study to demonstrate
the anti-fibrotic and anti-tumor effect of ET axis inhibition using genetically engineered
mouse model in PC. Further comparative gene expression analysis on fibrosis gene
array implies down- regulation of transcription factors such as Smad and TGF-β.
Moreover, studies have shown that the pleotropic action mediated by ET-1 can be
attributed to its interaction with various factors such as GATA, Smad, TGF-β and AP-1
[26, 27]
We speculate that anti-fibrotic effects of Bosentan can be attributed to its reduce
interactions with the transcription factors. Further observation that ET-1 is a downstream
mediator of TGFβ is elucidated by the observation that Bosentan blocks the ability of
TGFβ to induce the expression of the fibrotic gene signatures such as α-SMA in
fibroblasts isolated from scars of scleroderma patients [28]. Also, signaling pathways
induced by ET-1 and TGFβ signaling led to increase ECM synthesis and contraction
converge on a similar signaling pathway indicating synergistic association between the
two [29] [30]. Evidence also suggests that, ET-1 increases TGF-β expression and
collagen synthesis by eliciting Ca2+ release in an ETAR dependent manner [31, 32].
Also, in human stellate cells, TGF-β stimulated ET-1 release by stabilization of ET-1
mRNA through PI3K/AKT dependent pathway was abolished by ETAR antagonist,
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BQ123 [33]. One of the important finding of our study is that the stroma associated
genes identified through human TCGA database analysis displayed positive and
significant correlation with ET axis overexpression and gene expression analysis in
fibrosis array indicates significant down-regulation of the gene signature targeted by
Bosentan.
Accumulating evidence indicates the presence of heterogeneous population of
cancer-associated fibroblasts within the tumor microenvironment and controversy exists
whether it can promote or inhibit tumor growth. Alpha-smooth muscle actin (α-SMA)positive myofibroblasts have long been recognized as a prominent component of the
activated fibroblasts. In addition to α-SMA, various other markers such as FAP, FSP1,
vimentin can also detect stromal fibroblasts in tumors. Interestingly, FSP1 identifies a
unique population of fibroblasts, which is, distinct from alpha SMA positive fibroblasts
and it is also expressed on immune cells [34, 35]. Lineage tracing experiments also
implies that FSP-1 is not a marker for precursors of myofibroblasts but co-expressed on
cells with F4/80 and other markers of the myeloid-monocytic lineage [36]. We have
demonstrated that in addition to α-SMA, Bosentan treatment decreases the FSP1
positive cells in the PC stroma, however no colocalization was observed with α-SMA
positive myofibroblasts, an observation similar to earlier findings. One the contrary, our
immunofluorescence analysis using fibroblast activation protein (FAP) antibody indicates
no significant difference in the treated mice KPC tumor tissues. Elevated macrophage
infiltration in tumor tissues is associated with metastasis of many solid tumors [37].
Several observations have also linked the orchestrated actions of ETs in neutrophils,
monocytes and macrophages within the complex host microenvironment. ET-1 ligand
has been earlier shown to be strong chemo attractant for blood monocytes [38].
Interestingly, a 31 amino acid bioactive peptide exhibited significant chemotactic activity
towards monocytes and neutrophils compared to 21 amino acid ET-1 peptide and big
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ET-1. Grimshaw et al. reported that hypoxia induced increase in ET-2 production acted
as a chemo attractant for macrophages and monocytes, which are dependent on ETBR,
indicating a possible role of ET-2 in facilitating the recruitment of inflammatory cells [39,
40] Within the tumor microenvironment, autocrine and paracrine signaling between the
tumor and macrophages accelerate the infiltration towards the inflamed sites. In bladder
cancer, ET-1/ETAR interaction increase migration of both tumor cells and tumor
associated macrophages (TAMs) with enhance production of IL-6, MMPs and CCL2,
accompanied by increase in metastatic colonization in the lung via ruptured vascular
integrity [41].Very recently, in an experimental breast cancer model, it was reported that
ET axis mediates lung metastasis and transendothelial migration of breast cancer cells
stimulated by macrophages [42]. Additionally, in a rat model stromal deficiency of the
ETBR was correlated with reduced metastatic spread, infiltration of TAMs and production
of TNF-α, suggesting a pivotal role of the ETBR in tumor progression [43]. Our data
revealed that pharmacological inhibition of ET receptors significantly reduced infiltration
of F4/80 positive macrophages in the spontaneous mouse model. Our in vitro findings
also demonstrate that selective ETAR (BQ123) and ETBR (BQ788) antagonists inhibited
the increase migration of both murine macrophages (RAW 264.7) and human monocytic
cells (U937) towards UN-KPC-961 and Panc 1 cells respectively. These findings indicate
that ET-1 mediate chemo taxis of macrophages in PC stroma is dependent on both ET
receptors, however further studies are required to delineate the molecular mechanisms
of ET-1 mediated chemotactic interaction between tumor cell and TAMs.
We also evaluated the association of ET axis with tumor immunity following
Bosentan treatment in KPC tumor model. Previous studies have shown that ET-1 axis
also has a unique role to regulate immune response in tumor environment. In human
ovarian tumors selective blockade of ETBR by BQ788 leads to an increase in
intercellular adhesion molecule-1 (ICAM-1) expression and increased T cell homing and
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adhesion to tumors [44]. Also, in malignant gliomas, increased expression of ETBR with
tumor grade correlated with fewer infiltrations of cytotoxic T cells (CTLs), signifying the
critical role of ETBR signaling in the recruitment of T cell population to the tumors [45].
Therefore we hypothesized that ET axis antagonism can possibly regulate the T cell
homing. Thus, our data suggests that Bosentan treatment increases the CD3 positive T
cells compared to control. Furthermore, our immunofluorescence study indicates the
increase infiltration of cytotoxic T cell population, signifying the critical role of ET axis
modulating the immune response. However, further studies are required to decipher the
immunological potential of ET axis in PC. Experiments with selective and dual ET
inhibitors show that ET-1 treatment promotes migration of murine PSCs congruent with
the previous findings [46] [47]. The stimulation of migratory phenotype is dependent on
both ETAR and ETBR, which is in harmony with previous findings [48]. In addition, antiproliferative effects on both murine ImPSC.c2 and human CAFs were observed using
BQ788 and Bosentan in dose and time dependent manner with antagonism of ETAR
only having a minor effect. However, the mechanism by which ET-1 stimulates
phenotypic changes warrants further investigation.
In this study we have used murine ImPSC.c2 and human CAFs as an in vitro
model system with which we probe the role of ET-1 in the production of matrix
associated proteins. In this study we demonstrated the involvement of ET receptor
subtypes and the molecular mechanisms that govern the process. ET-1 induces CTGF
(connective tissue growth factor), a member of extracellular matrix proteins involved in
various biological process including migration, proliferation, wound healing and fibrosis
[49] [50]. Report suggests that the expression of this protein is induced by TGF-β in
Smad dependent manner [51] [52]. As previously stated, both ET-1 and TGF-β work in a
synergistic manner to induce expression of fibrotic genes, and it is speculated by CTGF
facilitates the downstream action mediated by TGF-β. Our study indicates that ET-1
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stimulates the synthesis of pro-fibrogenic genes in both murine ImPSC.c2 and human
CAFs. In this study we investigated the ability of selective and dual receptor inhibitors to
prevent the overexpression of pro-fibrotic genes. Enhanced production of ET-1 during
tissue repair [53] and patients with fibrotic disease implies that in addition to wound
healing process it also plays a key role in pathogenesis of fibrosis [54] [55] [56].
Evidence also indicates that endogenous ET-1 signaling appears to play a role in the
persistent fibrotic phenotype in lung fibroblasts [57]. However, we observed that
endogenous ET-1 signaling was unable to induce the expression of ECM proteins in
murine ImPSC.c2 when cultured in presence of UN-KPC-961 cells, however selective
ETBR and dual receptor antagonism reduced the expression of ECM proteins in these
cells, implicating that the fibrotic phenotype is independent of endogenous ET-1
signaling. Interestingly, exogenous treatment of ET-1 caused the induction of α-SMA,
collagen I, CTGF and fibronectin in ImPSC.c2. Perhaps more intriguingly, BQ788 and
Bosentan appeared to reverse the ET-1 mediated induction with antagonism of ETAR
having only a minimal effect. These results indicate that ET-1/ETBR signaling
predominantly stimulates the expression of pro-fibrotic gene signatures in murine
ImPSC.c2 cells. We also extended our studies in fibroblasts isolated from normal,
chronic pancreatitis and cancer patients. Using western blot , we first confirmed the
purity of our CAFs by examining the expression of ECM genes using appropriate
controls. We found that elevated expression of α-SMA, Collagen I, CTGF and fibronectin
in chronic pancreatitis and cancer associated fibroblasts compared to control. Using RTPCR analysis we also investigate the expression pattern of ET axis. Expression of ET-1
and ETAR was observed in all the fibroblasts tested, whereas ETBR is restricted to
cancer-associated fibroblasts and predominant expression is seen. Similar to murine
ImPSC.c2, our results also demonstrated increase expression of ECM proteins in time
dependent manner in human 10-03 CAFs, expressing both ETAR and ETBR. Contrary to
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our previous observations, our data revealed that both BQ123 and BQ788 abrogated the
ET-1 mediated effects in 10-03 CAFs. Our current data also indicate that both ETA/ETB
receptor antagonism synergistically appeared to reverse the phenotype of activated
fibroblasts. The results clearly indicate that ET-1 stimulates the expression of matrixassociated genes through both ETAR and ETBR. The inability of ETAR antagonism to
attenuate ET-1 effects and involvement of ET-1/ETBR signaling to promote the ECM
genes production in murine ImPSC.c2 can be explained on the low expression and
distribution of ETAR on ImPSC.c2, suggesting ETBR, but not ETAR is involved.
Indeed, our mechanistic data also implies ET-1 is able to aggravate the
production of matrix associated proteins via ERK/AKT dependent mechanism requiring
either the ETA or the ETB receptors. Our results are consistent with the previous reports
that have linked the ERK/AKT signaling cascade and fibrosis. For examples, in lung
fibroblasts ET-1 induces expression of matrix-associated genes through MEK/ERK
kinase pathway [58]. Also, in lung fibroblasts ET-1 mediated myofibroblast induction is
inhibited by blockade of PI3K/AKT pathway [59]. Altogether, our results indicate that
collective antagonism of ERK/AKT and ET axis may be of benefit as a part of
combinatorial drug strategy to combat fibrosis.
PC stroma is associated with structurally and functionally abnormal blood
vessels, which are tortuous, poorly connected, and irregularly shaped with areas of
dilation and constriction, thus resulting in turbulent and inefficient blood flow to the
tumors [60] [61]. Additionally, the tumor blood vessels have discontinuous endothelial
lining, abnormal pericytes and basement membrane, and are hence hyper permeable
[62] [63]. The leaky nature of the tumor vessels coupled with the absence of efficient
lymphatic system results in elevated interstitial fluid pressure (IFP) which in turn results
in poor uptake and heterogeneous distribution of both micro and macromolecules in the
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tumor tissue [64] [65]. Moreover, poor blood supply to the tumor results in regions of
hypoxia, which contributes to radioresistance and chemoresistance of tumor cells.
Therefore, selective enhancement in tumor blood flow can improve the drug delivery and
efficacy. Due to the increased production of ET1 and overexpression of ETAR in several
epithelial tumors, this vasomodulatory activity is believed to be an important contributor
to the tumor blood flow heterogeneity [66].Thus, ETA antagonists, in addition to their
direct antitumor effects also have an adjuvant effect that enhances tumor perfusion and
increased drug uptake [66]. Several ETAR antagonists including ZD4054, ABT-627
(atrasentan), are being investigated in clinical and preclinical studies for the treatment of
various cancers [67] [68]. These inhibitors specifically bind to ETAR and inhibit
downstream signaling pathways in tumor and stromal cells that are implicated in tumor
growth and metastasis. ETAR antagonists, ZD4054 and ABT-627 have been
demonstrated to inhibit tumor growth and metastasis and shown synergistic effects with
cytotoxic drugs in prostate and ovarian cancers [69] [70]. Although, ETAR antagonists
have been shown to improve tumor perfusion and decrease tumor blood flow
heterogeneity and improve uptake of cytotoxic drugs in the tumor [66], their utility to
improve the tumor perfusion in PC is yet to be demonstrated. Here, in this study we
show for the first time selective ETAR antagonism using subcutaneous xenograft tumors
derived from PC cell lines can improve perfusion in response to BQ123 indicating tumor
selective modulation. Additionally, our analysis also suggested that enhanced perfusion
induced by BQ123 resulted in decrease hypoxia in T3M4 tumors.
In conclusion , we have provided evidence that ET-1 signaling appears to play a
central role in the persistent of pro-fibrotic phenotype in PC. Our data provide an
experimental based rationale for the use of dual ETAR and ETBR antagonist, Bosentan to
ameliorate pathological scarring observed in pancreatic fibrosis. Our results further
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suggest that there may be a potential therapeutic advantage in selective ETAR inhibitor,
BQ123 to enhance tumor perfusion and increase drug uptake.
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Figure 1: ET axis antagonism increases apoptosis and decreases fibrosis in KPC
mice. A. Immunohistochemical analysis of cleaved caspase 3 and TUNEL staining in
tumor sections obtained from control and Bosentan treated mice showed increase in the
apoptotic cells. Quantitation of cleaved caspase -3 positive cells shows significant
increase in the number of apoptotic nuclei (p=0.01) after Bosentan treatment (average
count of cleaved caspase positive cells in 20 independent fields/section). B.
Representative Masson Trichrome staining of the 20 weeks KPC mice tissue after
challenged with either saline (control) or Bosentan (treated) for a period of 10 days. The
zoomed magnified image indicates reduction in the desmoplasia. Augmented fibrosis is
further represented in the semi-quantitative fashion where the staining score and
intensity score were multiplied to obtain the composite score and subsequently
represented as bar diagram.

189

Figure 1

A

B

190
Figure 2. Bosentan treatment reduces the pro-fibrotic gene signatures in KPC
mice. Volcano plot of the PCR array analysis in KPC mice treated with Bosentan or
control saline showing the distribution of gene expression (represented by white circles).
The genes in the green and red indicate the down regulated and upregulated genes
respectively on the plot. The table in the bottom depicts the absolute fold changes of
genes with p values. The pro-fibrotic and anti-fibrotic genes are indicated in green and
red respectively.
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Table I. Representation of the genes in the microarray. Heat map representation of
the expression of 84 genes in the PCR array. The array includes: Pro-Fibrotic genes
Acta2

(α-SMA),

Agt,

Ccl11

(Eotaxin),

Ccl12,

Ccl3(MIP-

1a),Ctgf,Grem1,Il13,Il13ra2,Snai1(Snail). Anti-Fibrotic: Bmp7, Hgf, Ifng, Il10, Il13ra2.
ECM Components:Col1A2, Col3A1. Remodeling Enzymes: Lox, Mmp1a (Collagenase
1), Mmp13, Mmp14, Mmp2 (Gelatinase A), Mmp3, Mmp8, Mmp9 (Gelatinase B), Plat
(tPA), Plau (uPA), Plg, Serpina1a (a1-antitrypsin), Serpine1 (PAI-1), Serpinh1, Timp1,
Timp2, Timp3, Timp4. Cellular Adhesion: Itga1, Itga2, Itga3, Itgav, Itgb1, Itgb3, Itgb5,
Itgb6, Itgb8. Inflammatory Cytokines & Chemokines: Ccl11 (Eotaxin), Ccl12, Ccl3
(MIP-1a), Ccr2, Cxcr4, Ifng, Il10, Il13, Il13ra2, Il1a, Il1b, Tnf. Growth Factors: Agt, Ctgf,
Edn1, Egf, Hgf, Pdgfa, Pdgfb, Vegfa. Signal Transduction: TGFß Superfamily: Bmp7,
Cav1, Dcn, Eng (EVI-1), Grem1, Inhbe, Ltbp1, Smad2, Smad3, Smad4, Smad6, Smad7,
Tgfb1, Tgfb2, Tgfb3, Tgfbr1 (ALK5), Tgfbr2, Tgif1, Thbs1, Thbs2. Transcription Factors:
Cebpb, Jun, Myc, Nfkb1, Sp1, Stat1, Stat6. Epithelial-to-Mesenchymal Transition:
Akt1, Bmp7, Col1a2, Col3a1, Itgav, Itgb1, Mmp2 (GelatinaseA), Mmp3, Mmp9, Serpine1
(PAI-1), Smad2, Snai1 (Snail), Tgfb1, Tgfb2, Tgfb3, Timp1.The map indicates up
regulation (red) and down regulation (green). The fold change of each individual gene is
shown in the table.
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Table II: Overall summary of gene expression profile identified by TCGA database
and targeted by Bosentan in fibrosis array. The pro-fibrotic genes have significant
correlation with overexpression of ET axis as predicted by human TCGA analysis and
the gene signatures targeted by Bosentan in KPC mice indicates decrease in the
absolute fold change with significant p value.
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Figure 3: In vivo evidence for effect of dual ET receptors antagonism in fibrosis. A.
The reduction in exaggerated fibrogenic response in Bosentan treated KPC mice is
further represented by western blot in tumor lysates against CTGF, α-SMA, Fibronectin
and FSP-1. B. Immunohistochemical staining against Collagen I, α-SMA, fibronectin,
FSP1 and CTGF in treated mice tissues compared to control shows decrease in fibrotic
growth.
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Figure 4: Bosentan treatment reduces the FSP1 but not FAP positive cancer
associated fibroblasts (CAFs).

Three-color

immunofluorescence showing

the

expression of epithelial marker, CK19 (green) and cancer associated fibroblasts, FSP1
(red) and α-SMA (purple) in KPC mice. Both the FSP1 and α-SMA positive fibroblasts
populations surround the CK19 positive ducts in the microenvironment and exhibit
minimal or no overlap with each other (Scale bar 20 μm). B. Dual confocal microscopy
indicates decrease in the α-SMA positive fibroblasts (red) and FSP1 positive fibroblasts
(green) following Bosentan treatment with significant p value. C. Immunofluorescence
analysis indicates co-localization of both α-SMA and FAP positive fibroblasts (green) and
no significant difference in the FAP positive fibroblasts population post Bosentan
treatment. (Scale bar 20 μm).
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Figure 5: ET receptors antagonism inhibits proliferation of murine pancreatic
stellate cells. (A) ET-1 promotes proliferation of ImPSC.c2 in concentration dependent
manner. Cells were plated in 96 well format (3000 cells/ 100μl/well) in DMEM containing
10% FBS for 24 hours and then stimulated with indicated concentrations of ET-1 in
DMEM containing 1% FBS for 24, 48 and 72 hours. Cell growth was measured by MTT
assay. Selective ETAR inhibitor, BQ123 (B), have minimal effects on the growth of
ImPSC.c2 cells whereas both selective ETBR, BQ788 (C) and dual ET receptor inhibitor
Bosentan (D) inhibits the proliferation of ImPSC.c2 as indicated by MTT assay in a dose
and time dependent manner.
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Figure 6: ET receptor antagonists induce apoptosis and cell cycle arrest in
ImPSC.c2 cells. A. The percentage of apoptotic cells was measured by Annexin-V and
propidium iodide (PI) staining using flow cytometric analysis following treatment with ET
inhibitors. Annexin-V+ and PI- cells are considered to be early apoptotic while Annexin
V+ and PI+ cells are considered to be late apoptotic. Treatment with both BQ788 (ETBR
inhibitor) and Bosentan (dual inhibitor) increases the apoptotic cells compared to control
cells whereas minimal effect with BQ123 (ETAR inhibitor) was observed. B. Flow
cytometry based cell cycle analysis was carried out in ImPSC.c2 cells after treatment
with inhibitors and the percentage of cells in G1, S, and G2/M phases of cell cycle are
represented. As compared to untreated cells, BQ788 and Bosentan treatment induces
cell cycle arrest in G1/S phase.
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Figure 7: ET receptors antagonism inhibits migration of murine pancreatic stellate
cells. Endothelin receptors antagonists inhibit the recombinant ET-1 induced migration
of ImPSC.c2. Cells were seeded at a density of 2×106 cells in 6 well plates and kept in
10% DMEM overnight. To determine the effect of BQ123, BQ788 and Bosentan upon
wound closure artificial wounds were created in 90% confluent cells. The cells were then
treated with ET-1 (100nm) or BQ123 (100µM), BQ788 (20µM) and Bosentan (25µM) in
complete medium. Representative images of the wounds at 0 and 24 h in the presence
of recombinant ET-1, antagonists or their combination. Histogram illustrates the relative
wound width at 0 and 24 h. (*p<0.01 vs. the Untreated group,
group).
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Figure 8: Anti-fibrotic effects of ET axis antagonism in vitro in ImPSC.c2 cells. A.
Expression of ET-1, ETAR and ETBR in UN-KPC-961 cells and ImPSC.c2 cells. B. After
24 hours coculture either in presence of UN-KPC-961 alone or ET inhibitors total protein
of ImPSC.c2 was extracted. Western blot analysis was performed using an antibody
against Collagen I, α-SMA, fibronectin and CTGF. C. Cells were plated in six well format
(0.8x 106/ 100μl/well) in DMEM containing 10% FBS for 24 hours. After 24 hours, cells
were serum starved for 24 hours and treated with ET-1 (100nm) or pre-treated with ET
inhibitors, BQ123 (100µM), BQ788 (20 µM) and Bosentan (25 µM) for 45 mins prior to
addition of ET-1. Protein lysates made was subjected to western blot analysis against
Collagen I, α-SMA, fibronectin and CTGF. β-actin was used as a loading control.
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Figure 9: Characterization of patient derived fibroblasts.

Expression was

determined in fibroblasts derived from normal pancreas, chronic pancreatitis and cancer
patients. A. Western blot analysis was done against α-SMA (fibroblast marker) and CK19 (epithelial marker) to demonstrate no contamination from other cellular components.
HEK-293 and Panc1 cell lines was used as positive control for α-SMA and CK19
respectively. B. To probe for other stromal associated genes protein lysates made were
subjected to western blot analysis against Collagen I, Fibronectin, CTGF and desmin. βactin as used as a loading control. RT-PCR was done using ET-1, ETAR and ETBR gene
specific primers in RNA isolated from patient derived fibroblasts. PC3 cell line was used
as positive control. β-actin as used as a loading control.
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Figure 10: Effect of endothelin receptor antagonists on growth of 10-03 cancer
fibroblasts. Cells were grown for 24hr, 48hr and 72hr in presence of increasing
concentration ETA receptor antagonist, BQ123 (A), ETB receptor antagonist, BQ788 (B)
and dual ETA and ETB receptor antagonist, Bosentan (C). The effect on cell growth after
ET antagonists treatment was measured by MTT assay and read as absorbance at
490nm.
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Figures 11: Anti fibrotic effect of ET axis antagonism in vitro in human CAFs. 1003 fibroblasts were grown in grown in complete DMEM for 24 hr. Cells were serum
starved for 24 hrs and treated with 100 nm of ET-1 or pre-treated with BQ123 (100 μM),
BQ788 (20 μM) and Bosentan (25 μM) 45 mins prior to addition of ET-1. Whole cells
protein extracts were collected at different time points and equal amounts of protein
were subjected to immunoblotting analysis with anti- α-SMA, anti-fibronectin (A) anticollagen I (B), β-actin as used as a loading control.
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Figure 12: ET-1 induces p42/44 MAPK and AKT phosphorylation in ImPSC.c2
stellate cells. Cells were cultured in complete DMEM medium for 24 hr, serum starved
for 24 hr and treated with 100nm of ET-1 or pre-treated with BQ123 (100 μM), BQ788
(20 μM) and Bosentan (25 μM) 45 mins prior to addition of ET-1. Whole cells protein
extracts were collected at different time points and equal amounts of protein were
subjected to immunoblotting analysis with anti-ERK, anti-phospho-ERK (A), anti-AKT
and anti-phospho-AKT (B) antibodies. β-actin as used as a loading control.
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Figure 13: ET-1 induces p42/44 MAPK and AKT phosphorylation in 10-03
fibroblasts. Cells were cultured in complete DMEM medium for 24 hr, serum starved for
24 hr and treated with 100nm of ET-1 or pre-treated with BQ123 (100 μM), BQ788 (20
μM) and Bosentan (25 μM) 45 mins prior to addition of ET-1. Whole cells protein extracts
were collected at different time points and equal amounts of protein were subjected to
immunoblotting analysis with anti-ERK, anti-phospho-ERK (A), anti-AKT and antiphospho-AKT (B) antibodies. β-actin as used as a loading control
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Figure 14: Proposed Model. Pancreatic cancer cells expressing the endothelin A
receptor (ETAR) and endothelin B receptor (ETBR) also secret high levels of endothelin-1
(ET-1). The ET-1 released from the tumor cells act on the nearby pancreatic stellate
cells and cancer associated fibroblasts in a paracrine manner expressing endothelin
receptors and activate the downstream signaling which in turn induces the expression of
pro-fibrotic gene signatures through ERK/AKT dependent manner. However, in presence
of dual receptor Bosentan the binding of ligand to the receptor is inhibited resulting in the
decrease expression of pro-fibrotic genes in an ERK/AKT dependent fashion.

220

Figure 14

221
Figure

15:

ET

axis

antagonism

inhibits

infiltration

of

tumor-associated

macrophages. A. Dual specificity ET axis antagonist b osentan reduces the number of
tumor associated macrophages in KPC mice. Macrophages were visualized by
immunostaining for F4/80 staining. Representative IHC images under low power (top)
and high power (bottom- boxed area represented). The number of F4/80 positive cells
per high power field (HPF) was counted in both control and Bosentan treated KPC
tumors. 26 HPFs in Bosentan treated mice (n=6) and 19 HPFs in control mice (n=4)
were counted. B. Immunofluorescence expression of CD206 was evaluated in KPC mice
sections following Bosentan treatment. The number of CD206 positive cells per high
power field (HPF) was counted in both control and Bosentan treated KPC tumors.
Reduced infiltration of CD206 positive macrophages is observed in the stromal
compartment in treated mice compared to control with significant p value.
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Figure 16: Bosentan treatment increases the CD3 T cell infiltration in KPC tumors:
Immunohistochemical analysis of CD3 was evaluated in KPC mice sections following
Bosentan treatment. Increase in the recruitment of CD3 positive T cells is observed in
the stromal compartment and tumor associated lymph node in treated mice compared to
control.
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Figure 17: Bosentan treatment increases the CD8 T cell infiltration in KPC tumors:
Immunofluorescence analysis showing the distribution of CD4 (A) and CD8 (C) positive
T cells in the microenvironment using mouse spleen as a positive control. Compared to
control, Bosentan administration in KPC mice increases CD8 T cell infiltration (D) with
significant p value whereas no difference in CD4 T cell is seen (B) (Scale bar 20 μm).
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Figure 18: ET axis antagonism inhibits tumor induced migration of human
monocytes and murine macrophages. A. Expression of ET receptors in human
macrophage-like U937 cells. Colo357 and T3M4 PC cells were used as controls for
ETAR and ETBR. U937 cells predominantly express ETBR and this expression does not
appear to be impacted by the differentiation status of the macrophages following
treatments. Actin was used as a loading control. ET-axis antagonists inhibit tumor cellinduced migration of human (B) and murine macrophage-line (C). Human (U937) and
Mouse (RAW264.7) macrophage-like cells were either cultured alone or co-cultured with
human PC cell line Panc 1 or KPC mouse tumor derived cell line (UN- KPC-961) with or
without selective or dual receptor specific antagonists of ET axis. The tumor induced
migration was inhibited by selective ETAR (BQ123), ETBR (BQ788) and dual ETAR/ETBR
(Bosentan) antagonists in U937 and RAW264.7 cells. (* p<0.05, ** p<0.005,
***p<0.0005)
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Figure 19: ETAR antagonism increases tumor perfusion and decreases hypoxia in
xenografts tumors. BQ123 improves perfusion and reduces hypoxia in xenograft PC
tumors. A. Perfusion mapping of BQ123 administered tumor. Mice bearing T3M4
(tumor1) and Colo 357 (tumor 2) xenografts were administered with BQ123 (2 mg/kg).
Perfusion mapping was done by flow sensitive alternating inversion recovery (FAIR) with
a rapid acquisition by refocused echo (RARE) readout (RARE factor = 16). Perfusion
was measured prior to administration of BQ123 (0 min) to establish baseline and
subsequently imaged for 120 min post-administration to monitor the change in perfusion.
Left panel shows the anatomic MRI scan to indicate the position of tumors and the
regions of interest (ROI) in the tumors and muscle used for perfusion analysis. The right
two panels show perfusion maps before and 120 min after injection of BQ123. Perfusion
maps were windowed between 0 to 500 ml/(100g tissue * min). In the lower right two
panels the ROI marker is removed to allow appreciation of the increased perfusion in
regions of interest. It is notable that the phantoms at the top of the image (left) are
completely absent in the perfusion maps, indicating proper balance of magnetization
transfer effects. B. Kinetics of changes in perfusion in response to ETAR antagonist
BQ123 in xenograft PC tumors. Blood flow values were determined from the serial
perfusion maps obtained by FAIR MRI. At zero time point, it can be appreciated that the
tumors were considerably less perfused than the muscle tissue. Changes in perfusion in
response to BQ123 were more pronounced in tumors than in the muscle. C. BQ123
treatment reduces hypoxia in T3M4 tumors. Tumor bearing animals were treated with
saline (left) or BQ123 (right). 90 min after treatment animals were injected with
pimonidazole HCl (Hypoxyprobe), which forms stable adducts with proteins in hypoxic
cells. Animals were euthanized 45 mins thereafter; tumors were harvested and
processed for immunohistochemistry for detecting Hypoxyprobe adducts (brown
staining).
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Chapter 5
Irreversible and sustained upregulation of endothelin axis
during K-Ras-oncogene associated pancreatic inflammation and
cancer
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1. Synopsis
Endothelin-1 (ET-1) and its receptors, endothelin A (ETAR) and endothelin B
(ETBR) are overexpressed and deregulated in pancreatic cancer and pancreatitis. Here,
we report that the expression of endothelin converting enzyme-1 (ECE-1), ET-1, ETAR
and ETBR is predominantly associated with acinar and islet cells of the pancreas and
progressive increase in ductal cells and stromal compartment is seen in the KC model
(Pdx-1 Cre; KrasG12D) of pancreatic cancer with increasing age. Upon cerulein
challenge, ETAR and ETBR expression is seen in amylase and CK19 double positive
ducts during pancreatic acinar to ductal metaplasia (ADM) in mouse pancreas harboring
KrasG12D mutation. In normal mice with wild type Kras, upon cerulein insult after an
initial increase in expression of ET-1 and ETAR and decrease expression of ETBR,
recovery in pancreatic parenchyma was observed. However, the kinetics of ET-1, ETAR
and ETBR alterations was distinct in in presence of KrasG12D mutation. Also,
expression of ECE-1 ET-1, ETAR and ETBR in spontaneous KrasG12D model subjected
to cigarette smoke also suggests increase expression in the pre-cancerous lesions
compared to sham control animals with WT kras. In addition to expression in early
pancreatic cancer lesions (smoking) and metaplastic ducts (cerulein), ETAR and ETBR
expression in also seen in infiltrating F4/80 positive macrophages and α-SMA positive
fibroblasts and high colocalization was seen in presence of oncogenic Kras. In
conclusion, presence of mutant KrasG12D in pancreas results the sustained activation
of ET axis components with increasing dysplasia in early lesions and stromal region of
pancreatic tissues following cerulein and smoke mediated inflammatory insult suggests a
possible role in tumor initiation and progression.
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2. Background and Rationale
Cellular plasticity is critical for tissue repair and regeneration. Cellular
reprogramming in the exocrine pancreas under benign conditions involves a reversible
trans-differentiation sequence of acinar cells to ductal- phenotype during repair and
resolution of inflammation [1]. The presence of constitutively active K-ras mutations
however, disrupt this sequence and initiate ductal reprogramming leading to the
development of pre-neoplastic lesions termed as pancreatic intraepithelial neoplasia
(PanIN),

which

are

the

precursor

lesions

the

malignant

pancreatic

ductal

adenocarcinoma (PC). These PanIN lesions undergo a series of histological and
morphological changes during the course of cancer progression. The first genetically
engineered mouse model generated by knock-in of mutant K-ras allele (G12D) exhibits
acinar to ductal metaplasia (ADM) and develop a complete spectrum of PanIN lesions
leading to PC. This process is characterized by the loss of acinar cell compartment
(markers like amylase) and gain of the ductal phenotype, characterized by CK19
expression [2]. [3] utilizing transgenic mice overexpressing TGF-α provide earliest
evidence of ADM. These animals develop fibrosis and dysplastic lesions accompanied
by loss of zymogen granules and acquisition of ductal features [4], implying that
maintenance of acinar cell organization is critical to prevent trans-differentiation into
ductal architecture [5]. Activation of the mutant Kras in the cells of the acinar lineage
under the control of elastase or Mist1 promoter lead to spontaneous low-grade lesion
formation in the mouse pancreas. However, high-grade PanIN formation is observed
following chronic inflammation [6]. Epidemiological studies also suggest that patients
with chronic pancreatitis exhibit an elevated risk of developing PC. In chronic
pancreatitis (CP) patients as well, constitutive activation of K-ras gene is associated with
malignant transformation of the pancreas [7]. Furthermore, cerulean-induced chronic
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pancreatitis in the mice expressing oncogenic Kras (KrasG12V) results in the
development of aggressive PC along with increased infiltration of inflammatory cells [8].
Similarly, repeated episodes of cerulein mediated insult in the presence of K-ras
mutation result in high-grade lesions, atrophy of pancreatic parenchyma, development of
metaplastic cells, and enhanced inflammatory response [9]. Carriere et al demonstrated
that episodes of cerulein induced pancreatitis favors rapid cancer progression and
initiate cascade of events in mice expressing mutated Kras in the nestin cell lineage [10]
[11]. Interestingly, in acute pancreatitis model, mutant Kras favors reprogramming and
metaplastic conversion of acinar cells into pre-cancerous lesions in a beta catenin
dependent manner [1].
Components of endothelin axis, which include endothelin-1 (ET-1), endothelin-2
(ET-2), endothelin-3 (ET-3), endothelin converting enzymes (ECEs) along with high
affinity G-protein couple receptors, endothelin A receptor (ETAR) and endothelin B
receptor (ETBR), are deregulated in inflammation and cancer. Accumulating evidence
suggest that ET-1 plays a significant role in the in pathophysiology of pancreatic
inflammation. In patients with severe acute pancreatitis, an elevated level of ET-1 is
correlated with disease severity and inflammation [12]. In addition, significantly elevated
circulating levels of ET-1 in the plasma and its strong expression in the pancreas of the
patients of chronic pancreatitis with a history of smoking was observed [13]. In
experimental pancreatitis model, the role of ET-1 and its antagonists has been well
studied. A remarkable increase in the serum ET-1 level and damage to pancreatic
parenchyma is observed upon cerulein or sodium taurocholate induced pancreatic
inflammation [14-16]. However, a synergistic effect is observed and a remarkable
change in the pancreas morphology is seen in presence ET-1 plus cerulein compared to
cerulein alone [17]. Administration of ET-1 favors acinar cell necrosis, edema, increase
in serum amylase and elastase levels and inflammatory response indicating the role of
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ET-1 in disease aggravation. Studies demonstrating the ability of several pancreatic
cancer cell lines to produce high levels of ET-1 suggested the possible role in ET-axis in
PC. [18, 19]. .A recent study has demonstrated the overexpression of ET-1 and ETBR in
human PC tissues [20] while we have observed the upregulation of ET-1, ETAR and
ETBR in tumor cells and various components of tumor microenvironment.
Given the functional involvement of ET-1 in pancreatic inflammation, expression
of ET-axis components in PC, the role of K-ras associated inflammation in driving
pancreatic neoplastic transformation, and ability of ET-axis to exert pleotropic effects to
promote tumorigenesis, it is possible that ET-axis plays a key role inflammation-driven
pancreatic tumorigenesis in the presence of K-ras oncogene. However, the expression
of ET axis proteins in pre-malignant lesions in acute and chronic pancreatic inflammation
associated with oncogenic Kras remains explored. We therefore examined the
expression pattern of ET-axis components in the murine models of chronic and acute
inflammation in the presence and absence of oncogenic K-ras. The findings from the
current study, demonstrated that cerulein induced inflammatory insult, a model of acute
inflammation, initially up-regulates the expression of ET-1 and ETAR, which was
subsequently restored to basal levels in normal mice. However, in the KC mice the
expression increases with progressive neoplasia. Smoke exposure, a model of chronic
inflammation in KC mice results in increase expression of ET axis in the pre-cancerous
lesions and also in pancreatic stroma indicating that mutated Kras results in sustained
activation of ET axis in the pancreatic tissues, suggesting its possible role in pancreatic
inflammation, repair and development of cancer.
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3. Results
A. Expression of ECE-1, ET-1, ETAR and ETBR in murine pancreas in the presence
of activated K-ras.
We first analyzed the expression of ET-axis components in the presence of
activated KrasG12D mutation at the transcript level in comparison to their levels in the
pancreas of age matched controls (Figure 1A). The levels of ECE-1, ET-1, ETAR and
ETBR transcripts were comparable in the pancreas of 20 week old WT and KrasG12D
mice. However, there was a progressive increase in the expression of ET axis
components in the pancreas of 30, 40 and 50 weeks old KrasG12D mice as compared
to that of WT animals. We next profiled their expression using immunohistochemistry on
the pancreatic tissues harvested from 20-50 week old mice. In the control pancreas from
50-week-old WT mice, a robust expression of ECE-1, ET-1, ETAR and ETBR was seen in
the islets and a relatively weak reactivity was detected in the acinar compartment
(Figure 1B). Importantly, the pancreatic ducts in the WT animals exhibited undetectable
expression of ET-1, ETAR and ETBR. In the presence of oncogenic K-ras, the expression
ECE-1, ET-1, ETAR and ETBR progressively increased in the ductal cells from preneoplastic lesions at 30 week of age to dysplastic lesions observed at 50 week of age
(Figure 1B). Interestingly, the expression was particularly localized to the ductal
structures exhibiting transition from acinar to ductal phenotype, a characteristic observed
during ADM. Further analysis revealed that the expression was not only restricted to the
ductal lesions but was present in the surrounding stromal compartment.

B. Expression of ET axis during Cerulein induced pancreatic injury.
Cerulein is a cholecystokinin analogue that aggravates secretion of pancreatic
enzymes, promotes inflammation, and induces ADM. The injury to pancreatic
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parenchyma in the presence of oncogene results in in the development of s preneoplastic lesions and transformation of acinar cells to the ductal phenotype [23]. To
analyze the changes in the ET-axis components in response to acute pancreatic
inflammation in the presence and absence of oncogenic K-ras, we examined pancreatic
tissues from 6 week old KC and WT mice treated with cerulein. On day 0 after treatment,
both the WT and KC mice show acinar specific expression for ETAR and ETBR, as
evident by their co-localization with amylase (Figure 2A & 2B). On day 2-post cerulein
treatment, in KC mice metaplastic ducts undergoing ADM observed, characterized by
simultaneous expression of both amylase and CK19, and elevated ETAR and ETBR
expression. The expression of ET receptors were more pronounced in CK19 positive
ducts with increased dysplasia at day 7 and day 21-post cerulein administration. In
contrast, the WT mice showed recovery of pancreatic parenchyma and restoration of
pancreatic architecture (Figure 3). Further, comparison of the WT and KC mice at the
transcript levels after cerulein treatment showed difference in the kinetics and magnitude
of ET axis upregulation. While ET-1 and ETAR expression between WT and KC mice
were unaltered and comparable on day 2, there was significant increase in both ET-1
and ETAR levels in Kras mutant animals at day 7 and day 21-post cerulein administration
(Figure 4A & 4B). In contrast, the levels of ETBR showed increase at day 2 and day 7post cerulein injection and decreased at day 21 (Figure 4C). Inflammatory insult in WT
animals increased the expression of ET-1, ETAR at day 2 while the levels of ETBR
decreased gradually. However, during recovery phase the expression restored to basal
level at day 7 and 21 (Figure 5A). In KC mice harboring KrasG12D mutation in the
pancreas, after initial increase during inflammation the levels of ETBR returned to normal
whereas the ETAR levels remained high with increasing dysplasia (Figure 5B).
Quantitative qRT- PCR showed no difference in the levels of ET-2 and ET-3 in KrasG12D
mice compared to WT mice after cerulein treatment (Figure 6A &6B).
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C. Expression of ET axis during Smoke induced pancreatic injury.
The effect of cigarette smoke induced alterations in the ET axis in presence of Kras mutation showed on statistically significant difference in ECE-1 transcript levels in
WT and K-ras animals however, there was slight increase in ECE-1 transcript levels.
(Figure 7A). Interestingly, qRT-PCR analysis revealed 7 fold increase in the ET-1
transcript levels in the K-ras mutant mice compared to sham control (p=0.04) (Figure
7B). Additionally, the ET-3 mRNA levels in the WT and K-ras mice showed no significant
difference with and without exposure to cigarette smoke (Figure 8). Comparison of the
ETAR and ETBR mRNA levels in KrasG12D mice reveals significantly increase in both
ET receptors (Figure 7C & Figure 7D). Smoke-induced inflammation in the mutant Kras mice showed increase of 4.5 fold and 5 fold in ETAR (p=0.03) and ETBR (p=0.01)
mRNA levels respectively compared to sham controls. Further, histological analysis of
the mice pancreas also showed increase in the expression of the ET axis components in
response to smoke mediated inflammatory insult. Similar to our previous observation in
spontaneous KC model, in the unfloxed mice pancreas with and without exposure to
cigarette smoke, the expression of ECE-1, ET-1 and both ET receptors is associated
with acinar compartment of the pancreas and prominent staining in islet cells is seen
(Figure 7E & Figure 7F). Interestingly, smoke exposure in the K-ras mice resulted in the
increase in ECE-1 expression in the pancreatic duct while no difference was observed in
the expression of ET-1, ETAR and ETBR in pancreatic ductal cells. In addition,
comparison of the sham control mice reveals significant expression of ECE-1, ET-1 and
the receptors in the pre-cancerous lesions and acinar compartment of the pancreas.
Further analysis of the mice pancreas also demonstrated expression of ET axis proteins
in the stromal region, and infiltrating immune cells. As compared to sham control, smoke
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exposure in K-ras mice pancreas showed significant expression of ECE-1, ET-1, ETAR
and ETBR in the pre-neoplastic lesions. Importantly, the increased expression in the
early pre-cancerous lesions is accompanied by enhanced expression ET axis in the
pancreatic stroma and immune cells. The co-expression of epithelial marker CK19 and
ET-1, ETAR and ETBR in the pancreatic ductal cells further validated our findings (Figure
9).

D. Increase infiltration of F4/80 positive macrophages is associated with ETAR and
ETBR expression in Cerulein and Smoke induced pancreatitis.
One of the key events that determines the onset of inflammation and severity of
acute pancreatitis is the activation of macrophages [24] [25]. Similar to acute
pancreatitis, increased infiltration of macrophages is reported in inflamed sites in both
human and mouse chronic pancreatitis and are considered as master regulators of
inflammation and disease progression [26]. Previous studies has reported increased
accumulation of F4/80 positive macrophages in response to smoking in spontaneous KC
mice model [27] [22] . In response to cerulein induced inflammation the median number
of F4/80 positive macrophage population was not significantly different at day 2 of
treatment, however a substantial increase was seen at day 7 (average number of cells/
field =13) and day 21 (average number of cells/ field =17) of cerulein treatment in mutant
K-ras mice as compared to WT (Figure 10A). Immunohistochemical analysis in both KC
mice model and smoking induced inflammation demonstrated increased expression of
both ETAR and ETBR in ductal cells as well as stromal compartment, particularly on the
infiltrating immune cells. We further confirmed our findings using immunofluorescence
analysis in both cerulein and smoking model of pancreatitis. Validating our earlier
findings, in at day 0 both ETAR and ETBR show expression in the acinar region and
pancreas show fewer number of macrophages (Figure 11A & Figure 11C). At day 2-
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post cerulein in the KC mutant mice the infiltrating F4/80 positive macrophages were
found to be co-localized with ETAR, although the co-expression was not statistically
significant. On the other hand, as demonstrated, the expression of both ETAR and F4/80
appeared in the double positive macrophages and significant co-localization was seen at
day 7 and day 21 of treatment in the KC mice. Quantitative analysis of the F4/80 positive
macrophages with ETAR showed significant increase in the overlapping fractions at day
7 (p=0.0035) and day 21 (p=0.0029) of treatment (Figure 11B). Unlike ETAR, analysis of
the mice pancreas for the dual expression of ETBR and F4/80 in the macrophages
suggests higher degree of co-association at day 2 of treatment in mutant mice compared
to control with significant p value (p=0.0001). The greater degree of co-localization is
also witnessed in pancreas at day 7 (p=0.0005) and day 21 (p=0.0008) post cerulein
trauma in presence of oncogenic Kras (Figure 11D). We also extended our studies in
the smoking induced pancreatitis using three-color immunofluorescence. In WT animals
with and without exposure to cigarette smoke the expression of both ET receptors is
seen in pancreatic acini and no significant association was observed (Figure 12A). In
sham control mice the increase infiltration of F4/80 positive macrophages in the
pancreatic stroma is accompanied by co-expression of both ETAR and ETBR with the
F4/80 macrophages with significant p value (p=0.003 for ETAR and p=0.005 for ETBR) as
compared to unfloxed mice subjected to smoke exposure. Smoke exposed animals in
presence of Kras oncogene driven progression of PC demonstrate high co-expression of
both ETBR and F4/80 in double positive macrophages. Quantitative analysis using
ImageJ further indicates that the F4/80 positive fractions overlapping with ETBR show
significant p value (p=0.05) as observed by Mander’s correlation coefficient (Figure
12C). Unlike ETBR, the increase infiltration of macrophages in the mice pancreas reveal
limited co-expression with ETAR and the overlapping fractions did not show statistical
significance (p=0.06) (Figure 12B).
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E. Increase accumulation of α-SMA fibroblasts in Cerulein and Smoke induced
pancreatitis is associated with associated ETAR and ETBR.
Accumulating evidence indicate that activation of pancreatic stellate cells (PSCs)
is pivotal in development of pancreatitis and pancreatic cancer by excessive deposition
of extracellular matrix proteins [28] [29]. Studies have demonstrated that smoking leads
to activation of PSCs and express myofibroblasts marker α-SMA in KrasG12D
genetically engineered mouse model of PC [22]. Histological examination of the mice
tissues from KrasG12D progression model and smoke exposed KrasG12D animals
reveals enhanced expression of the ET axis components, particularly ET receptors in the
pancreatic stroma. We further corroborated our findings using dual confocal microscopy
utilizing the well-established myofibroblasts marker α-SMA in both acute and chronic
models of pancreatitis. The degree of PSCs activation following cerulein administration
was analyzed in both normal and KC mutant mice. In KrasG12D mice significant
increase in the number of myo-fibroblasts is seen at day 2 post cerulein induced
inflammatory insult (p=0.04), reflecting increased activation of PSCs (Figure 10B).
Additionally, in KC mice harboring KrasG12D mutation in the pancreas substantial
increase in the number of α-SMA positive myofibroblasts is seen at day 7 (average
number of cells/field= 27) and day 21 (average number of cells/field= 32) with significant
p value (p=0.02 for both ETAR and ETBR) compared to mice with WT Kras. Further, dual
color immunofluorescence analysis reveals limited colocalization of both ETAR and ETBR
with α-SMA positive myofibroblasts as demonstrated by no overlapping of the two
fractions in the pancreas stroma at day 0 and day 2 of cerulein-mediated insult in normal
and mutant mice (Figure 13A & 13C). Compared to wild type, in KC mice the increase
activation of PSCs is followed by enhanced expression of ETAR in the fibroblasts
fractions at day 7-post cerulein administration with significant p value (p=0.001). Similar
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to day 7-post trauma, the fraction of α-SMA fibroblasts shows high degree of coexpression with ETAR in KC mutant mice as compared to WT mice with significant p
value (p=0.003) (Figure 13B). Similar to ETAR, co-association with activated PSCs
after day 2 treated KC mice reveal limited colocalization with ETBR compared to control
mice (Figure 13C). Similar to ETAR, co-association with activated PSCs after day 2
treated KC mice reveal limited colocalization with ETBR compared to control mice
(Figure 7c). In addition to ductal expression in the pancreas at day 7 and day 21 post
cerulein treatment in KC mice, the fibroblasts surrounding the duct cells also show
positivity for ETBR expression and demonstrate extensive colocalization at day 7
(p=0.0006) and day 21 (p=0.0002) post cerulein trauma (Figure 13D). The activation
status of PSCs in smoke treated unfloxed and floxed KC mice and its possible
association with ET receptor expression was evaluated using immunofluorescence in
tissues. Analysis of the unfloxed and floxed mice tissues shows prominent expression of
both ETAR and ETBR in the pancreatic islet cells and acinar compartment with and
without smoke exposure (Figure 14A & 14C). In sham control KC mice, in addition to
the prominent expression in the early cancerous lesions, activated PSCs displays high
colocalization with ETAR (p=0.0001) compared to smoked unfloxed mice. Importantly,
quantitative analysis of the smoke exposed KC mice show increase co-expression in the
α-SMA and ETAR double positive fibroblasts (p=0.04) (Figure 14B). Analysis of the
histological features in the sham control mice compared to smoked unfloxed mice
illustrate prominent increase and association of ETBR with the stromal fibroblasts
(p=0.0002). Contrary to ETAR, α-SMA positive fibroblasts exhibit minimal and nonsignificant overlap with ETBR compared to sham control (Figure 14D).
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Discussion
Acinar to ductal metaplasia is the earliest recognizable morphological event in
the pancreas in response to inflammation or oncogene activation and is regarded as a
key event during the development of PC. It is characterized by the trans-differentiation of
amylase-expressing acinar cell into CK19 positive ductal phenotype. The trigger for such
intense morphological and histological change in the pancreas can either be due to
accumulation of genetic changes or an inflammatory insult leading to increasing degree
of atypia and ultimately to cancer. It has been firmly established that formation of
precursor lesions (PanINs) precedes the formation of Kras driven PC initiation in
experimental mouse model [8] [9]. These precursor lesions are derived from acinar cells
of the pancreas undergoing a trans-differentiation from acinar to ductal phenotype, an
event usually induced by pancreatitis [6] [30]. Further support for this view comes from
various mechanistic studies implicating various transcription factors and signaling
pathways in driving this switch from acinar to ductal phenotype [5] [31] [32] [33].
Endothelin axis plays significant role in tissue repair and inflammation of various
tissues and has been implicated in the pathophysiology of pancreatic inflammation.
Previous studies have shown aberrant expression of ET axis components in surgically
resected pancreatic cancer patients and its association with tumorigenesis [20]. ET-1,
most predominant and well-characterized ligand of the family is detected abundantly in
pancreatic cancer cell lines as compared to the other two isoforms, ET-2 and ET-3 [18]
[19]. In addition to its pathophysiological role in pancreas evidence also suggests its
crucial role in normal pancreas physiology and also pancreatitis. Studies have
demonstrated the presence of ETAR and ETBR in the rat pancreas and their differential
binding affinities towards the three endothelin ligands [34]. The present study revealed
the expression of ET axis components, ECE-1, ET-1, ETAR and ETBR in pancreatic
acinar cells and islet cells and their minimal or low levels in the pancreatic ducts of WT
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mice. In murine progression model of pancreatic cancer, a progressive increase in the
expression was observed in the trans-differentiated or neoplastic ductal cells. The acinar
specific expression of the ET axis in the normal pancreas implies a possible role of this
axis in maintenance of acinar cell differentiated state. Metaplasia is regarded as the
conversion or transformation of one cell type into another by an abnormal stimulus and
are associated with early phase of tumor development. In the context of acinar to ductal
metaplasia, metaplastic ducts are transitional structures and are characterized by
presence of both acinar cell markers such as amylase and duct cell marker CK19. Our
analysis reveals elevated expression of both ETAR and ETBR in amylase and CK19
double positive metaplastic ducts in the KrasG12D mutant mice pancreas following
cerulean-induced injury.
Pancreatitis is an established risk factor for pancreatic cancer and is
characterized by acinar cell necrosis, infiltration of inflammatory cell populations, stromal
fibrosis and release of insoluble and soluble mediators [35] [36]. Previous study from our
lab has revealed that ceruelin induced inflammatory damage to the pancreas is followed
by decrease in the amylase expression in the mutant KrasG12D mice compared to
control [21]. We observed that post cerulein induced inflammation metaplastic ducts can
be seen in the mice pancreas and appearance of both ETAR and ETBR can be
witnessed. In the KrasG12D mutant mice at day 7 and 21 post trauma, cerulein induced
acinar to ductal metaplasia in pancreas display greater dysplasia and higher colocalization with CK19 positive ducts and progressed more rapidly to tumor
development. In contrast, in normal mice with WT kras a recovery in the pancreatic
parenchyma is observed after day 2-cerulein treatments, suggesting that oncogenic Kras
results in enhanced and sustained activation of ET axis following inflammatory insults. In
mice with WT Kras, cerulein treatment resulted in a notable increase in the expression of
ET-1 and ETAR mRNA levels at day 2, while the levels of ETBR increased marginally;
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however a recovery to basal level was observed for all three molecules by day 7. In
contrast, significant increase in ET-1, ETAR and ETBR transcripts was observed following
cerulein treatment and these levels continued to remain high even at 21 days posttrauma in KC mice. The expression of ET receptors in the normal mice is constrained in
the pancreatic acini suggests its possible role in maintain the differentiating state of the
acinar cells. Our data indicate that in mice harboring KrasG12D mutation in the pancreas
the persistent activation of the ET axis components following cerulein treatment favors
reprogramming of acinar cells into ductal morphology and favors neoplastic
transformation. Therefore, we may speculate that the elevated levels of ET-1 in
presence of KrasG12D oncogene favors acinar to ductal metaplasia changes to promote
formation of pre-neoplastic lesions.
In the context of acute pancreatitis, the role of ET-1 has been widely studied and
is known to promote disease aggravation. In experimental rat model of pancreatitis, ET-1
was identified as one of the candidate gene associated with pancreatic inflammation
[37]. Additionally, in both sodium taurocholate and cerulein induced pancreatitis,
exogenous administration of ET-1 damages the pancreatic parenchyma, promote acinar
cell necrosis and increases amylase and elastase levels [38] [17]. ET-1 is considered to
be significant risk factor for acute pancreatitis and elevated levels correlates with
disease severity [12]. Similar to acute pancreatitis, elevated levels of ET-1 and
significant correlation was observed in smoking individuals with chronic pancreatitis
when compared to normal pancreatic tissues and non-smoking chronic pancreatitis
patients [13]. In addition, studies also demonstrate a significant increase in the plasma
ET-1 levels under the influence of tobacco smoking suggesting direct effect on
endothelium facilitating the peptide release [39] [40]. Cigarette smoke is an established
risk factor for PC and smoke induced inflammation accelerates the cancer progression in
presence of constitutively active Kras mutation. Our recent study revealed that smoking
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accelerates tumor progression by aggravating lesion formation in the pancreas and
influences tumor microenvironment of the pancreas by activating pancreatic stellate cells
and increase accumulation of macrophages [22]. We observed that cigarette smoke up
regulates the transcript levels of ET-1, ETAR and ETBR in KrasG12D mice after smoke
exposure as compared to mice with WT Kras. Interestingly mouse genotype determined
the response to smoke induced inflammation. Further observation also suggests the
acinar specific expression of ET axis components in WT mice with and without exposure
to smoke further signifying its possible role in maintenance of differentiated state of
acinar cells. Our results further indicate that in presence of KrasG12D oncogene smoke
exposure significantly increase the expression in the pancreatic ductal cells.
In vivo observations suggest that the pancreatic inflammation elicits macrophage
infiltration and secreted cytokines are considered as potent inducers of pancreatitis
initiated acinar cell transformation to ductal progenitor phenotype [41]. These infiltrated
macrophages are considered as drivers of ADM formation and in presence of oncogenic
signaling favors tumor development [42]. A recent study demonstrated that acinar cells
harboring mutant Kras up regulates ICAM-1 expression, which serves as chemo
attractant for macrophages to drive tumor initiation [43] [44]. Several observations have
also shown to modulate the migration of monocytes and macrophages in complex tumor
microenvironment in endothelin dependent manner. Very recent study demonstrated that
ET-1 through its interaction with receptors induced polarization of human macrophages
[45] and favors cross talk between breast cancer cells and endothelial cells in an integrin
dependent manner [46]. Also, in bladder cancer, ET-1/ETAR interaction favors stromal
cross talk and enhances metastatic colonization in the lung by increase migration and
infiltration of tumor cells and tumor associated macrophages respectively [47]. In
addition to promote tumor- stromal interactions, endothelin(s) also serves as potent
chemoattractant for monocytes and macrophages. ET-1 has been shown to stimulate
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chemotaxis of blood monocytes [48] and induced chemo-kinetic migration of peritoneal
macrophages in an ETAR dependent manner [49]. In addition to ET-1, ET-2/ETBR
signaling promotes chemotaxis and modulates the distribution of macrophages in tumor
via MAPK pathway [50]. Therefore we may speculate that the elevated levels of ET-1 in
pancreatitis associated inflammation in presence of KrasG12D oncogene drives acinar to
ductal conversion in pancreas by increase infiltration of macrophages in an ET-1
dependent manner. We found that in response to inflammation (cerulein or smoking) the
recruitment of activated macrophages in the pancreas stroma is dependent on mouse
genotype and degree of inflammation. Also, the expression on the ET receptors on the
infiltrating macrophage population is dependent on the mouse genome. In KC mice upon
cerulein inflammation, significant co-localization of ETBR and not ETAR can be observed
with F4/80 positive macrophages. However, F4/80 macrophages show high degree of
co-localization with both the ET receptors at day 7 and day 21-post trauma. Our careful
observation in the smoke treated mice tissues in presence of mutant KrasG12D also
indicate higher fractions of F4/80 positive macrophages overlapping with ET receptors.
Smoke treated mice carrying the KrasG12D oncogene show higher co-localization of
F4/80 positive macrophages with ETAR and ETBR in the stromal compartment. It
appears that the elevation in the ET-1 levels in inflammation associated pancreatitis
serves as a potential chemo attractant for infiltrating macrophages expressing the
receptors and favors neoplastic transformation by allowing acinar cells to be
reprogrammed into ductal phenotype. However, to fully understand and delineate the
molecular mechanisms of ET- axis mediated acinar cell reprogramming by recruiting
macrophages in mutant KrasG12D mice, further studies involving macrophage targeted
conditional knock-out of ETAR and ETBR need to be undertaken.
In addition to active infiltration of immune cell populations in response to
pancreatic injury, activation of PSCs is recognized as central event in development of
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pancreatitis and PC. These PSCs are activated by a variety of soluble and insoluble
mediators such as cytokines, growth factors, oxidative stress, ethanol and its
metabolites and pancreatitis. Once activated, they trans-differentiate into myo-fibroblasts
like cells and the phenotypic transformation results in fibrosis and extensive deposition
of extracellular matrix proteins [51]. The pro-fibrotic role of ET-1 in various pathologies is
well documented and is regulated at transcriptional levels by interaction with various
transcription factors such as Smad, TGF-β and activator protein-1 (AP-1) [52] [53]. ET-1
induces a pro-fibrogenic response in lung fibroblasts by increase expression of α-SMA
and CTGF by JNK-AP1 and TGF-β pathway [54] [55]. Accumulating evidence imply that
activated PSCs play a pivotal role in development of pancreatic fibrosis and
inflammation. Activated PSCs express ET-1, ETAR and ETBR and are ET-1 responsive
suggesting an autocrine and paracrine loop to stimulate contraction and migration of
PSCs by inducing phosphorylation of ERK and MLC but not AKT [56]. Further, studies
by Stumpe and co-workers indicate that ET-1/ETAR interactions increase cytosolic
calcium concentrations and possibly act as an autocrine and paracrine factor for
activated PSCs [57]. In addition to stimulate myofibroblasts differentiation, ET-1 has also
been shown to promote inflammatory reaction in the pancreas by release of proinflammatory mediators such as IL-6 and IL-1β [58]. Moreover, Fitzner et al
demonstrated that the pro-fibrogenic effect of ET axis is attenuated by dual ETAR and
ETBR antagonist Bosentan in experimental chronic pancreatitis model [59]. Our results
suggest that acute and chronic inflammation induced by cerulein and smoking
respectively accelerates the desmoplastic reaction in the KrasG12D mice and the
concomitant expression of endothelin receptors on activated PSCs can possibly promote
stromal cross talk by autocrine and paracrine interactions and aid in tumor progression.
Our current study revealed that endothelin receptors are expressed in metaplastic ducts
signifying its possible role in trans-differentiation. In addition, increase accumulation of
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fibrotic stroma in mutant Kras mice after post cerulein administration suggests in addition
to metaplastic ducts, the expression of ET receptors is also observed in
microenvironment of the pancreas. Importantly, significant co-localization of α-SMA
positive fibroblasts is observed with both ETAR and ETBR dependent on mouse genome
and degree of inflammation. Our real time PCR analysis infers significant increase in the
ET-1 transcript levels in pre-cancerous lesions in the KrasG12D mice further strengthen
the involvement of possible interaction with the activated stellate cells. In addition to
acute inflammation model, in smoke induced chronic pancreatitis elevated levels of αSMA in presence of oncogenic signaling is followed by prominent expression of ETBR
and limited co-association of ETAR. Quantitative analysis further indicates that fractions
of α-SMA fibroblasts exhibit significant overlapping fractions with ETBR positive
fibroblasts. We speculate that persistent increase and activation of ETAR and ETBR with
increasing dysplasia in the activated myo-fibroblasts in presence oncogenic Kras
signaling plays an essential role in maintenance of PSC activation through ET-1
autocrine loops. However, the molecular mechanisms underlying this phenomenon are
not completely understood and warrant further investigation.
To summarize, our study profiles the expression of endothelin axis during acute
and chronic inflammation associated pancreatic tumor progression in presence of
mutated KrasG12D. Under physiological conditions, the expression of ET axis
components is restricted to pancreatic acinar and islet cell compartments (Figure 15).
However, during inflammation or injury the acinar expression is abrogated and elevated
expression is seen in early pre-cancerous lesions and neoplastic cells. The sustained
upregulation of ET-axis components in the presence of oncogenic K-ras and
overexpression in advanced lesions, suggest that signaling along ET-axis possibly
contributes to reprogramming of acinar cells into metaplastic ductal cells and drives their
transformation into neoplastic lesions. The increased expression in pre-neoplstic lesions
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is followed by excessive accumulation of ECM proteins and inflammation in the
pancreas, indicating further involvement of ET axis in influencing microenvironmental
factors during the initiation and progression of pancreatic cancer.
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Figure 1: Expression pattern of ECE-1, ET-1, ETAR and ETBR in Pdx1-Cre; KrasG12D
(KC) murine pancreatic cancer model. A. RT-PCR analysis showing age wise
expression of ECE-1 ET-1, ETAR and ETBR on pancreas of control and KC mutant mice.
The expression for all four molecules can be observed at all weeks analyzed and the
levels maintained throughout. In contrast, a robust expression in the expression is seen
in 20, 30,40 and 50 wk KC mice compared to littermates controls. Actin was used as
loading control. B. Immunohistochemistry analysis of ET-1, ETAR and ETBR after
staining with respective antibodies (1b). Normal pancreas (unfloxed mice) isolated from
50 week old mice shows predominant expression for ECE-1, ET-1 and receptors in the
islet cells (black arrow heads) while low immunoreactivity is seen in the pancreatic acini
(zoom). In the control mice (unfloxed) pancreas the low expression of ECE-1 can be
seen in the pancreatic duct (inset) whereas no expression was detected for ET-1 and
receptors. In the early PanIN lesions of pancreas of Pdx1-Cre;KrasG12D mice starting
from 30 weeks of age, the elevated expression can be seen and progressive increased
expression is observed both in the tumor cells and the stromal compartment (inset) with
the mutant Kras expression.
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Figure 2: ETAR and ETBR expression during pancreatic injury in normal and KC
mice. Three color Immunofluorescence images of ETAR (A) and ETBR (B) expression
(purple) of with acinar cell marker amylase (red) and ductal cell marker CK19 (green) in
cerulein and saline treated mice at days 2, 7 and 21 post cerulein injection. Expression
of both ETAR and ETBR is seen in the pancreatic acini in normal and KC mutant mice
under control conditions. At day 2 post trauma, ETAR and ETBR expression appears in
amylase and CK19 double positive metaplastic ducts in KC mice under cerulein treated
metaplastic conversion. In control mice, normal pancreatic architecture is restored and
the acinar cells displaying increases expression of amylase and colocalization with ETAR
and ETBR. In the KC mice at day 7 and 21 post inflammatory insult, the pancreas show
dysplastic changes and appearance of metaplastic ducts and gradual increase
expression of both ET receptors can be seen in the CK19 positive ducts.
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Figure 3: Histological analysis of ETAR and ETBR expression in normal mice with
and without cerulein treatment. Immunohistochemical analysis of ETAR and ETBR in
the mice pancreas after cerulein treatment. Analysis reveal low expression of both
receptors in the pancreatic acini whereas a predominant expression in the islet cells is
seen (black arrowheads) at all day 0, 2, 7 and 21 of treatment. Interestingly, no
expression in the normal pancreatic duct was seen (inset) and recovery in the pancreatic
parenchyma is observed at day 7 and day 21 of treatment
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Figure 4: ET-1, ETAR and ETBR expression during pancreatic injury in normal and
KC mice. Real time PCR analysis of ET-1 mRNA levels between normal and KC mice
under control and cerulein treated conditions showed significant increase in the ET-1
mRNA levels in the KrasG12D

mutant mice at day 7 and day 21 after cerulein

administration (A). Comparison of the of ETAR transcript levels showed elevated
expression in the Kras mutant mice at day 7 and day 21 of treatment with significant p
value (B). A predominant and significant increase in the ETBR mRNA was seen at day 7
of treatment with a marginal increase being observed at day 21-post trauma (C).
* p<0.05, ** p<0.005, ns=not significant.
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Figure 5: ET-1, ETAR and ETBR expression during pancreatic injury in normal and
KC mice. Real time PCR analysis of ET-1, ETAR and ETBR expression alterations in the
normal (A) and KC (B) mice under control and cerulein treated conditions at various time
points. In the normal mice, increase expression of ET-1 and ETAR and decrease
expression of ETBR was seen due to cerulein induced inflammatory insult at day 2 and
recovery for all three molecules being observed for all three molecules by day 21. In KC
mice, harboring Kras mutation in the pancreas ETAR mRNA levels gradually increased
with progressive acinar to ducal phenotype switch following cerulein treatment. ETBR
mRNA levels on the other hand, increases due to metaplastic changes in the mice
pancreas at day 7 but falls backs to basal levels subsequently.
* p<0.05, ** p<0.005, ns= not significant
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Figure 6: Expression of ET-2 and ET-3 in normal and KC mice with or without
cerulein treatment. Real time PCR analysis show no significant difference in the
expression of ET-2 (A) and ET-3 (B) in KC mice compared to control over the treatment
period. * p<0.05, ** p<0.005, ns=not significant.
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Figure 7: Expression of ET-1, ETAR and ETBR in spontaneous KC mice model
subjected to cigarette smoke. Quantitative real time PCR analysis show no significant
difference in the expression of ECE-1 in the RNA isolated from the pancreas of sham
and smoke exposed mice (A). Comparison of ET-1(B), ETAR (C) and ETBR (D) transcript
levels show significant difference in mRNA levels in Kras mutant mice exposed to
cigarette smoke as compared to sham controls. E. Immunohistochemical analysis of the
unfloxed animals with and without exposure to cigarette smoke induced inflammatory
insult show difference in the expression of ET axis components and low immunostaining
in acinar cells and predominant staining in islet cells is observed (inset). Smoke
exposure to unfloxed mice reveal increase expression of ECE-1 in normal pancreatic
duct while the expression of other markers remain unchanged (inset). The expression of
ECE-1, ET-1 and receptors can be seen in pre-cancerous lesions in the Sham floxed
animals and stromal region. In presence of oncogenic Kras overexpression of ECE-1,
ET-1 and receptors can be observed in both tumor lesions and stromal compartment.
The box plot represents the quantitative expression of ECE-1 (F), ET-1 (G), ETAR (H)
and ETBR (I).
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Figure 8. Expression of ET-3 in unfloxed and floxed KC mice with and without
cigarette smoke exposure. Real time PCR analysis show no significant difference in
the expression of ET-3 in the RNA isolated from the pancreas of sham and smoke
exposed mice. * p<0.05, ** p<0.005, ns=not significant.
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Figure 9: Expression of ET-1, ETAR and ETBR in spontaneous KC mice model with
and without cigarette smoke exposure. Dual immunofluorescence analysis showing
the expression of ET-1, ETAR and ETBR in sham controls and smoke exposed floxed
mice. Smoking in the Kras mutant mice accelerated the PanIN formation and increase
expression in the CK19 positive ducts.
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Figure 10: Increase accumulation of F4/80 positive macrophages and α-SMA
fibroblasts

following

cerulein

treatment.

Bar

diagram

representation

Immunofluorescence analysis of the pancreas of saline and cerulein treated mice show
significant increase in the F4/80 cells after cerulein induced injury at day 7 and day 21
treatment (average count of F4/80-positive cells in five independent fields/tissue
section). Quantitative analysis of the α-SMA fibroblasts indicate significant increase
starting at day 2 of treatment compared to control (average count of α-SMA positive cells
in five independent fields/tissue section). * p<0.05, ** p<0.005, ns=not significant.
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Figure 11: Increase infiltration of F4/80 positive macrophages is associated with
both ETAR and ETBR expression in cerulein induced inflammation: Dual color
immunofluorescence images of the ETAR and ETBR expression (red) with macrophage
marker F4/80 (green) in cerulein and saline treated mice at days 2, 7 and 21 post
cerulein administration. A. In the control and KC mutant mice under control conditions,
expression of ETAR is restricted to acinar compartment and no overlap is seen with
F4/80 positive macrophages. At day 2 post cerulein treatment in KC mice, limited
localization of ETAR is seen (inset) with F4/80 while no difference is seen in normal
mice. In KC mice at day 7 and 21 post inflammatory insult, significant overlap of ETAR is
observed with the infiltrating F4/80 populations in the stromal region (inset), while
minimal or no overlap is seen in control mice. B. The degree of overlap between F4/80
positive macrophages and ETAR was measured using ImageJ using Manders overlap
coefficients. C. Similar to ETAR, acinar specific expression of ETBR shows no
colocalization with F4/80 in normal and KC mice under control conditions. Brief episode
of cerulein treatment at day 2 in KC mice shows substantial colocalization with F4/80
populations (inset) with significant p value compared to control mice. In KC mice at day 7
and 21 of cerulein treatment, the ETBR expression in the metaplastic ducts is
accompanied by significant overlap with F4/80 positive macrophages in the stroma,
while limited colocalization is seen in the normal mice. D. The degree of overlap
between F4/80 positive macrophages and ETBR was measured using ImageJ using
Manders overlap coefficients * p<0.05, ** p<0.005, ns= not significant (Scale bar =
20µm; zoom scale bar =10µm).
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Figure 12: Increase infiltration of F4/80 positive macrophages is associated with
ETBR expression in smoke induced inflammation. Three color immunofluorescence
images of the ETAR (purple), ETBR (red) and F4/80 (green) expression in the
spontaneous KC model with and without exposure to cigarette smoke. A. In the unfloxed
mice with and without exposure to cigarette smoke exposure expression of both ET
receptors is seen in acinar region of pancreas . The pancreas displays fewer infiltration
of F4/80 macrophages and exhibits minimal overlap with both ETAR and ETBR (zoom).
Smoke exposed KC mutant mice exhibits significant colocalization of both ETBR and
F4/80 (zoom) as compared to sham control. C. The degree of overlap between ETAR
and F4/80 (zoom) in smoke exposed animals reveals no significant fractions of F4/80
overlapping fractions with ETAR (B) as measured using ImageJ with Manders overlap
coefficient * p<0.05, ** p<0.005, ns= not significant (Scale bar = 20µm; zoom scale bar
=10µm).
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Figure 13: Increase expression of α-SMA positive fibroblasts is associated with
both ETAR and ETBR expression in cerulein induced inflammation. Dual color
immunofluorescence images of the ETAR and ETBR expression (red) with α-SMA
(myofibroblast marker) (green) in cerulein and saline treated mice at days 2, 7 and 21
post cerulein administration. A. In the control and KC mutant mice under control
conditions, expression of α- SMA is detected in the mice pancreas and shows limited
colocalization with ETAR. At day 2 post cerulein treatment in KC mice, increase
expression of α- SMA is seen in the KC mutant mice as compared to control, however
limited colocalization with ETAR is detected in mice pancreas (zoom). In KC mice with
constitutive active Kras mutation, higher expression of α-SMA in the pancreas is
associated with significant overlap with ETAR in the mice pancreas at day 7 and 21
cerulein insult with significant p value. B. The degree of overlap between α-SMA positive
fibroblasts and ETAR was measured using ImageJ using Manders overlap coefficients.
C. Parallel to ETAR, expression of α-SMA fibroblasts reveals limited co-association with
ETBR in the control and KC mutant mice under control conditions. At day 2 post
injection, under cerulein induced metaplastic conversion, the increase number of α-SMA
fibroblasts is marginally associated with ETBR expression. With increase in dysplasia at
days 7 and 21 of treatment increase activation of stellate cells and higher expression of
α-SMA fibroblasts in pancreas is shows extensive colocalization with ETBR with
significant p value. D. The degree of overlap between α-SMA positive fibroblasts and
ETBR was measured using ImageJ using Manders overlap coefficients. * p<0.05, **
p<0.005, ns= not significant (Scale bar = 20µm; zoom scale bar =10µm).
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Figure 14: Increase expression of α-SMA positive fibroblasts is associated with
ETAR epression in smoke induced inflammation. Dual color immunofluorescence
images of the ETAR and ETBR staining (red) with α-SMA (myofibroblast marker) staining
(green) in smoke exposed and sham control floxed mice. A. Immunofluorescence
images of the ETAR and α-SMA colocalization in the pancreas of sham and smoke
exposed unfloxed mice reveals no significant difference in the fractions of α-SMA
myofibroblasts overlapping with ETAR. In kras mutant mice exposed to cigarette smoke
higher expression of α-SMA in the pancreas of smoke-exposed animals is accompanied
by significant colocalization was observed (zoom). B. The degree of overlap between αSMA myofibroblasts and ETAR was measured using ImageJ using Manders overlap
coefficients. C. Dual confocal microscopy analysis of ETBR and α-SMA overlap in the
pancreas of sham and smoke exposed unfloxed mice displays no significant overlap
between two fractions. Contrary to ETAR, smoke exposure in KC mutant mice shows no
significant co-association between the two populations in the pancreas stromal region as
compared to control (zoom). D. The degree of overlap between α-SMA myofibroblasts
and ETAR was measured using ImageJ using Manders overlap coefficients * p<0.05, **
p<0.005, ns= not significant (Scale bar = 20µm; zoom scale bar =10µm).
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Figure 15: Proposed Model. In summary, in the normal pancreas, expression of both
endothelin receptors (ETAR and ETBR) is restricted to pancreatic acinar and islet cells. In
presence of mutated Kras (G12D), inflammatory insult (cerulein or smoking) results in
transdifferentiation of acinar phenotype into ductal phenotype and favors metaplastic
conversion accompanied by downregulation acinar cell marker genes (Amylase) with
simultaneous upregulation of ductal markers (CK19). In the Kras mutant mice, the
expression of the endothelin axis components is seen in early pre-neoplastic lesions and
in tumor microenvironment of PC and increase gradually with increase in neoplasia. The
sustained activation of the ET axis in presence of oncogenic Kras both in the tumor cells
and in stromal compartment of PC, suggest its possible role in tumor initiation and
progression.
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Chapter 6
Summary, Conclusions and Future directions
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1. Summary
Over the past several years various studies have attempted to understand the role
of endothelin axis in solid cancers and melanomas[1]. In the context of pancreatic
cancer a recent study has shown the overexpression of ET-1ligand and endothelin B
receptor (ETBR) but not endothelin A receptor (ETAR) [2]. However, a number of
questions remain unanswered. For instance, what is the expression of overall ET axis as
such in the in PC and in early pancreatic lesions? Also, what is the expression status of
the axis in the context of complex TME of PC? What is the pathobiological significance
of the ET axis proteins? Importantly, what is the impact of targeting the axis in PC
microenvironment?
The overarching goal of the studies presented in this thesis was to examine the
pleotropic actions of the ET axis in pancreatic tumor microenvironment. Briefly, we
examined the following aspects of ET axis expression and function: 1) Expression in
tumor cells and stromal compartment, 2) Pathobiological significance of ET
upregulation in PC

axis

3) Impact of ET-axis antagonists in the murine model of

autochthonous tumorigenesis 4) Involvement of ET-axis in K-ras oncogene associated
chronic and acute pancreatic inflammation
Overall, our major findings were: 1) Compared to normal pancreas, components
of ET axis, ECE-1, ET-1, ETAR and ETBR are overexpressed in primary tumor and
metastatic sites. 2) ETAR and ETBR are expressed in immune cells and tumor blood
vessels. The expression of ETBR on blood vessels is associated with poor prognosis of
PC patients 3) It was observed that overexpression of the ET receptors is associated
with pro-fibrotic gene signatures, suggesting that signaling along the ET promotes
fibrosis in PC 4) Pharmacological inhibition of the axis using dual ETAR and ETBR
antagonist Bosentan reduces the pro-fibrotic genes in autochthonous mice model. These
results suggest that targeting this axis can possibly modulate the complex TME of PC. 5)
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In stellate cells and cancer-associated fibroblasts, exogenous administration of ET-1
induces expression of stromal associated genes in an ERK/AKT dependent manner. We
are generating mouse model to determine the effect of ET-1 loss on pancreatic cancer
progression. The mice will be analyzed further to determine the loss of ET-1 in Kras/p53
driven PC in mice. Below, I summarize the findings of each project and implications
thereof.
A. Expression of endothelin converting enzyme (ECE-1), endothelin-1 (ET-1),
endothelin A receptor (ETAR) and endothelin B receptor (ETBR) in PC and its
microenvironment
The rationale for this study was based on earlier scattered evidence about the
expression pattern of ET axis in PC, including a very recent study, which reported the
ET-1 and ETBR expression in PC patients [2] . First, we examined the expression of
ECE-1, ET-1 and both ET receptors in PC cell lines and PC tissues. We observed that
ET-1 expression is seen in majority of cell lines tested, however both ETAR and ETBR
showed an inverse association, either of one expressing at a time with few exceptions.
Immunohistochemical analysis in PC tissues isolated from Whipple resected patients
(RAP) and tissue microarray from rapid autopsy program suggests overexpression both
in the primary tumor as well metastatic sites. The incidence of ECE-1, ET-1, ETAR and
ETBR was 88%, 86%, 75% and 68% cases respectively in the primary tumors. Our
tissue analysis also revealed expression of the ET-1 and its receptors in the stromal
region of the tissues studied. The expression was predominantly seen in the infiltrating
immune cells and the blood vessels. Further scoring of the slides by a pathologist
implied elevated expression of ETAR and ETBR on tumor vessels in 60.5% and 31.5%
cases respectively. In the immune cells, ET- 1 expression was seen in31.5% of cases
while the incidence of ETAR and ETBR expression was 34.1% and 39.4% ,respectively.
Very importantly, survival analysis from surgically resected primary tumors suggested
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that elevated expression of ETBR on blood vessels and not tumor cells was associated
with poor prognosis in these patients. The median survival of the patients with elevated
expression for ETBR was 14.7 months as compared to 10.3 months with low ETBR
positivity, indicating that looking at the expression in the tumor microenvironment is also
essential to delineate the pathological significance of the axis. Due to limitation in the
sample size of the Whipple and RAP cases we screened the TCGA database and
expression of ET-1 and receptors was correlated with tumor grade and stage. To further
demonstrate the pathobiological implication of axis we did bioinformatics study to look
for the genes that correlated with ET axis overexpression. Interestingly, significant
correlations of the fibrotic associated genes, predominantly collagen isoforms, FAP,
PDGRFβ, SPARC were seen. In addition, regulatory pathways involved in fibrosis, tumor
growth and metastasis were also upregulated, suggesting that overexpression of ET axis
correlates with the extracellular matrix associated gene signatures.
One of our long-term quests with this study was to develop approaches to
selectively

modulate

the

TME

to

improve

the

therapeutic

efficacy

of

the

chemotherapeutic regimens. So to explore the potential of targeting this ET axis we also
analyzed the expression in KPC model of PC.
Our RT-PCR and immunohistochemical result indicated progressive increase in
the expression of ET axis components in advanced lesions at 25 weeks of age. Similar
to human PC tissues, the expression of axis components is also seen in tumor stroma.
The expression in various compartments of TME was confirmed using dual
immunofluorescence studies using markers for stellate cells (α-SMA), blood vessels
(CD31) and tumor associated macrophages (CD68 and F4/80). These observations
indicate that mouse pancreas recapitulates the expression pattern in human PC.
Taken all together, the study for the first time established the prognostic potential
of ET axis in PC. The expression on TME compartments and correlation with pro-fibrotic
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genes further establishes the potential of axis as a “druggable” target that can be
exploited in PC therapy.
B. Targeting endothelin axis in pancreatic cancer using selective and dual
receptor inhibitors under in vivo (KPC, K-rasG12D; Trp53R172H/+; Pdx-1-Cre) and in
vitro (pancreatic stellate cells and cancer associated fibroblasts) system
Our aforementioned expression and bioinformatics analysis data suggested that
ET receptors are expressed in TME and exhibit significant correlation with the profibrotic gene signatures. Due to the expression in of ET receptors on various cell types in
TME, the ET axis possibly exerts pleotropic effects to modulate the pathophysiological
hallmarks of PC such as fibrosis and hypo-vascularity [3]. Given the attraction of this
pathway as a “druggable” target and the availability of both selective and dual inhibitors
for ET receptors, an overarching goal was to unravel the pathobiological significance of
ET-axis PC in the context of TME and define the manner in which the ET axis
antagonism can be exploited in PC therapy.
Having established an apparent correlation between fibrotic gens and ET axis we
investigated the consequences of targeting ET axis in vivo with Bosentan, a dual ET
receptor antagonist. Bosentan is a FDA approved drug and is firmly established in the
clinics for the treatment of pulmonary arterial hypertension (PAH) and chronic heart
diseases [4, 5]. We utilized the 20-week KPC animal (widely used model for PC) where
the tumor is fully formed and abundant stroma outnumbers the cancer cells. Bosentan
given as a monotherapy increases apoptosis and decreases desmoplasia in KPC tumors
evident by IHC analysis against cleaved caspase-3 and Masson’s trichrome staining
respectively. Further using mouse fibrosis array, we observed Bosentan treatment
induced significant reduction in the profibrogenic gene signatures which were
concordant with the genes found to associated with ET-axis upregulation in TCGA
database analysis. This led us to conclude that ET axis promotes desmoplasia in PC

302
and ET axis antagonist’s exhibit anti-fibrotic effects. In addition to pro-fibrotic genes, dual
ET axis antagonism also resulted in marginal increase in in anti-fibrotic genes such as
IL-10, Bmp 7 and IFN-γ. The next step was to identify the specific population(s) of
cancer-associated

fibroblasts

that

are

affected

by

ET

axis

antagonism.

Immunofluorescence analysis confirmed that Bosentan treatment reduces the FSP1 and
α-SMA positive fibroblasts but not FAP positive fibroblasts.
The next step was to validate ET axis mediated fibrogenic effects in vitro. It was
observed that treatment of murine pancreatic stellate cells (ImPSC.c2) and human
cancer associated fibroblasts (10-03) with ET-1, resulted in increased expression of profibrotic genes (α-SMA, Collagen I, CTGF, Fibronectin) in time dependent manner. To
identify the ET receptor exerting this effect,

we used selective inhibitor for ETAR

(BQ123) and ETBR (BQ788). ET-1 mediated induction of matrix associated genes was
attenuated by BQ788 whereas minimal effects were observed with BQ123. A synergistic
effect was seen using dual ETAR and ETBR inhibition using Bosentan. In contrast, in
human CAFs, both BQ123 and BQ788 abrogated ET-1 induced expression. One
speculation could be the distribution of ETAR on murine stellate cells. The ImPSC.c2
expresses high level of ETBR and low level of ETAR, while 10-03 CAFs expresses both.
We next investigate the molecular mechanism(s) underneath the ET-1 stimulated
fibrosis. Immunoblotting analysis confirmed that ET-1 treatment provokes a rapid
phosphorylation of the p-ERK and p-AKT in both ImPSC.c2 and 10-03 CAFs. This is in
line with the literature, which suggests that in rat PSCs and lung fibroblasts ET-1
stimulate phosphorylation of ERK/MEK pathway [6] [7]. In conclusion, our in vivo and in
vitro findings demonstrates that ET-1 release from tumor cells act on acts on stellate
cells and CAFs and through and ERK/AKT dependent manner induces pro-fibrotic
phenotype and promotes extensive desmoplastic reaction in PC. The second part of the
study dealt with the functional effects of ET inhibitors on these cells. It was observed that
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both BQ788 and Bosentan displayed anti-proliferative effects on the growth of ImPSC.c2
and 10-03 CAFs, with minimal effects were observed with BQ123. Further, flow
cytometry studies indicate that both BQ788 and Bosentan stimulate apoptosis and G1/S
arrest in ImPSC.c2 cells. Additionally, we observed that ET-1 promotes migration of
ImPSC.c2 cells which was inhibited by selective and dual ET antagonists.
Given the significance of infiltration of immune cells in PC progression [8] [9], we
examined the consequence to ET axis inhibition on the infiltration of immune cells.
Tissue immunohistochemistry and immunofluorescence analysis showed reduction in
F4/80 positive macrophages and increase in the recruitment of cytotoxic T cells in the
KPC mice stroma upon Bosentan treatment. In addition, our in vitro studies also
demonstrated that the migration of RAW264.7 macrophages and U937 monocytic cells
in response to murine and human pancreatic cancer cell lines respectively, was
abrogated by Bosentan and ETBR antagonist. .
In addition to fibrosis or desmoplasia, tumor hypovascularity and heterogenous
tumor blood flow is also one of the hallmarks of PC. Due to increased production of ET-1
and overexpression of ETAR, the vasomodulatory activity of ET axis is believed to
contribute to tumor blood flow heterogeneity by selectively modulating the tone of
vessels. Thus, ETAR antagonists, in addition to their direct anti-tumor effects also exhibit
an adjuvant effect that enhances tumor perfusion and increases drug uptake [10]. We
studied the effect of selective ETAR antagonist BQ123 on subcutaneous xenograft
tumors derived from human pancreatic cancer cell lines. The change in perfusion was
studied by MRI using flow sensitive alternating inversion recovery (FAIR). Baseline
perfusion was higher in muscles as compared to tumors, however, the chnages in
perfusion in response to BQ123 were more pronounced in tumors than in the muscle
where only marginal increase in perfusion was observed. We also found that enhanced
perfusion induced by BQ123 reduces tumor hypoxia in xenograft tumors.
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Overall, these results demonstrate for the first time, the unequivoal role of ET
axis in establishing desmoplastic, poorly perfused and possibly immunosuppresive
micrenvironement in PC. These studies also suggest that it is possible to selectively
modulate the determinants of therapy resistance (tumor stroma and vasculature) that
contribute to poor drug delivery by targeting ET axis. suggests.
C. Irreversible and sustained upregulation of endothelin axis during K-rasoncogene associated pancreatic inflammation and cancer.
Inflammation is believed to promote tumorigenesis and chronic pancreatitis and
smoking (causes chronic pancreatic inflammation) are well recognized risk factors for
PC. Given the potential involvement of ET-1 ligand in promoting pancreatic inflammation
[11] and the fact that several studies indicating elevated ET-1 levels during acute and
chronic pancreatitis [12-14], we examined the role of ET axis in the pancreatic
inflammations (acute and chronic) in presence and absence of oncogenic Kras and in
pre-neoplastic lesions. No study thus far has examined the expression of ET axis
proteins in acute and chronic pancreatic inflammation in the presence of K ras
oncogene. Thus the goal of this part of the study the role of ET axis in inflammation
associated pancreatic cancer initiation and progression in presence of mutated KrasG12D.
As a part of this project we have utilized murine models of acute (ceruleaninduced) and chronic (smoking-induced) pancreatic inflammation described previously
by our lab [15] [16]. We first analyzed the expression of ET axis components in the KC
model (Pdx-1 Cre; KrasG12D) of the PC. Similar to our observations in KPC model,
there was a progressive increase in the expression of ET axis components with the
advancement of preneoplastic lesions. Further, careful analysis of the tissues revealed
that the expression was not only restricted to be lesions but can also be detected in the
surrounding stromal compartment and inflammatory cells. In cerulein induced pancreatic
injury in KrasG12D mutant mice, metaplastic ducts can be seen suggesting acinar-to-
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ductal transdifferentiation. Both ETAR and ETBR were found to be expressed in such
metaplastic ducts that stained positively for amylase (acinar marker) and CK19 (ductal
marker); however, no change in normal mice was observed. At day 7 and day 21-postcerulein administration, expression of both ET receptors was more pronounced in CK19
positive ducts with increase in dysplasia accompanied by loss in amylase staining. In
addition, real time PCR analysis of ET-1 and ETAR mRNA levels in KC mice showed
significant increase in transcript levels at day 7 and day 21-post trauma. In contrast,
ETBR mRNA levels showed increase at day 2 and day 7-post cerulein injection;
however; at day 21 a fall in expression was seen. In contrast to KC mice, the wild-type
mice exhibited restoration of the pancreatic acinar architecture and pancreatic
parenchyma and recovery of transcripts of ET-axis components to basal level at day 7
and 21.
Cigarette smoke induced alterations in the ET axis in the pancreas of KC mice
harboring KrasG12D mutation. There was significant increase in the transcripts of ET-1,
ETAR and ETBR compared to sham control. Similar to our observations in spontaneous
KC model, in the mice pancreas with and without exposure to cigarette smoke, the
expression of ECE-1, ET-1 and both ET receptors was associated with acinar
compartment of the pancreas and prominent staining in islet cells was noticable for all
four molecules. In sham control mice prominent expression of ECE-1, ligand ET-1 and
the receptors was observed in the pre-cancerous lesions and acinar region of the
pancreas.
In addition to expression in early pancreatic cancer lesions (smoking) and metaplastic
ducts (cerulein), ETAR and ETBR expression was also seen in infiltrating F4/80 positive
macrophages and α-SMA positive fibroblasts. Tissue immunofluorescence analysis
demonstrated that both ETAR and ETBR are expressed in F4/80 positive macrophages in
KC mutant mice in response to smoke and cerulein induced injury. Quantitative analysis
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using ImageJ software further indicated significantly higher number of F4/80 positive
cells expressing ETAR and ETBR as determined by Mander’s correlation coefficient. Dual
color immunofluorescence analysis revealed enhanced expression of both ETAR and
ETBR in the fibroblasts at day 7 and day 21-post cerulein administration. Importantly,
quantitative analysis of the smoke exposed double transgenic KC mice showed
increased co-expression of ETAR and not ETBR in α-SMA positive fibroblasts.
In conclusion, in the presence of oncogenic Kras, acute and chronic inflammation
resulted in irreversible reprogramming of acinar phenotype into metaplastic ducts and
accelerated progression of pre-neoplastic lesions respectively, along with increased and
persistent elevation of ET axis components. These observations suggest a possible role
of ET-axis in the neoplastic transformation and early stages of pancreatic cancer.

2. Future directions
A. Expression of endothelin converting enzyme (ECE-1), endothelin-1 (ET-1),
endothelin A receptor (ETAR) and endothelin B receptor (ETBR) in pancreatic
cancer (PC) and its microenvironment
(i) Could loss of ET-2 and ET-3 in cancer development contribute to ET-1
overexpression and circumvent competition with ET-1 for its receptors?
While out studies in PC provide evidence supporting the involvement of ET-1 and
ET receptors in pancreatic cancer, these studies raise number of questions. For
instance, numerous studies have stated silencing of ET-2 and ET-2 in early cancer
development. For example in colon cancer, ET-2 and ET-3 are potential targets for
epigenetic inactivation [17]. In addition, Espinosa et al and Sun et al revealed that
expression of ET-3 was down regulated in cervical cancer [18] [19] and levels are
decreased in cervical cancer cells as compared to normal epithelial cells, respectively
[20]. In breast cancer as well, frequent inactivation of ET-3 is observed due to promoter
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methylation in cell lines and carcinoma tissues [21]. Earlier studies in PC also revealed
that ET-1 is frequently produced by PC cell lines but not ET-2 and ET-3 [22]. Given that
epigenetic modification of EDN2 and EDN3 favor the overexpression of EDN1 gene
potentially causing the aberrant activation of ET axis, it will be of interest to study the
interrelationship of the three ET ligands in the context of pathophysiology of PC and
pancreatitis. A critical question that remains unanswered is: what mechanism(s) and
factors contrinbute to deregulated expression of ET-axis components? Also, whether the
loss of EDN2 and EDN3 is associated with adverse patient outcome in human PC?
These tantalizing questions could be addressed by future studies.
(ii) Do ET-2 and ET-3 play a role in PC?
Our analyses on the expression pattern of ET axis components revealed their
presence in various cellular compartments of tumor microenvironment. , We observed
the expression of ECE-1 enzyme, ligand ET-1 and both ET receptors on pancreatic
stellate cells, endothelial cell and immune cells. Given that ET-2, like ET-1, enhances
the invasive and metastatic potential of tumor cells when co-cultured in presence of
macrophages [23] it will be of interest to examine the effect of ET-2 on cancer and
stromal cells. Also, ET-2 is a potent chemo-attractant for macrophages and leads to their
increased activation via ETBR signaling [24], suggesting a reciprocal cross talk between
the tumor cells and the macrophages along ET-2-ETBR axis. One possible explanation is
that autocrine and paracrine signaling across the ET-2/ETAR or ET-2/ETBR signaling
between tumor cells and tumor microenvironment components might contribute to tumor
aggressiveness and metastasis. However, these ideas are purely speculative and need
to be verified. As already mentioned in chapter 3, significant expression of ET-1 is seen
in TME of pancreatic cancer, it is likely that ET-2 and ET-3 are also expressed on these
cell types and further contribute to permissive tumor milieu. These aspects can be
addressed by future studies.
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B. Targeting endothelin axis in pancreatic cancer using selective and dual
receptor inhibitors under in vivo (KPC, K-rasG12D; Trp53R172H/+; Pdx-1-Cre) and in
vitro (pancreatic stellate cells and cancer associated fibroblasts) system
(i) Will ETAR and ETBR inhibition improve the delivery and efficacy of
chemotherapeutic agents ?
Earlier studies have shown that targeting stromal components like hyaluronan
and collagen using collagenase and hyaluronidase [25-27] decrease both interstitial fluid
pressue (IFP) and microvascular pressure (MVP). resulting in enahancement in delivery
and efficacy of Gemcitabine (Gem) in KPC mouse models. However, both collagenase
and hyaluronidase lack specificity and cannot distinguish their targets in normal and
cancer tissues and would lead to harmful side effects if administered in patients [28]
thus, limiting their use in clinical settings. Similarly, inhibition of SHh signalling has been
shown to increase uptake and efficacy of Gem in KPC mouse tumors [29]. Yet targeting
TME in PC has recently become controversial due to the failure of clinical trials and
preclinical studies demonstrating that genetic ablation of stroma results in more
agrresive tumors [30] [31]. Our studies using dual ETAR and ETBR antagonist, Bosentan
represents more tunable pharmacological approach that selectively modulates
desmoplsia (not altogether abrogates) in the KPC mice model.
In addition our studies on xenografts tumors also demonstrate that ET-1/ETAR
axis contributes to heterogenous blood flow and selective ETAR antagonist BQ123
enhances perfusion in xenograft tumors and reduces tumor hypoxia. Hence selective
modulation of TME particularly blood vessels and extracellular matrix can not only
improve the delivery of macromolecule (Abraxane) or small molecule (Gemctabine) into
tumors but also improve the the sensitivity of tumor cells to cytotoxic effects of
Gemcitabine. In future we will be interested in determining the effect of targeting ETAR
alone (BQ123) and both ETAR and ETBR (Bosentan) on the delivery and distribution of
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chemotherapeutic agents in spontaneous tumor models of PC. However, these ideas
are purely hypothetical and the effect of ET antagonists on the uptake and distribution of
Gemcitabine in vivo can be addressed by future studies.
(ii) Will ETAR and ETBR inhibition enhance the therapeutic efficacy of
chemotherapeutic agents?
Our expression analysis of ET-axis indicated that in addition to the stromal
compartment, tumor cells also express ETAR and ETBR. Further, inhibition of ET-axis in
autochthonous tumors (in the absence of any chemotherapeutic agent) resulted in the
apoptosis of tumor cells. Studies have demonstrated that activation of ETAR in tumor
cells promotes proliferation, and cell survival (anti-apoptotic signals) by activating
different signaling pathways including MAPK, PKC, EGFR and Akt [32]. Thus, it is likely
that ET axis antagonism can have direct anti-tumor effects and synergistically enhance
the efficacy of other chemotherapeutic drugs. Studies have demonstrated that
pancreatic stellate cells promote therapy resistance in cancer cells and assays involving
co-culture of both cell types provide a more accurate prediction of therapeutic response
in vivo [33].
In future, we will be interested in investigating the molecular mechanisms by
which ET-axis contribute to PSC-mediated chemoresistance in PC? Does ET axis
activate pathways of cancer stem cells (CSCs) enrichment and maintenance to drive
chemo resistance? These questions can be addressed by using knockdown,
overexpression and inhibitor based studies in using 3D co-culture and organoid models.
(iii) Does the cellular cross talk between tumor and stellate cell along ET-axis
contribute to desmoplastic tumor microenvironment in PC?
Our preliminary studies indicated that inhibition of ET- axis by Bosentan reduces
desmoplasia. To elucidate the underlying mechanism, it is important to understand the
cellular cross talk between cancer and stellate cells. In vitro system allows for the
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analysis of cell-cell interaction in a controlled environment without the interference from
other components. Our results indicated that ETAR is expressed on tumor cells while
pancreatic stellate cells predominantly expressed ETBR and low levels of ETAR. In our
studies we performed limited studies in vitro studies using immortalized pancreatic
stellate cells to elucidate the signaling network via which ET-axis regulates profibrotic
genes. However, these studies were perfumed using monoculture approaches and do
provide intricacies of cellular cross-talk between cancer cells and pancreatic stellate
cells. Elucidating the mechanisms and significance of the cellular cross talk along ETaxis would entail co-culture studies in the presence of specific ET-receptor antagonist to
define the predominant receptor involved in the cellular cross talk. It will be more
informative if such in vitro studies are undertaken using approaches that closely
recapitulate in vivo environment. For example, 2D- cultures in the presence of
extracellular matrix proteins, 3D culture in scaffolds or mixed organoid cultures involving
cancer cells and immortalized pancreatic stellate cells can be used. It will be of interest
to determine: a) which signaling pathways are specifically regulated by ETAR and ETBR?
b) Is there a functional overlap between the two ET-receptors? c) What specific genes
are regulated by ET axis and what is the pathobiological significance of these genes? d)
How does this cellular cross talk contribute to the survival, proliferation, migration and
aggressiveness of tumor cells?

(iv) What are the molecular mechanisms that govern the infiltration of
macrophages via ET axis?
Our in vitro studies indicated that U937 cells express high levels of ETBR at all
stages

of

differentiation

and

ETBR

signaling

possibly

contributes

to

monocyte/macrophage migration and recruitment in TME. Previous reports indicated
that ETBR on macrophage surface has been shown to promote the recruitment of
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macrophages in breast cancer [24] while ETAR was shown to be involved in the tumor
cells and macrophage recruitment during metastatic colonization of lungs in bladder
cancer [34]. While we observed that the tumor cell-induced migration of RAW 264.7 and
U937 cells was abrogated by Bosentan and BQ123, our studies did not provide
information about the underlying mechanisms. It will be of interest to define the cellular
mechanisms by which ET-receptors contribute to macrophage migration and define the
downstream signaling along ET axis. It will be equally important to determine the impact
of ET-axis in regulating the chemotactic molecules (chemokines and cytokines) in both
cancer cells and macrophages. Another important question to address would be to
define what role ET-axis plays in TAM differentiation and polarization. Such studies can
be undertaken using bone marrow derived macrophages isolated from conditional
knockout mice for ET-receptors and studying their differentiation, polarization and
migration in the presence of tumor cells.

(v) Does endothelin axis play a role in Immunomodulation in PC?
In addition to high desmoplasia and heterogeneous tumor vasculature in PC
extreme immunosuppressive microenvironment, also pose a challenge in successful
immunotherapy. Our data suggests that pharmacological inhibition of the ET axis using
Bosentan not only reduces the stromal growth in KPC mice tumors but also affects the
infiltration of immune cells in PC stroma. ET axis antagonism resulted in a significant
decrease F4/80 positive and CD206 positive tumor associated macrophages (TAMs).
Like macrophages, solid tumors are spontaneously infiltrated by T cells and trafficking
through lymphoid organs is tightly regulated by endothelium. In human ovarian tumors, it
has been shown that endothelial permeability to cytotoxic T lymphocytes cells is
negatively associated with ETBR overexpression on endothelial cells, and correlates with
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poor prognosis [46]. In response to Bosentan treatment in KPC mice, we observed an
increased accumulation of CD8 T cells, while the number of CD4 T cells remained
unchanged, suggesting a similar role of ET-axis in T-cell recruitment in PC. These
observations

further

raise

the

possibility

of

the

involvement

of

ET-axis

in

immunomodulation of pancreatic TME. To understand the significance of ET-axis
upregulation in the context of tumor immune environment, we performed bioinformatics
analysis on TCGA database using Immuno Quant tool developed at Harvard Medical
School (by Dr, Manoj Bhasin). This tool utilizes gene signature patterns associated with
the differentiation, trafficking, and polarization of immune cells thereby, allowing virtual
immunophenotyping of the tumor. These analyses indicated that tumors with high
expression of ET-1, ETAR and ETBR were enriched in gene signatures associated with
elevated levels of immunosuppressive myeloid-derived suppressor cells (MDSCs),
regulatory T cells (Treg), regulatory B cells (Bregs) and TAMs (Figure 1). The data
suggests

that

ET-axis

upregulation

possibly

contributes

to

establishing

an

immunosuppressive microenvironment in PDAC. Our experimental observations
indicating reduced TAMs and increased CTLs following Bosentan treatment in KPC
mice, align well this predicted role of ET axis. As I mentioned earlier (Chapter 3), we
observed that elevated ETBR positivity on blood vessels is correlated with poor
prognosis of the PC patients. Also, a recent report in patients with malignant gliomas
also suggested that the increase expression of ETBR on blood vessels interfere with
homing of cytotoxic T lymphocytes and exhibit more infiltration of Tregs around the
tumor [47] suggesting a potential role of ETBR in maintaining the immunosuppressive
microenvironment. We performed a preliminary analysis of the abundance of T-regs
using dual immunofluorescence staining for CD4 and FoxP3 (master regulator of Tregs)
in samples from patients with high and low levels of ETBR expression on tumor blood
vessels. Our data indicated that the tumors of patients, with elevated expression of ETBR
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in blood vessels have higher proportion of Tregs as compared to those with basal level
of blood vessel ETBR (Figure 2). These preliminary observations open an exciting
avenue to investigate the role of ET-axis in establishing an immunosuppressive TME in
PC. An immediate first step would be to expand these observations in a larger cohort
and study the correlation of ET-axis with tumor immunophenotype. Why a subset of
patients fail to respond to checkpoint blockade agents remains an open question and
resistance has been attributed in part, to the poor infiltration of CTLs. It is likely that ETaxis contributes to CTL exclusion in TME and pharmacological modulation may tilt the
balance towards improved outcome on immunotherapy with vaccines and checkpoint
blockade agents. Thus, it will be of interest to evaluate the impact of ET axis anatgonism
in combination with anti-PD1 antibody on anti-tumor immunity in autochthonous models.

C. Irreversible and sustained upregulation of endothelin axis during K-rasoncogene associated pancreatic inflammation and cancer.
(i) Does Endothelin axis play a role in acinar to ductal metaplasia?
As mentioned previously in chapter 5, our in vivo studies in cerulein treated KC
mutant mice suggested that ETAR and ETBR are expressed in the metaplastic ducts
(intermediate between acinar and ductal cells) at day 2 post trauma.; With the increase
in dysplasia at day 7 and day 21 elevated expression of both ETAR and ETBR is
maintained in CK19 positive ducts. These observations suggest the possible
involvement of ETAR and ETBR in acinar to ductal metaplasia (ADM). A previous study
from our own lab has demonstrated that cerulein treated KC mice progress towards
neoplastic transformation with increased CK19 and decreased amylase expression [15] .
Further, in order to elucidate the role of ETAR and ETBR in ADM in vitro, cerulein treated
mouse pancreatic acinar cells (266-6) will be analyzed for ET receptors expression. In
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order to explore whether ET axis directly participates in the process of ADM, we will
knock down of ETAR and ETBR using shRNA in 266-6 cells. Another experiment that
could validate this hypothesis would be analyzing the acinar cell markers such as
elastase, amylase and ductal markers CK19, CA II (carbonic anhydrase). These
experiments can suggests that variation in acinar and ductal lineage markers due to
knockdown of ETAR and ETBR can favor acinar cell plasticity and trans-differentiation
into ductal phenotype.
(ii) What are the molecular mechanism(s) through which cigarette smoke
upregulates the expression of ET axis?
As previously discussed in chapter 5, our IHC and real time PCR analyses
suggested an increase expression of ET axis in KC mice tissues subjected to cigarette
smoke. Our results also demonstrated that, in addition to increase expression on the
pre-cancerous lesions, expression of ET receptors was also enhanced in α-SMA positive
fibroblasts and F4/80 positive macrophages. Given the aberrant expression of ET-1 and
receptors in response to cigarette smoke extract will be of interest to elucidate the
mechanisms by which such deregulation of ET-axis components occur. Accumulating
evidence indicate that smoke extract increases ET-1 and receptors expression in
endothelial cells, pulmonary artery and bronchi by ERK and PKC dependent pathway
[35] [36] [37]. However, this effect was abolished by dual ET receptors antagonism using
Bosentan [35]. Given the paucity of studies in the context of cancer, future studies could
address the function and mechanism of ET axis in PC in presence of oncogenic Kras.
More specifically studies should be focused on cell lines developed in our lab derived
from KC (UN-KC-6141) and KPC (UN-KPC-961) mice models [38] or organoid cultures
from conditional ET-receptor mice. The role of ET-axis in cigarette smoke induced
accelerated progression can be examined in vivo using selective inhibitors or conditional
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ET receptor KO mice. These studies will entail examination of alterations in the Et-axis
components in response to cigarette smoke, impact of ET-axis antagonists on the
progression of smoke-induced injury to pancreatic cells and impact of ET- receptor KO in
tumor progression in response to smoking. Focus of such studies should be to delineate
the cellular mechanisms, identify of signaling networks and discern the role of immune
cells in exacerbating the effects of smoking via ET axis
D. Generation of ET-1-/-, KrasG12D, Trp53R172H/+, Pdx1-Cre mice model
(i) Does ET-1 aid in pro-fibrotic phenotype in pancreatic cancer?
Previous studies using knockout mice models have indicated that ET-1 is
necessary for normal mouse development and play a key role in normal homeostasis.
For example, mice homozygous for ET-1 gene deletion were neonathal and displays
craniofacial and cardiac abnormalities [39]. In contrast mice with heterozygous deletion
of ET-1 gene (ET-1-/+) appeared normal but had elevated mean arterial blood pressure
[39]. Furthermore, mice with ET-1 deletion from the endothelium using Tie2-Cre have
reduced cardiac hypertrophy and lower levels of TGFβ, collagen I and III, suggesting
that endothelium derived ET-1 is a crucial mediator of fibrosis [40] [41]. In addition,
increased oxidative stress and inflammation resulting due to ischemia/reperfusion
mediated injury is attenuated in ET-1 KO mice [42]. Likewise, ET-1 overexpressing mice
is presented with increase chronic inflammation, renal cyst formation and renal interstitial
fibrosis [43] [44] [45].
Despite the utility of the aforementioned studies in shedding light on the role played by
ET-1 in normal physiological and pathological conditions, no study thus far has studied
whether the loss of ET-1 in the pancreas has any significant effect in promoting the profibrogenic phenotype in pancreatic cancer. With a goal to analyze the role played by ET1 ligand, we initiated efforts to generateET-1-/-KPC mice. For this, we crossed the ET-
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1flox/flox mice with K-rasG12D; Trp53R172H/+; Pdx-1-Cre (KPC) mice to generate the
intermediate crosses, which were intercrossed in order to generate the final ET-1-/- KrasG12D; Trp53R172H/+; Pdx-1-Cre (ET-/- KPC) genotype. We euthanized and collected
tissues from the 5 week, 15 week and 25 week of age from the ET-1-/-KPC mice and
KPC mice. Our preliminary analysis of the animals scarified indicated that loss of ET-1
has minuscule effect on the stromal score compared to mice with wild type ET-1. In
addition, H&E analysis of the ET-1 KO mice also reveals small effect on the
inflammatory score (Figure 3). We further analyzed the tissues with IHC and observed
slight reduction of in the expression of pro-fibrotic genes such as α-SMA (Figure 4A and
4C) and Collagen I (Figure 4B and 4C). However, due to the limitation in the sample
size one must be cautious before coming to a conclusion from a very limited sample
size. However, a marginal effect is not surprising given the fact that ET-1 and other
ligands can also be produced by other cell types (fibroblasts, immune cells and
endothelial cells). Given the mosaic expression patterns of the ET-receptors in the tumor
microenvironment, more definitive answers will come from models with ET-receptor
knockout in various cellular compartments (tumor cells, stellate cells, immune cells and
tumor vasculature) to fully comprehend the complex role of this axis in the evolution of
complex tumor microenvironment.
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Figure 1. ET axis overexpression is correlated with Immuno-suppressive
phenotype in PC. Immune Quant analysis of the TCGA database for ET-1, ETAR and
ETBR demonstrating high tumor expression is significantly correlated with elevated
pathways involved in MDSCs, Tregs, Bregs and TAMs recruitment/differentiation.

318

Figure 1

319
Figure 2. Immunofluorescence analysis of CD4 T cells and FoxP3 in human PC A.
Dual immunofluorescence staining for CD4 and FoxP3 in human PC samples with

low and elevated ETBR expression on blood vessels (BV). B. Quantitation of
proportion of Tregs in the total T cells population suggest higher infiltration of
Tregs in PC tissue with elevated ETBR BV positivity.
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Figure 3. Representation of the stromal and inflammatory score in the mice
pancreas. Bar graph representation of the stromal score and inflammatory score in ET1-/- KPC mice and ET-1+/+KPC based on the H&E staining. The intensity was calculated
on a scale of 0-4, with ‘0’ being the lowest and ‘4’ being the highest. Compared to ET1+/+KPC mice, pancreas with homozygous deletion of ET-1 showed minimal difference in
the stromal and inflammatory score.
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Figure 4. Immunohistochemical analysis of α-SMA and Collagen I in mice
pancreas. A. Staining of α-SMA in pancreas of mice isolated from 5 week, 15 week and
25 week of age. The staining shows gradual increase in the α-SMA positive fibroblasts
surrounding the pancreatic duct with increase in age of mice. Staining intensity and the
overall composite score reveals slight reduction in 25week ET-1-/- KPC mice compared
to ET-1+/+KPC mice. B. Immunostaining for Collagen I in ET-1-/- KPC mice pancreas
suggest minor decrease in the composite score as compared to ET-1+/+KPC mice. Note
the prominent collagen I staining in the tumor stroma surrounding the ducts. C.
Quantitation of the composite score for SMA and collagen I in ET-1-/- KPC mice and ET1+/+KPC.
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